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ABSTRACT 
Reactive oxygen species (ROS) are a series of molecules, ions, and radicals 
derived from oxygen that possess remarkable reactivity. They act as signaling 
molecules when their concentration in cells is within a normal range. When the levels 
of ROS increase, reaching a concentration in which the antioxidants cannot readily 
quench them, oxidative stress will affect the cells. These excessive levels of ROS 
result in direct or indirect ROS-mediated damage of proteins, nucleic acids, and 
lipids. Excessive oxidative stress, particularly in chronic inflammation, has been 
linked with mutations and carcinogenesis. One of the main targets of ROS in severe 
oxidative stress is mitochondrial DNA (mtDNA). The synthesis of analogues of α-
tocopherol is described as potential compounds with the ability to remediate defective 
mitochondria. An interesting possibility for eradicating cancer cells is to selectively 
target them with oxidative species while avoiding any deleterious effects on healthy 
cells. To accomplish this, analogues of the β-hydroxyhistidine moiety of the 
antitumor agent bleomycin (BLM) were synthesized. 
The first part of this thesis focuses on the synthesis of simplified analogues of 
α-tocopherol. These analogues possess a bicyclic pyridinol as the antioxidant core 
and an alkyl group as the lipophilic chain to mimic α-tocopherol. Additionally, 
analogues with a completely oxidized pyridinol core were synthesized. Some of these 
analogues showed promising properties against ROS production and lipid 
peroxidation. The protection they conferred was shown to be tightly regulated by their 
concentration. 
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The second part of this thesis focuses on the synthesis of analogues of β-
hydroxyhistidine. BLMs are glycopeptides that possess anticancer activity and have 
been used to treat testicular carcinomas, Hodgkin’s lymphoma, and squamous cell 
carcinomas. The activity of BLM is based on the degradation of DNA, or possibly 
RNA, caused by a Fe(II)⋅BLM complex in the presence of O2. The β-hydroxyhistidine 
moiety of BLM contributes to metal coordination via two ligands: the N-3 nitrogen 
atom of imidazole and possibly the nitrogen atom of the amide. A series of β-
hydroxyhistidine analogues has successfully been synthesized. 
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CHAPTER 1 - INTRODUCTION 
1.1 General introduction 
1.1.1 Redox homeostasis 
Redox reactions are a class of reactions in which electrons are transferred from 
one molecule or atom to another. The reduction of one molecule is always coupled to 
the oxidation of another molecule. A molecule that gains electrons is termed an 
oxidizing agent while a molecule that loses electrons is called a reducing agent.1 
Redox reactions play a vital and complex role in the life of cells. They are necessary 
for proper metabolism, they are vital components of cofactors, and they are essential 
in assuring effective responses against endogenous and exogenous stimuli. The 
extensive list of oxidizing and reducing agents present in every organism interacts 
with each other forming a complex network. A balance between oxidizing and 
reducing agents is required for the proper functioning of cells. This balance is called 
redox homeostasis and it is an integral part of cells’ environment and metabolism.2  
Two types of antagonistic molecules serve as the main constituents of redox 
homeostasis: oxidants and antioxidants. Their interactions occur within a 
sophisticated and extensive redox network. Redox signaling is employed by a diverse 
range of organisms, including bacteria. Its goal is to induce protective mechanisms 
against oxidative stress and to reestablish the state of redox homeostasis after a stress 
phase.3 
 
1.1.2 Oxidants 
The normal oxidative metabolism observed in cells produces oxidants. The 
majority of these oxidants are known as reactive oxygen species (ROS).4 Other 
 2 
 
oxidants include cofactors, reactive nitrogen species (RNS), and reactive chlorine 
species (RCS). It must be noted that while ROS act mainly as oxidants on different 
organic substrates, some of them possess important functions as reductants. For 
example, superoxide (O2•−) is an important reductant of metal ions, such as Fe3+. By 
reducing Fe3+ ions, Fe2+ ions are regenerated. These Fe2+ ions are toxic and can 
generate hydroxyl radicals via the Fenton reaction in the presence of hydrogen 
peroxide.5 Also, Fe2+ ions are able to reduce disulfide bonds.6 Despite possessing a 
reductant nature, superoxide is considered a ROS due to its close relationship with 
other oxygen-containing substrates. 
 ROS possess different functions in organisms and their dysregulation has the 
ability to cause damage to cells. RNS are also important oxidants that are involved in 
cellular signaling processes. Additionally, their dysregulation can lead to cellular 
impairment.7 
 
 
Figure 1.1. Molecular orbitals of selected ROS.8 
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ROS can be classified either as free radicals or non-radicals. Free radicals are 
a diverse species of independent existence that hold one or more unpaired electrons in 
their molecular or atomic orbitals (Figure 1.1).9 Free radicals can be formed by the 
homolytic cleavage of a covalent bond, giving two radicals as products. The 
chemistry of these radicals consists of the transfer of only one electron. This is in 
contrast to the two electron processes observed in the majority of reactions of non-
radicals.10  
 
  Free radicals Non-radicals 
ROS (Reactive oxygen 
species) Superoxide, O2•− 
Hydrogen peroxide, 
H2O2 
  Hydroxyl, HO• 
Hypochlorous acid, 
HClO 
  Peroxyl, ROO• Ozone, O3 
  Alkoxyl, RO• Singlet oxygen, 1O2 
  Hydroperoxyl, HOO•   
RNS (Reactive nitrogen 
species) Nitric oxide, NO• Nitrosyl cation, NO+ 
  
Nitrogen dioxide, 
NO2• Nitrous acid, HNO2 
    
Dinitrogen trioxide, 
N2O3 
    
Peroxynitrite, 
ONOO− 
Figure 1.2. Most common reactive species.11 
 
The list of reactive species is extensive and diverse (Figure 1.2). The most 
common ROS in biological systems include singlet oxygen, hydrogen peroxide 
(H2O2), superoxide, and hydroxyl radical (HO•).12 Additionally, nitric oxide (NO•) is 
an important RNS mediator used in numerous biological processes (Figure 1.3).13  
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Figure 1.3. Chemical relationship between the major forms of ROS.14 
 
Hydrogen peroxide is mainly produced in the mitochondria as a product of the 
enzyme superoxide dismutase reacting with superoxide.15 The other product of this 
dismutation is molecular oxygen. Additionally, hydrogen peroxide is produced by the 
divalent reduction of molecular oxygen by several different oxidases, including 
uricase,16 glucose oxidase,17 and D-amino acid oxidase.18 The toxicity of hydrogen 
peroxide is due to its reaction with Fe2+, called the Fenton reaction (Figure 1.4). The 
product of this reaction is hydroxyl radical, which is responsible for the damage 
caused by hydrogen peroxide.19 
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Figure 1.4. Fenton reaction and its two different mechanisms.20 
 
Superoxide is obtained when molecular oxygen is reduced by one electron.21 
This radical is formed as a mitochondrial byproduct and it is produced by complexes I 
and III.22 In complex I, superoxide is produced when one electron is transferred from 
the iron-sulfur cluster N1a to molecular oxygen. This is thermodynamically 
unfavorable because the reduction potential of cluster N1a (E1/2 = −380 mV) coupled 
with the oxidation potential of NADH (E1/2 = −320 mv) yields a negative reaction 
potential value.23 This explains why superoxide production is very low compared to 
the normal processes of the electron transport chain. Additionally, the production of 
ROS in complex I is increased at higher ratios of NADH/NAD+.24 In complex III, 
ubiquinol (QH2) is oxidized to produce ubisemiquinone (Q•−) and reduces cytochrome 
c1. This ubisemiquinone transfers its electron to cytochrome b and reaches an 
ubiquinone (Q) from an ubiquinone pool, generating ubisemiquinone. This process 
occurs in order to generate a proton gradient from the matrix to the intermembrane 
space of the mitochondrion. This ubisemiquinone generated in the cytochrome b will 
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be reduced to ubiquinol by the oxidation of a second ubiquinol molecule (Figure 
1.5).25 However, on a significantly lesser scale, ubisemiquinone can donate one 
electron to molecular oxygen and produce superoxide.26 The production of ROS by 
both complexes I and III may also be increased by the action of certain inhibitors.27 
Superoxide is also produced as a defensive mechanism during phagocytosis by 
neutrophils and macrophages.28 The reactivity of superoxide is highlighted by its 
reaction with nitric oxide, in which peroxynitrite (ONOO−) is produced. Peroxynitrite 
is a strong oxidizing molecule that decomposes to nitrogen dioxide (NO2•) and 
hydroxyl radical, both of which are extremely reactive.29 In addition, superoxide 
reacts with several enzymes by attacking their Fe-S clusters and releasing Fe3+ which 
is then followed by the Fenton reaction.30  
 
QH2 + cyt c1 (Fe3+) + + 2H+ (To intermembrane space)cyt c1 (Fe2+)
QH2 + cyt c1 (Fe3+)
Q + +cyt c1 (Fe2+)
Q+ + 2H+ (From matrix)
QH2 + 2 cyt c1 (Fe3+)
+2 cyt c1 (Fe2+)
+ 2H+ (From matrix)
+QH2
Q +
2H+ (To intermembrane space)
4H+ (To intermembrane space)
Reaction 1
Reaction 2
Overall
reaction
Q
 
Figure 1.5. The cycle of ubiquinone (Q). Intermediate ubisemiquinone is encircled.31 
 
As described earlier, hydroxyl radical is synthesized by the decomposition 
reaction of peroxynitrite. It is also the main product of the Fenton reaction (Figure 
1.4).32 Additionally, it is the decomposition product of the light excitation of 
hydrogen peroxide.9 This radical is known as one of the most reactive chemical 
species, possessing second-order rate constants of more than 107 M−1 s−1 when it 
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oxidizes other biological molecules.33 It is responsible for the majority of damage 
caused to DNA that is attributed to ROS.34  
Nitric oxide is produced by a diverse group of nitric oxide synthase (NOS) 
enzymes.35 In this reaction, two molecules of L-arginine react with three molecules of 
NADH, forming two molecules of L-citrulline, two molecules of nitric oxide, and 
three molecules of NAD+ (Figure 1.6).36 Nitric oxide reacts with hydroxyl radical to 
produce peroxynitrite which is known as a powerful agent involved in nitration, 
nitrosation, and oxidation.37  
 
 
Figure 1.6. The nitric oxide synthase reactions. 38 
 
Even though these reactive species are generally recognized by their negative 
effects, they also have important roles in cellular signaling. Hydrogen peroxide has 
been linked to the activation of mitogen-activated protein kinase (MAPK) signaling 
pathways, inhibition of protein phosphatases, and activation of transcription factors.39 
The major part of these mechanisms involves the oxidation of cysteine residues by 
hydrogen peroxide.40  
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Superoxide activates protein kinases by promoting the phosphorylation of 
serine and threonine residues.41 Additionally, superoxide is produced by neutrophils 
and mononuclear phagocytes to combat external pathogens.42  
Hydroxyl radical also has an essential role in phagocytosis. Hydroxyl radicals 
are produced after superoxide releases Fe3+ from Fe-S clusters. These Fe3+ ions react 
with hydrogen peroxide forming hydroxyl radicals, which are the main oxidative 
forces against pathogens.43At the same time, the damage caused to tissue by hydroxyl 
radical initiates an inflammatory response.44 
Nitric oxide has several diverse roles in cell signaling. Among these functions, 
nitric oxide and other vasodilators can activate soluble guanylyl cyclase in the 
endothelium to produce cyclic GMP (cGMP), leading to smooth muscle relaxation.45 
Additionally, nitric oxide can be added to the cysteine thiols of different proteins. 
This reaction is called nitrosylation, which can activate or inactivate proteins creating 
reversible and diverse signals.46 
 
1.1.3 Antioxidants 
Antioxidants compose the second type of species involved in redox 
homeostasis. These compounds are reducing agents that cells synthesize in order to 
delay, prevent, or remove oxidative damage. Their activity is crucial to afford redox 
homeostasis. A marked imbalance between antioxidants and oxidants will cause 
deleterious oxidative stress.47 
Similar to oxidants, antioxidants exist in a variety of structural subtypes 
(Figure 1.7). These subtypes can be divided into two main groups: enzymatic and 
non-enzymatic antioxidants. The major enzymatic antioxidants are superoxide 
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dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx). It must be noted 
that since superoxide is considered a reductant and not an oxidant, SOD must be 
referred to as an antireductant instead of as an antioxidant.48 However, since 
superoxide dismutase is part of the protective mechanisms used against oxidative 
damage caused by ROS, sometimes it is discussed as an antioxidant. The major non-
enzymatic antioxidants are ascorbate (vitamin C), tocopherol (vitamin E), glutathione 
(GSH), carotenoids (derived from vitamin A), and coenzyme Q10 (ubiquinone or Q).49  
 
 
Figure 1.7. Classification of antioxidants.50 
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 The enzymatic antioxidants quench different oxidants (or reductants in the 
case of superoxide dismutase) and their function is often complemented by other 
enzymes. Superoxide dismutase is responsible for converting superoxide into 
hydrogen peroxide (Figure 1.8). This reaction is normally coupled with other enzymes 
in order to remove the hydrogen peroxide formed.51 These antioxidants possess one or 
several metal ions as active sites. The superoxide dismutase family is considered 
diverse since they possess Cu2+, Zn3+, Mn3+, or Fe3+ at their catalytic center.52 
 
M(n+1)+ + +
Mn+ + M(n+1)+ ++ 2H+
+ 2H+
H2O2
O2 +
Reaction 1
Reaction 2
Overall
reaction
Mn+O2 O2
H2O2
O2
2O2
 
Figure 1.8. Mechanism of superoxide dismutase.53  
 
Enz (Por-Fe3+) + +Cpd I (Por   +-Fe4+=O)
Cpd I (Por   +-Fe4+=O)
Enz (Por-Fe3+) +
H2O2+
+H2O
Reaction 1
Reaction 2
H2O2 H2O
O2
2H2O2 2H2O +Overall
reaction
O2
 
Figure 1.9. Mechanism of catalase.54  
 
Catalase is responsible for reducing one molecule of hydrogen peroxide to 
water. In a secondary step, catalase oxidizes an additional molecule of hydrogen 
peroxide to molecular oxygen (Figure 1.9). The reactive site of catalase contains a 
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heme-iron cluster.55 One of the main features of the catalase family is the formation of 
a high-valent iron intermediate after the first reaction. This intermediate is called 
Compound I (Cpd I).56 
Glutathione peroxidase is responsible for reducing hydrogen peroxide to 
water. This enzyme has the same function as catalase, but it reduces hydrogen 
peroxide by a completely different mechanism. Additionally, glutathione peroxidase 
can transform lipid peroxides to their corresponding alcohols.57 Glutathione 
peroxidase possesses a selenocysteine as its active site and utilizes glutathione (GSH) 
as a reducing agent.58 Since the fate of this enzyme is exclusively tied to glutathione, 
more information is presented below regarding this non-enzymatic antioxidant. 
 
N
H
H
N
NH2
OHS
O
O
O
O
O
H
HO
O
OH
O
10
O
OHHO
O
HO
HO
O
HO
glutathione (GSH) coenzyme Q10 (Q)
β-carotene (precursor to vitamin A)
L-ascorbic acid
(vitamin C)
α-tocopherol
(vitamin E)
 
Figure 1.10. Structures of non-enzymatic antioxidants. 
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The non-enzymatic antioxidants can be divided into metabolic antioxidants 
and nutritionally derived antioxidants. Glutathione and ubiquinone are biologically 
important metabolic antioxidants while ascorbate (Vitamin C), tocopherol (Vitamin 
E), and the carotenoids are essential nutritionally derived antioxidants (Figure 1.10).59  
 Glutathione is composed of three amino acids: L-glutamate, L-cysteine, and 
glycine. In this molecule, glutamate is attached to cysteine through a gamma peptide 
bond while cysteine is attached to glycine by an alpha peptide bond.60 Glutathione is 
capable of neutralizing hydrogen peroxide and lipid peroxides (Figure 1.11) as 
mentioned above. Glutathione can react with a wide array of oxidants. For example, 
glutathione can react in enzymatically catalyzed processes with other toxic species, 
such as formaldehyde and methylglyoxal, giving the relatively less toxic species 
formic acid and lactate, respectively.61 Also, glutathione can react non-enzymatically 
with numerous oxidants. Glutathione has the ability to quench alkyl and peroxyl 
radicals. The coordination between superoxide dismutase and glutathione to quench 
alkyl radicals, peroxyl radicals, and superoxide is called a “free radical sink” (Figure 
1.12).62 Additionally, glutathione can react with superoxide generating glutathione 
thiyl radical (GS•) in order to protect other thiols. The final step of these reactions is 
the production of oxygen and peroxide by superoxide dismutase (Figure 1.12).63  
 
2GSH + +GSSGH2O2 2H2O
2GSH + +GSSGROOH ROH + H2O
 
Figure 1.11. Reactions of glutathione with hydrogen peroxide and lipid peroxide.64 
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Figure 1.12. Molecular oxygen as radical sink for radicals generated from the 
reaction between glutathione and alkyl radicals.65  
 
 Coenzyme Q10 (ubiquinone or Q) is present in all cell membranes. The 
reduced form of coenzyme Q10 (ubiquinol or QH2) is an important antioxidant that 
can neutralize peroxyl radicals (Figure 1.13).66 It should be noted that the intermediate 
ubisemiquinone can undergo undesirable reactions such as the production of 
superoxide (Figure 1.5).26 Additionally, ubiquinol can regenerate α-tocopherol from 
its oxidized form. Tocopherols are more efficient at quenching radicals than 
ubiquinol.67 
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QH2 + + +Q ROOH H+
Q + +Q ROOH+ H+
2Q + 2H+ +Q QH2
ROO
ROO
 
Figure 1.13. Reactions between peroxyl radicals and derivatives of ubiquinone (Q).68 
 
 Ascorbate (vitamin C) is an antioxidant that has the ability to react with a wide 
range of oxidants and radicals. It is present in significant quantities in the body and it 
can be regenerated.69 Ascorbate interacts with several antioxidants, but its interaction 
with glutathione is vital in suppressing ROS (Figure 1.14). It is synthesized from D-
gulonic acid in the majority of animals and from L-galactose in plants. Humans are 
among the few species that cannot synthesize this compound therefore it must be 
obtained in their diet.70 Ascorbate can be regenerated by the dismutation of two 
molecules of ascorbate radical producing ascorbate and dehydroascorbate as 
products.71 Additionally, ascorbate can be regenerated from dehydroascorbate by 
complex III of the electron transport chain (Figure 1.15). 72 
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Figure 1.14. Major scavenging pathways by non-enzymatic oxidants. Dashed lines 
show less favorable reactions.73 
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Figure 1.15. Oxidation products of ascorbate.74,75 
 
 The carotenoids are a family of natural pigments. More than a thousand have 
been identified in nature.76 The carotenoids are biosynthesized from two 
geranylgeranyl moieties attached tail-to-tail producing a skeleton of forty carbons.77 
Their antioxidant properties are similar to those possessed by ubiquinol (Figure 1.12). 
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They are involved in the quenching of peroxyl radicals.78 Additionally, carotenoids 
have the ability to regenerate tocopherol from the tocopheroxyl radical.79 
Please note that vitamin E will be described in detail in section 2.1. 
 
1.1.4 Balance between reactive species and antioxidants 
As stated before, both oxidants and antioxidants possess properties that make 
them essential for proper cell signaling. At redox homeostasis, the concentration of 
ROS will be at low but measurable levels.80 However, ROS concentrations can 
quickly change to address different situations. For example, during phagocytosis the 
cells involved enter into a state of oxidative stress. In this particular case, oxidative 
stress confers several advantages and becomes essential in order to combat external 
pathogens.81  
When the presence of oxidants is at a significantly higher level than normal, 
severe oxidative stress can be observed (Figure 1.16). Severe oxidative stress results 
in direct or indirect ROS-mediated damage of proteins, nucleic acids, and lipids.82 
Severe oxidative stress has been implicated in carcinogenesis,83 neurodegeneration,84 
aging,85 and apoptosis.86 The impact of oxidative stress in mitochondrial impairment 
and carcinogenesis will be reviewed in more detail below. 
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Figure 1.16. Consequences of dysregulated production of ROS.87 
 
1.1.4.1 Oxidative stress and mitochondrial impairment 
One of the main targets of ROS in severe oxidative stress is mitochondrial 
DNA (mtDNA). This is due to the close proximity between the mitochondrial DNA 
and the electron transport chain, which resides in the mitochondrial membrane.88 
Additionally, the absence of histones increases the susceptibility of mitochondrial 
DNA to the deleterious effects of ROS.89 The net production of ROS and the 
accumulation of mitochondrial DNA mutations are important contributors to aging90 
and to several neurodegenerative such as Alzheimer’s disease, Parkinson’s disease, 
Friederich’s ataxia (FRDA), hereditary spastic paraplegia, and amyotrophic lateral 
sclerosis, among others.91 A second area of the human body with increased 
susceptibility to ROS is the central nervous system (CNS). The CNS is extremely 
sensitive to oxidative damage since it is the organ system that consumes the most 
oxygen in the body.92 
In the majority of trials, nutritionally derived antioxidants have shown no 
effect in treating diseases caused by defective mitochondria.93 However, drugs 
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derived from these antioxidants have the possibility of becoming pharmaceutical 
agents that may alleviate mitochondrial dysfunction. For example, the lipophilic 
cation triphenylphosphonium (TPP+) accumulates in the mitochondria and has been 
attached to the core of several antioxidants generating MitoVit E and MitoQ10. 94 
MitoVit E and MitoQ10, derived from vitamin E and ubiquinol respectively, target 
mitochondria selectively.95 However, both compounds accumulate irreversibly in the 
mitochondria and eventually reach toxic concentrations. Another series of antioxidant 
analogues is derived from the modification of their core in order to increase its 
potency. For example, 5-pyrimidinols possess a core that is comparable in activity to 
the core of α-tocopherol, a component of vitamin E (Figure 1.18).96 Chapter 2 will 
focus on the synthesis of modified core analogues of α-tocopherol. 
 
O
O
OH
OH
O
HO
P
MitoQ10MitoVit E
P
P X
Triphenylphosphonium 
(TPP+) moiety
 
Figure 1.17. Structures of TPP+ and antioxidant analogues possessing TPP+ moiety.94 
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Figure 1.18. Structures of α-tocopherol and 5-pyrimidinol.96 
 
1.1.4.2 Oxidative stress and carcinogenesis. 
 Excessive oxidative stress, particularly in chronic inflammation, has been 
linked with mutations and carcinogenesis.97 Additionally, the organelle peroxisome 
and inflammatory cells such as neutrophils, eosinophils, and macrophages may be 
involved in carcinogenesis by producing high levels of ROS.98 From ROS, hydroxyl 
radical is considered the major contributor of oxidative damage to DNA.99 Hydroxyl 
radical is mainly produced inside the organism by the sources mentioned above and 
by the Fenton reaction.100 
 Nutritionally derived antioxidants have failed to provide any significant 
activity to prevent or to treat cancer.101 However, some analogues of antioxidants 
have proven to be successful agents against cancer cells. One example is α-tocopheryl 
succinate (Figure 1.19), which is effective against several cancer cell lines. However, 
the anticancer activity of α-tocopheryl succinate occurs through pathways that do not 
involve ROS quenching.102 
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Figure 1.19. Structure of α-tocopheryl succinate. 
 
Since the restoration of redox homeostasis in cancer cells by antioxidants does 
not seem to be possible, other mechanisms are being studied. An interesting 
possibility for eradicating cancer cells is to selectively target them with oxidative 
species while avoiding any adverse effects on healthy cells. Cancer cells carry higher 
levels of ROS in their mitochondria compared to healthy cells. Even in this situation, 
cancer cells are still susceptible to excessive levels of ROS.103 The anticancer agent 
bleomycin has the ability to specifically target several tumor cell lines while having 
no effect on normal cell lines. Bleomycin is an anticancer agent that cleaves DNA and 
that is selective to cancer cells due to its disaccharide domain (Figure 1.20).104 
Analogues of bleomycin constitute an important target in order to increase the 
selectivity and potency against cancer cells. Chapter 3 will focus on the synthesis of 
analogues of β-hydroxyhistidine, which is one of the building blocks of bleomycin. 
These analogues will be used in the formation of new analogues of bleomycin after 
fully assembling the glycopeptide. 
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Figure 1.20. The different domains of BLM A6. The β-hydroxyhistidine moiety is 
highlighted in red. 
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CHAPTER 2 - SYNTHESIS OF A NEW SERIES OF SIMPLIFIED α-
TOCOPHEROL ANALOGUES 
2.1 General introduction 
The damage caused to mitochondria by excessive oxidative species impairs 
their function and also increases their susceptibility to further oxidative damage.105 
Defective mitochondria are considered one of the causes of disease progression in a 
wide range of diseases including Friedreich’s ataxia, Alzheimer’s disease, Parkinson’s 
disease, hereditary spastic paraplegia, and Huntington’s disease among others.106 
Nutritionally derived antioxidants have failed to show any effect in the 
majority of clinical trials against diseases whose progression is caused by defective 
mitochondria. Experimental drugs structurally related to vitamin E and coenzyme Q 
are used to treat these mitochondrial dysfunctions.107 Employing the knowledge 
obtained from the study of both antioxidants, more potent agents have been obtained. 
Vitamin E is the common name of a group of eight molecules, each containing 
a chromanol ring and a lipophilic side chain.108 Among this family, the most potent 
radical scavenger is α-tocopherol (Figure 2.1).109 This compound reacts with lipid 
peroxyl radicals forming a stable tocopheroxyl radical. The stability of this radical is 
due to the resonance stabilization of the system. These tocopheroxyl radicals are 
quenched by reacting with other peroxyl radicals.110 However, in the absence of 
another radical to terminate the radical propagation, the tocopheroxyl radical will act 
as an oxidant by reacting with fatty acids.111 α-Tocopherol can be recycled in the 
body by ascorbic acid.112 Both antioxidants in conjunction form the most efficient 
defense against lipid peroxidation in vivo.113 Following the literature related to the 
structure and activity of α-tocopherol,114 a thoughtful modification of its structure was 
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pursued. The synthesis of active analogues of α-tocopherol represents an interesting 
strategy to obtain potent and efficient antioxidants.115 The activity of these new 
structures will be compared to α-tocopherol.  
 
O
HO
R5
R7
α -T
β -T
γ -T
δ -T
R5         R7
CH3      CH3
H         CH3
CH3       H
H          H
Chromanol ring Aliphatic side chain
 
Figure 2.1. Structures of components of vitamin E. 
 
 The Hecht laboratory has focused on the synthesis of diverse analogues of 
coenzyme CoQ10.116 Because of the potential of α-tocopherol analogues as promising 
antioxidants, research exploring these antioxidants has gained attention. 6-Amino-3-
pyridinols possess cores that make them interesting antioxidants because biological 
assays have shown that they can quench peroxyl radicals better than α-tocopherol. 
Pyridinols 2.1 and 2.2 are 28 and 88 times more potent than α-tocopherol in 
quenching the peroxidation of methyl linoleate in benzene solution (Figure 2.2).117  
For antioxidant 2.3, it was proposed by Hecht and coworkers to synthesize an 
analogue possessing the same core as 2.1 and a lipophilic tail to improve its delivery 
to the mitochondrial membranes. This new antioxidant possessed a phytyl tail as a 
lipophilic group in position 4 of the pyridinol ring. Bicyclic antioxidant 2.3 was found 
to block peroxidation of the mitochondrial membranes and to protect cells against 
ROS more efficiently than α-tocopherol. However, the main drawback of 2.3 is that 
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its synthesis required sixteen steps. Additionally, several steps gave unexceptional 
yields and toxic reagents such as selenium dioxide (SeO2) were used.118 
 
N N
HO
2.1
N
HO
2.2
HO
O
α-tocopherol
(α-TOH)
N
 
Figure 2.2. Structures of α-tocopherol and 6-amino-3-pyridinol cores 2.1 and 2.2. 
 
N N
Bicyclic core
O NH2N OMe
OMe
Lactam acetal Enaminone
Annulation
 
Figure 2.3. Retrosynthetic analysis of the bicyclic core by annulation. 
 
In order to overcome these obstacles, Hecht and coworkers developed a novel 
method to synthesize bicyclic pyridinols 2.1 and 2.2 in a shorter and more 
manageable fashion. The main improvement consisted of the annulation of a lactam 
acetal with an enaminone (Figure 2.3).119 With the efficient synthesis of the desired 
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cores, the lipophilic chain can be attached via regioselective metalation of the methyl 
group at the position 2 of the pyridine ring. Additionally, the phytyl tail was 
substituted with a linear alkyl chain. The role of the phytyl tail is to deliver the active 
core to the mitochondria efficiently therefore it can be replaced with an alkyl chain. 
Hecht and coworkers have studied the optimization of the length of the alkyl chain in 
ubiquinone analogues and discovered that the ten carbon chain was optimal.120 Hecht 
and coworkers replaced the phytyl tail with alkyl substituents having five, ten and 
sixteen carbons (Figure 2.4). Among these analogues (2.4-2.9), only those possessing 
a ten carbon chain strongly decreased ROS levels, quenched lipid peroxidation, and 
maintained cell viability against induced oxidative stress. The analogues possessing 
five and sixteen carbons showed significantly less activity than 2.6 and 2.7.121  
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Figure 2.4. Structures of α-TOH analogues 2.3-2.9 synthesized by Hecht and 
coworkers. 
 
The fact that only 2.6 and 2.7 had useful antioxidant properties while the 
analogues with shorter (2.4 and 2.5) and longer alkyl (2.8 and 2.9) chains showed 
significantly less activity, raised the question of the optimal length of the side chain 
for this series of analogues. To answer this question, additional analogues were 
synthesized (Figure 2.5). 
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N N
RO
2.12, R = H
2.13, R = Ac
N N
RO
2.14, R = H
2.15, R = Ac
 
Figure 2.5. Structures of new antioxidant analogues 2.10-2.15. 
 
To further elucidate properties of α-tocopherol analogues, a new core has been 
studied. Pyrrolopyridine 2.16, the unsaturated form of 2.1, offers a promising nucleus 
for an additional series of analogues (Figure 2.6). The extended planar structure and 
larger resonance of 2.16 compared with 2.1 could possibly contribute in the 
stabilization of the radical intermediate. Analogues 2.10-2.15 and 2.17-2.24 were 
tested for lipid peroxidation, mitochondrial membrane potential, cell viability, and 
ROS protection in cells depleted of glutathione. These results are presented below. 
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Figure 2.6. Structures of unsatured antioxidant 2.16 and antioxidant analogues 2.17-
2.24. 
 
2.2 Results and discussion 
2.2.1 Synthesis of bicyclic antioxidants 
 The synthesis of these analogues followed the retrosynthetic pathway that 
Hecht and coworkers used previously to obtain 2.4-2.9 (Figure 2.7).121 The synthesis 
of these analogues used 1,4,6-trimethy-2,3-dehydro-1H-pyrrolo[2,3-b]pyridine (2.26) 
as a common intermediate.  
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Figure 2.7. Retrosynthetic analysis of analogues 2.6, 2.10, 2.12, 2.14, 2.17, 2.19, 
2.21, and 2.23.  
 
Lactam acetal 2.25 was produced by reacting 1-methyl-2-pyrrolidone with 
dimethyl sulfate at 90 °C and subsequent treatment with sodium methoxide in 
methanol at −10 °C. Desired lactam acetal 2.25 was obtained in 29% yield after 
distillation and was stored in a desiccator after being purged with argon. The synthesis 
of bicyclic core 2.26 was the most important step in the scheme because it generates 
this complicated bicyclic core in one step. Lactam acetal 2.25 was cyclocondensed by 
treatment with 4-amino-3-penten-2-one in toluene at reflux followed by the addition 
of sodium tert-butoxide and tert-butanol at 90 °C to give bicyclic species 2.26 in 32% 
yield. Bicyclic core 2.26 was the main intermediate for all products (Scheme 2.1). 
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Scheme 2.1. Synthesis of pyridinol acetates 2.7, 2.11, 2.13, 2.15, 2.18, 2.20, 2.22, and 
2.24. 
 
The synthesis of pyridinol acetate 2.11, containing an eight carbon side chain, 
continued with the alkylation of 2.26 using n-butyllithium and bromoheptane in 
tetrahydrofuran at −78 °C to afford bicyclic intermediate 2.27 in 57% yield. Bicyclic 
intermediate 2.27 was brominated using 1,3-dibromo-5,5-dimethylhydantoin 
(DBDMH) in chloroform at 0 °C to obtain bromide 2.28 in 71% yield. Bromide 2.28 
was first treated with tetramethylethylenediamine (TMEDA) and n-butyllithium in 
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tetrahydrofuran at −78 °C. For the second step, trimethoxyborane was added at −78 
°C; and for third step, peracetic acid was added at −78 °C to give the desired phenol. 
This phenol was acetylated using triethylamine, 4-dimethylaminopyridine and acetic 
anhydride to afford pyridinol acetate 2.11 in 48% yield. Oxidation of 2.11 with nickel 
peroxide gave oxidized pyridinol acetate 2.18 in 48% yield. 
The synthesis of pyridinol acetate 2.7, containing a ten carbon side chain, 
continued with the alkylation of 2.26 using n-butyllithium and bromononane in 
tetrahydrofuran at −78 °C to afford bicyclic intermediate 2.29 in 42% yield. Bicyclic 
intermediate 2.29 was brominated using 1,3-dibromo-5,5-dimethylhydantoin 
(DBDMH) in chloroform at 0 °C to obtain bromide 2.30 in 87% yield. Bromide 2.30 
was first treated with tetramethylethylenediamine and n-butyllithium in 
tetrahydrofuran at −78 °C. For the second step, trimethoxyborane was added at −78 
°C; and for third step, peracetic acid was added at −78 °C to give the desired phenol. 
This phenol was acetylated using triethylamine, 4-dimethylaminopyridine and acetic 
anhydride to afford pyridinol acetate 2.7 in 43% yield. Oxidation of 2.7 with nickel 
peroxide gave oxidized pyridinol acetate 2.20 in 63% yield. 
The synthesis of pyridinol acetate 2.13, containing a twelve carbon side chain, 
continued with the alkylation of 2.26 using n-butyllithium and bromoundecane in 
tetrahydrofuran at −78 °C to afford bicyclic intermediate 2.31 in 41% yield. Bicyclic 
intermediate 2.31 was brominated using 1,3-dibromo-5,5-dimethylhydantoin 
(DBDMH) in chloroform at 0 °C to obtain bromide 2.32 in 84% yield. Bromide 2.32 
was first treated with tetramethylethylenediamine and n-butyllithium in 
tetrahydrofuran at −78 °C. For the second step, trimethoxyborane was added at −78 
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°C; and for third step, peracetic acid was added at −78 °C to give the desired phenol. 
This phenol was acetylated using triethylamine, 4-dimethylaminopyridine and acetic 
anhydride to afford pyridinol acetate 2.13 in 49% yield. Additionally, oxidized 
pyridinol acetate 2.22 was obtained as a byproduct in 25% yield. 
The synthesis of pyridinol acetate 2.15, containing a fourteen carbon side 
chain, continued with the alkylation of 2.26 using n-butyllithium and bromotridecane 
in tetrahydrofuran at −78 °C to afford bicyclic intermediate 2.33 in 64% yield. 
Bicyclic intermediate 2.33 was brominated using 1,3-dibromo-5,5-dimethylhydantoin 
(DBDMH) in chloroform at 0 °C to obtain bromide 2.34 in 66% yield. Bromide 2.34 
was first treated with tetramethylethylenediamine and n-butyllithium in 
tetrahydrofuran at −78 °C. For the second step, trimethoxyborane was added at −78 
°C; and for third step, peracetic acid was added at −78 °C to give the desired phenol. 
This phenol was acetylated using triethylamine, 4-dimethylaminopyridine and acetic 
anhydride to afford pyridinol acetate 2.15 in 29% yield. Additionally, oxidized 
pyridinol acetate 2.24 was obtained as a byproduct in 16% yield. 
Free pyridinols were obtained from their respective pyridinol acetates by 
deacetylation using diisobutylaluminium hydride in dichloromethane at −78 °C. Then, 
pyridinols were converted to their triflate salts by treatment with a dilute solution of 
trifluoroacetic acetic acid (TFA) in water. The results of each final reaction can be 
observed in Scheme 3.2. The pyridinols and their respective acetates were tested in 
biological assays. 
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Scheme 2.2. Synthesis of free pyridinols 2.6, 2.110, 2.12, 2.14, 2.17, 2.19, 2.21, and 
2.23 from their respective acetates. 
 
2.2.2 Biochemical and biological evaluation of synthesized analogues 
2.2.2.1 Assessment of lipid peroxidation in cultured cells 
Lipid peroxidation was determined in FRDA cells by monitoring the 
fluorescence of the peroxidation-sensitive dye C11-BODIPY
581/591
. Diethyl maleate 
(DEM) was used to deplete glutathione. The depletion of glutathione in FRDA cells 
increases the levels of ROS produced inside the cell and the mitochondria. 
Pretreatment of FRDA cells with phenolic compounds 2.14 (fourteen carbon chain, 
reduced core), 2.21 (twelve carbon chain, oxidized core), and 2.23 (twelve carbon 
chain, oxidized core) blocked lipid peroxidation even at 250 nM. Their acetates 
exhibited significantly smaller quenching activity, suggesting that the cleavage of the 
acetates’ ester did not occur in a significant fashion. 
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Figure 2.8. Lipid peroxidation in FRDA cells depleted of glutathione. Following 
pretreatment with the indicated compounds at 250 nM, 500 nM, and 2.50 µM 
concentration, the cells were treated with 5 mM of diethyl maleate (DEM) for 80 
minutes to deplete glutathione. The cells were then treated with 500 nM C11-
BODIPY581/591 in the dark at 37 °C for 30 minutes. The cells were washed twice in 
phosphate buffered saline and resuspended in Hanks’ Balanced Salt Solution buffer 
before they were subjected to flow cytometry analysis using the FL1-H channel for 
C11-BODIPY581/591 – green (oxidized form). The figure shows a representative 
example of three independent experiments. In each analysis, 10,000 events were 
recorded. The bottom panel shows a bar graph of mean C11-BODIPY581/591 – green 
(oxidized form) fluorescence (a.u.) recorded by FACS and represents the percentage 
of the fluorescence means of the above flow cytogram profiles calculated using  
CellQuest software. Data are expressed as means ± SEM (n = 3). This experiment was 
performed by Dr. Omar Khdour. 
0
20
40
60
80
100
120
%
 S
u
p
re
ss
io
n
 o
f 
li
p
id
 p
e
ro
x
id
e
 b
y
 C
1
1
-B
O
D
IP
Y
 
g
re
e
n
 m
e
d
ia
n
 m
e
a
n
 f
lu
o
re
sc
e
n
ce
 i
n
te
n
si
ty
0.25 uM
0.50 uM
2.50 uM
 35 
 
2.2.2.2 Assessment of ROS production in cultured cells 
Additionally, ROS quenching of these compounds was analyzed using FRDA 
cells depleted of glutathione. Diethyl maleate was used to deplete glutathione. 
Pretreatment of FRDA cells with phenolic compounds 2.14 (fourteen carbon chain, 
reduced core), 2.21 (twelve carbon chain, oxidized core), and 2.23 (fourteen carbon 
chain, oxidized core) quenched ROS even at 500 nM. Their respective acetates 2.15 
(fourteen carbon chain, reduced core), 2.22 (twelve carbon chain, oxidized core), and 
2.24 (fourteen carbon chain, oxidized core) were as effective as the phenolic 
compounds in the suppression of ROS. The most potent agent was 2.24. It was the 
only compound able to quench ROS at 250 nM. From both studies, it can be observed 
that both twelve and fourteen carbon analogues were the most effective at protecting 
cells against ROS. 
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Figure 2.9. ROS production in FRDA cells depleted of glutathione. Following 
pretreatment with the indicated compounds (250 nM, 500 nM and 2.50 µM) for 16 h, 
the cells were treated with 5 mM of diethyl maleate (DEM) for 80 min to deplete 
glutathione. The cells were then washed in phosphate-buffered saline and suspended 
in phosphate-buffered saline containing 20 mM of glucose. Cells were loaded with 10 
µM dichlorodihydrofluorescein diacetate (DCFH-DA) for 20 min and the green 
fluorescence (DCF) was measured by flow cytometry (C6 Accuri, BD Biosciences, 
San Jose, CA) using a 488 nm excitation laser and the FL1-H channel 530 ± 15 nm 
emission filter. The figure shows a bar graph of ROS % scavenging activity. Data are 
expressed as the mean ± SEM (n = 3). This experiment was performed by Dr. Omar 
Khdour. 
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2.2.2.3 Assessment of inhibition on the mitochondrial electron transport chain 
 The inhibitory effect of the synthesized compounds on bovine heart 
mitochondrial complexes I, II, and IV was studied. For each compound, higher 
concentrations correlated with a decrease in the activity of NADH oxidase. The 
acetates of the pyridinols that possessed oxidized cores showed an increase in NADH 
oxidase activity. This increase in activity correlated with an increase in length of the 
carbon side chain.  
 
 
Figure 2.10. Inhibitory effects on bovine heart mitochondrial NADH oxidase activity.  
The inhibitory effects of the test compounds on bovine heart mitochondrial complexes 
I, III and IV were evaluated. The compounds were dissolved in N,N-
dimethylsulfoxide (DMSO). Bovine heart submitochondrial particles were diluted to 
0.5 mg/mL. NADH oxidase activity was determined in a reaction medium (2.5 mL 
total volume) containing 50 mM of Hepes, pH 7.5, and 5 mM of magnesium chloride. 
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The final mitochondrial protein concentration was 30 µg. After the pre-equilibration 
of submitochondrial particles with inhibitor for 5 min, the initial rates were calculated 
from the linear portion of the traces. The figure shows a bar graph of % NADH 
oxidase activity. Activity was expressed as the percentage of untreated cells. Data are 
expressed as the mean ± SEM (n = 3). This experiment was performed by Sriloy Dey. 
 
2.2.2.4 Assessment of cell viability in cultured cells 
The effect of the synthesized phenolic compounds on cell viability was 
assessed using FRDA cells depleted of glutathione. Diethyl maleate was used to 
deplete glutathione. Pretreatment with all compounds except 2.10 protected FRDA 
cells against oxidative stress at 0.5 µM. No compound offered protection at 0.1 µM. 
 
 
Figure 2.11. Cytoprotection of FRDA cells depleted of glutathione. Following 
pretreatment with the indicated compounds (0.10 µM and 0.50 µM) for 17 h, the cells 
were treated with 5 mM of diethyl maleate for 6 h to deplete glutathione and to induce 
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oxidative stress. Trypan blue was used to determine cell viability. Cell viability was 
expressed as the percentage compared to the untreated control. Data are expressed as 
means ± SEM. (n = 3). This experiment was performed by Basab Roy. 
 
2.2.2.5 Assessment of maintenance of mitochondrial membrane potential (∆ψm) 
 The ability of these phenolic compounds to maintain mitochondrial membrane 
potential (∆ψm) was analyzed using FRDA cells depleted of glutathione. Diethyl 
maleate was used to deplete glutathione. Carbonyl cyanide-4-(trifluoromethyl) 
phenylhydrazone (FCCP) was used as a negative control, since FCCP depolarizes the 
mitochondrial membrane. JC-1 was used as a specific probe. JC-1 accumulates and 
attaches to healthy mitochondria exhibiting red fluorescence. Conversely, JC-1 
fluoresces green when mitochondria lose potential and aggregates of JC-1 do not 
form. Pretreatment of FRDA cells with phenolic compounds 2.10 (eight carbon chain, 
reduced core) and 2.14 (fourteen carbon chain, reduced core) protected the 
mitochondria partially at 1 µM. Interestingly, no protection was provided by either 
compound at 5 µM. These data show the importance of the optimal concentration of 
these phenolic compounds to obtain protection of mitochondria (Figure 2.12).  
The impact of these pyridinols in healthy FRDA cells (which means they were 
not treated with DEM) was also studied. The presence of compounds 2.10 (eight 
carbon chain, reduced core), 2.6 (ten carbon chain, reduced core), and 2.14 (fourteen 
carbon chain, reduced core) had no impact on mitochondrial potential at 1 µM. All 
these experiments were carried in absence of DEM. However, when the concentration 
was increased to 5 µM, all three compounds depolarized the mitochondria to different 
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degrees. The compound with the longest carbon chain 2.14 (fourteen carbon chain, 
reduced core) depolarized the mitochondria significantly, reaching levels comparable 
to FRDA cells treated with diethyl maleate. In contrast, the compound with the 
shortest chain 2.10 (eight carbon chain, reduced core) minimally depolarized the 
mitochondria (Figure 2.13).  
  
 
  
  
 
 
 
 
  
 
Figure 2.12. Maintenance of ∆ψm in FRDA cells depleted of glutathione. 
Representative flow cytometric two-dimensional color density dot plot analyses of 
∆ψm
 
in FRDA lymphocytes stained with JC-1. The percentage of cells with intact 
∆ψm
 
is indicated in the top left section of captions. In each analysis, 10,000 events 
2.10 (1 µM) 2.14 (1 µM) 
2.10 (5 µM) 2.14 (5 µM) 
control FCCP DEM 
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were recorded. Data are expressed as means ± SEM of three independent experiments 
run in duplicate. The bar graph shows the percentage of cells with intact ∆ψm
 
calculated using CellQuest software. This experiment was performed by Dr. Omar 
Khdour. 
 
 
 
 
 
 
  
 
 
 
 
Figure 2.13. Maintenance of ∆ψm in FRDA cells. Representative flow cytometric 
two-dimensional color density dot plot analyses of ∆ψm
 
in FRDA lymphocytes 
stained with JC-1. The percentage of cells with intact ∆ψm
 
is indicated in the top left 
section of captions. In each analysis, 10,000 events were recorded. Data are expressed 
as means ± SEM of three independent experiments run in duplicate. The bar graph 
control FCCP 
2.10 (1 µM) 2.6 (1 µM) 2.14 (1 µM) 
2.10 (5 µM) 2.6 (5 µM) 2.14 (5 µM) 
 42 
 
shows the percentage of cells with intact ∆ψm
 
calculated using CellQuest software. 
This experiment was performed by Dr. Omar Khdour. 
 
In conclusion, the best compounds to protect FRDA cells from lipid 
peroxidation and ROS are the pyridinols that possess twelve and fourteen carbon 
chain. However, it seems that cytoprotection is only afforded at low concentrations 
(250-500 nM). At higher concentrations (5 µM or higher), the data obtained from the 
mitochondrial membrane potential assay suggests that these compounds may be 
causing oxidative stress. 
 
2.3 Experimental Section 
General methods: Chemicals and solvents were of reagent grade and were used 
without further purification. Anhydrous tetrahydrofuran (THF) was distilled from 
sodium/benzophenone under argon. Anhydrous dichloromethane (CH2Cl2) was 
distilled from calcium hydride under argon. Anhydrous diethyl ether (Et2O) was 
distilled from sodium/benzophenone under argon. All reactions involving air or 
moisture sensitive reagents or intermediates were performed under an argon 
atmosphere. Flash chromatography was carried out using Silicycle 200-400 mesh 
silica gel. Analytical TLC was carried out using 0.25 mm EM silica gel 60 F250 
plates that were visualized by UV irradiation (254 nm) or by staining with ceric 
ammonium molybdate stain. 1H NMR and 13C NMR spectra were obtained using 400 
or 500 MHz Varian NMR spectrometers. Chemicals shifts were reported in parts per 
million (ppm, δ) referenced to the residual 1H resonance of the solvent (CDCl3, 7.26 
ppm; CD3CN, 1.94 ppm; C6D6, 7.16 ppm). 13C spectra were referenced to the residual 
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13C resonance of the solvent (CDCl3, 77.0 ppm; CD3CN, 1.32 ppm; C6D6, 128.06 
ppm)). Splitting patterns were designated as follows: s, singlet; br, broad; d, doublet; 
dd, doublet of doublets; t, triplet; q, quartet; quint, quintuplet; m, multiplet. High 
resolution mass spectra were obtained at the Arizona State University CLAS High 
Resolution Mass Spectrometry Laboratory. 
N OMe
OMe
 
2,2-Dimethoxy-1-methylpyrrolidine (2.25).121 A mixture containing 10.0 mL (10.3 
g, 104 mmol) of 1-methyl-2-pyrrolidinone and 10.0 mL (13.3 g, 105 mmol) of 
dimethyl sulfate was stirred and heated at 90 °C for 1.5 h, then allowed to cool to 
room temperature. A solution containing 25.0 mL of 25% methanolic sodium 
methoxide and 72.0 mL of methanol was added at −10 °C under Ar over a period of 1 
h. The precipitated solid was filtered and the solvent was concentrated under 
diminished pressure. The residue was dissolved in 100 mL of diethyl ether and stirred 
for 1 h, and then the precipitated solid was filtered. The solid was washed with two 
10-mL portions of diethyl ether. After concentration of the combined filtrate under 
diminished pressure, the residue was distilled under diminished pressure to give 2.25 
as a yellow liquid: yield 4.42 g (29%); 1H NMR (CDCl3) δ 1.50-1.61 (m, 2H), 1.71 (t, 
2H, J = 7.8 Hz), 2.14 (s, 6H), 2.64 (t, 2H, J = 6.6 Hz), and 3.01 (s, 3H). 
N N
 
1,4,6-Trimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (2.26).121 To a solution 
containing 1.20 g (12.1 mmol) of 4-amino-3-penten-2-one in 8 mL of toluene was 
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added 3.00 g (20.7 mmol) of 2.25. The reaction mixture was heated at reflux and 
stirred for 2 h, then cooled to 90 °C and treated with 2.38 g (24.8 mmol) of sodium 
tert-butoxide and 2 mL of tert-butanol. The reaction mixture was stirred at 90 °C for 
another 16 h. The cooled reaction mixture was quenched by the addition of 10 mL of 
sat aq NH4Cl. The reaction mixture was extracted with three 30-mL portions of ethyl 
acetate. The combined organic layer was washed with brine, dried over anh MgSO4, 
filtered, and concentrated under diminished pressure. The residue was purified via 
flash chromatography on a silica gel column (42 x 4 cm). Step gradient elution with 
1:4  1:1 ethyl acetate−hexanes as eluant gave 2.26 as a brown oil: yield 0.62 g 
(32%); silica gel TLC Rf 0.15 (1:4 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 1.91 
(s, 3H), 2.20 (s, 3H), 2.65 (t, 2H, J = 8.4 Hz), 2.76 (s, 3H), 3.23 (t, 2H, J = 8.4 Hz), 
and 5.98 (s, 1H). 
N N
 
1,4-Dimethyl-6-octyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (2.27). To a solution 
containing 490 mg (2.71 mmol) of 2.26 in 7.2 mL of tetrahydrofuran was added 2.70 
mL (4.34 mmol) of n-butyllithium (1.6 M in hexanes) followed by 450 µL (509 mg, 
2.85 mmol) of 1-bromoheptane at −78 °C. The reaction mixture was warmed slowly 
to room temperature and stirred for 16 h. The reaction mixture was quenched by the 
addition of 25 mL of sat aq NH4Cl at 0 °C. The reaction mixture was extracted with 
three 40-mL portions of ethyl acetate. The combined organic layer was washed with 
brine, dried over anh MgSO4, filtered, and concentrated under diminished pressure. 
The residue was purified via flash chromatography on a silica gel column (42 x 4 cm). 
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Step gradient elution with 1:9  1:4 ethyl acetate−hexanes as eluant gave 2.27 as a 
yellow oil: yield 402 mg (57%); silica gel TLC Rf 0.36 (8:1:1 hexanes−ethyl 
acetate−methanol); 1H NMR (CDCl3) δ 0.79 (t, 3H, J = 7.2 Hz), 1.16-1.30 (m, 10H), 
1.58 (quint, 2H, J = 8.0 Hz), 2.00 (s, 3H), 2.48 (t, 2H, J = 8.0 Hz), 2.72 (t, 2H, J = 8.4 
Hz), 2.82 (s, 3H), 3.30 (t, 2H, J = 8.4 Hz), and 6.05 (s, 1H); 13C NMR (CDCl3) δ 14.1, 
18.0, 22.7, 24.4, 29.4, 29.4, 29.6, 30.0, 32.0, 33.3, 38.1, 52.5, 112.5, 118.3, 141.2, 
159.2, and 163.8; mass spectrum (EI), m/z 260.2247 (M)+ (C17H28N2 requires 
260.2253).  
N N
Br
 
5-Bromo-1,4-dimethyl-6-octyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (2.28). To a 
solution containing 402 mg (1.54 mmol) of 2.27 in 6 mL of chloroform was added 
220 mg (0.77 mmol) of 1,3-dibromo-5,5-dimethylhydantoin in five portions at 0 °C. 
The reaction mixture was stirred at 0 °C for 30 min. The reaction mixture was 
quenched by the addition of 8 mL of sat aq NaHCO3. The reaction mixture was 
extracted with three 25-mL portions of chloroform. The combined organic layer was 
washed with brine, dried over anh MgSO4, filtered, and concentrated under 
diminished pressure. The residue was purified via flash chromatography on a silica 
gel column (43 x 4 cm). Step gradient elution with 1:9 ethyl acetate−hexanes as eluant 
gave 2.28 as a yellow oil: yield 371 mg (71%); silica gel TLC Rf 0.65 (8:1:1 
hexanes−ethyl acetate−methanol); 1H NMR (CDCl3) δ 0.87 (t, 3H, J = 6.0 Hz), 1.10-
1.43 (m, 10H), 1.67 (quint, 2H, J = 8.0 Hz), 2.14 (s, 3H), 2.75-2.82 (m, 4H), 2.75-
2.86 (s, 3H), and 3.37 (t, 2H, J = 8.4 Hz). 13C NMR (CDCl3) δ 14.1, 19.5, 22.7, 25.2, 
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28.7, 29.3, 29.5, 29.6, 31.9, 33.0, 38.1, 52.4, 110.9, 120.4, 141.1, 156.7, and 161.7; 
mass spectrum (APCI), m/z 339.1435 (M+H)+ (C17H28N2Br requires 339.1436).  
N N
AcO
 
1,4-Dimethyl-6-octyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl Acetate (2.11). 
To a solution containing 202 mg (0.60 mmol) of 2.28 in 5 mL of tetrahydrofuran was 
added 90.0 µL (69.7 mg, 0.60 mmol) of tetramethylethylenediamine at −78 °C 
followed by 0.75 mL (1.20 mmol) of n-butyllithium (1.6 M in hexanes). After 30 min, 
147 µL (137 mg, 1.32 mmol) of trimethoxyborane were added and the resulting 
reaction mixture was stirred for another 1 h. To the reaction mixture was added 
dropwise 277 µL (100 mg, 314 mg total solution, and 1.32 mmol) of peracetic acid 
(32% wt.) and the solution was then warmed to 0 °C. The reaction mixture was 
diluted with 20 mL of water and extracted with three 25-mL portions of ethyl acetate. 
The combined organic layer was washed with brine, dried over anh MgSO4, filtered, 
and concentrated under diminished pressure. The resulting oil was dissolved in 10 mL 
of dichloromethane at 0 °C, followed by the addition of 485 µL (352 mg, 3.48 mmol) 
of triethylamine, 6.10 mg (0.05 mmol) of 4-dimethylaminopyridine and 164 µL (177 
mg, 1.74 mmol) of acetic anhydride. The reaction mixture was stirred at room 
temperature for 1 h and quenched by the addition of 10 mL of sat aq NH4Cl. The 
solution was extracted with three 30-mL portions of ethyl acetate. The combined 
organic layer was washed with brine, dried over anh MgSO4, filtered, and 
concentrated under diminished pressure. The residue was purified via flash 
chromatography on a silica gel column (46 x 3 cm). Step gradient elution with 1:9  
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1:4 ethyl acetate−hexanes as eluant gave 2.11 as a yellow oil: yield 92.0 mg (48%); 
silica gel TLC Rf 0.22 (3:7 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.86 (t, 3H, J 
= 7.2 Hz), 1.21-1.37 (m, 10H), 1.62 (quint, 2H, J = 7.2 Hz), 1.94 (s, 3H), 2.30 (s, 3H), 
2.46 (t, 2H, J = 8.0 Hz), 2.83 (t, 2H, J = 8.4 Hz), 2.88 (s, 3H), and 3.42 (t, 2H, J = 8.4 
Hz); 13C NMR (CDCl3) δ 12.9, 14.1, 20.5, 22.6, 24.6, 28.7, 29.2, 29.5, 29.6, 31.9, 
32.5, 33.3, 52.8, 120.1, 134.7, 136.5, 149.6, 161.2, and 169.9; mass spectrum (ESI), 
m/z 319.2390 (M+H)+ (C19H31N2O2 requires 319.2386).  
N N
HO
.CF3COOH
 
1,4-Dimethyl-6-octyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-ol and its 
Trifluoroacetic Acid Salt (2.10). To a solution containing 20.4 mg (64.1 µmol) of 
2.11 in 1.0 mL of dichloromethane was added 200 µL (200 µmol) of 
diisobutylaluminium hydride (1.0 M in toluene) at −78 °C. The reaction mixture was 
stirred at the same temperature for 1 h before 2 mL of sat aq sodium potassium 
tartrate was added slowly. The reaction mixture was warmed slowly to room 
temperature over a period of 30 min. The solution was extracted with three 5-mL 
portions of ethyl acetate. The combined organic layer was washed with brine, dried 
over anh MgSO4, filtered, and concentrated under diminished pressure to give the 
crude product as a yellow oil: silica gel TLC Rf 0.22 (1:9 methanol−hexanes). The 
residue was then dissolved in 1 mL of acetonitrile and 1% aq trifluoroacetic acid 
(TFA), frozen and lyophilized. The crude product was purified on a Luna C8 reversed 
phase semi-preparative (250 x 10 mm) HPLC column using gradients of methanol and 
1% aq TFA. Linear gradients were employed using 1:4 methanol−1% aq TFA  4:1 
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methanol−1% aq TFA over a period of 20 min, and then 4:1 methanol−1% aq TFA  
methanol over a period of 40 min, at a flow rate of 3.5 mL/min (monitoring at 260 
nm). Fractions containing the desired product eluted at 28 min, and were combined, 
frozen, and lyophilized to give 2.10 as a light yellow solid: yield 18.4 mg 
(quantitative); 1H NMR (CD3CN) δ 0.91 (t, 3H, J = 7.0 Hz), 1.28-1.40 (m, 10H), 1.57 
(quint, 2H, J = 8.0 Hz), 2.15 (s, 3H), 2.72 (t, 2H, J = 8.0 Hz), 3.03 (t, 2H, J = 8.5 Hz), 
3.08 (s, 3H), 3.77 (t, 2H, J = 8.5 Hz), and 7.73 (br s, 1H); 13C NMR (CD3CN) δ 13.0, 
13.4, 22.4, 24.4, 27.3, 28.6, 28.7, 29.0, 29.0, 31.6, 32.4, 53.1, 126.3, 131.8, 140.3, 
141.6, and 152.0; mass spectrum (EI), m/z 276.2207 (M)+ (C17H28N2O2 requires 
276.2202).  
N N
AcO
 
1,4-Dimethyl-6-octyl-1H-pyrrolo[2,3-b]pyridin-5-yl Acetate (2.18). To a solution 
containing 65.0 mg (0.20 mmol) of 2.11 in 5 mL of benzene was added 56.0 mg (0.61 
mmol) of nickel peroxide. The reaction mixture was stirred at reflux for 18 h. The 
reaction mixture was filtered through a silica gel plug and washed with three 25-mL 
portions of benzene, followed by two 25-mL portions of ethyl acetate. The combined 
organic layer was washed with brine, dried over anh MgSO4, filtered, and 
concentrated under diminished pressure. The residue was purified via flash 
chromatography on a silica gel column (25 x 1.7 cm). Step gradient elution with 1:9 
 1:4 ethyl acetate−hexanes as eluant gave 2.18 as a colorless oil: yield 50 mg 
(48%); silica gel TLC Rf 0.29 (3:7 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.98 (t, 
3H, J = 7.2 Hz), 1.24-1.40 (m, 10H), 1.73 (quint, 2H, J = 7.6 Hz), 2.32 (s, 3H), 2.37 
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(s, 3H), 2.72 (t, 2H, J = 8.0 Hz), 3.83 (s, 3H), 6.38 (d, 1H, J = 3.6 Hz), and 7.07 (d, 
1H, J = 3.6 Hz); 13C NMR (CDCl3) δ 12.8, 14.1, 20.6, 22.7, 28.9, 29.3, 29.5, 29.7, 
31.3, 31.9, 33.2, 97.8, 119.4, 128.3, 131.0, 138.7, 144.9, 148.3, and 169.5; mass 
spectrum (FAB), m/z 317.2230 (M+H)+ (C19H29N2O2 requires 317.2229).  
N N
HO
.CF3COOH
 
1,4-Dimethyl-6-octyl-1H-pyrrolo[2,3-b]pyridin-5-ol and its Trifluoroacetic Acid 
Salt (2.17). To a solution containing 14.0 mg (44.2 µmol) of 2.18 in 1.0 mL of 
dichloromethane was added 140 µL (135 µmol) of diisobutylaluminium hydride (1.0 
M in toluene) at −78 °C. The reaction mixture was stirred at the same temperature for 
1 h before 2 mL of sat aq sodium potassium tartrate was added slowly. The reaction 
mixture was warmed slowly to room temperature over a period of 30 min. The 
solution was extracted with three 5-mL portions of ethyl acetate. The combined 
organic layer was washed with brine, dried over anh MgSO4, filtered, and 
concentrated under diminished pressure to give the crude product as a yellow oil: 
silica gel TLC Rf 0.39 (1:9 methanol−hexanes). The residue was then dissolved in 1 
mL of acetonitrile and 1% aq TFA, frozen and lyophilized. The crude product was 
purified on a Luna C8 reversed phase semi-preparative (250 x 10 mm) HPLC column 
using gradients of methanol and 1% aq TFA. Linear gradients were employed using 
1:4 methanol−1% aq TFA  4:1 methanol−1% aq TFA over a period of 20 min, and 
then 4:1 methanol−1% aq TFA  methanol over a period of 40 min, at a flow rate of 
3.5 mL/min (monitoring at 260 nm). Fractions containing the desired product eluted at 
28.6 min, and were combined, frozen, and lyophilized to give 2.17 as a colorless 
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solid: yield 13.6 mg (quantitative); 1H NMR (C6D6) δ 0.89 (t, 3H, J = 7.5 Hz), 1.21-
1.48 (m, 10H), 2.00 (quint, 2H, J = 8.0 Hz), 2.18 (s, 3H), 2.20 (t, 2H, J = 8.0 Hz), 
3.42 (s, 3H), 4.25 (br s, 1H), 6.29 (d, 1H, J = 3.5 Hz), and 6.60 (d, 1H, J = 2.5 Hz); 
13C NMR (C6D6) δ 12.0, 14.4, 23.1, 29.4, 29.8, 29.9, 30.1, 30.2, 30.9, 32.3, 33.6, 97.2, 
120.1, 123.9, 143.2, 143.3, and 145.0; mass spectrum (EI), m/z 274.2043 (M)+ 
(C17H26N2O requires 274.2045).  
N N
 
1,4-Dimethyl-6-decyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (2.29).121 To a 
solution containing 600 mg (3.70 mmol) of 2.26 in 10 mL of tetrahydrofuran was 
added 3.70 mL (5.92 mmol) of n-butyllithium (1.6 M in hexanes) followed by 742 µL 
(805 mg, 3.89 mmol) of 1-bromononane at −78 °C. The reaction mixture was warmed 
slowly to room temperature and stirred for 16 h. The reaction mixture was quenched 
by the addition of 35 mL of sat aq NH4Cl at 0 °C. The reaction mixture was extracted 
with three 60-mL portions of ethyl acetate. The combined organic layer was washed 
with brine, dried over anh MgSO4, filtered, and concentrated under diminished 
pressure. The residue was purified via flash chromatography on a silica gel column 
(43 x 4 cm). Step gradient elution with 1:9  1:4 ethyl acetate−hexanes as eluant 
gave 2.29 as a yellow oil: yield 448 mg (42%); silica gel TLC Rf 0.44 (8:1:1 
hexanes−ethyl acetate−methanol); 1H NMR (CDCl3) δ 0.89 (t, 3H, J = 7.2 Hz), 1.22-
1.40 (m, 14H), 1.67 (quint, 2H, J = 8.0 Hz), 2.09 (s, 3H), 2.57 (t, 2H, J = 8.0 Hz), 
2.82 (t, 2H, J = 8.0 Hz), 2.92 (s, 3H), 3.40 (t, 2H, J = 8.0 Hz), and 6.14 (s, 1H). 13C 
NMR (CDCl3) δ 14.2, 18.1, 22.8, 24.5, 29.5, 29.6, 29.7, 29.7, 29.8, 30.0, 32.0, 33.3, 
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38.1, 52.6, 112.5, 118.3, 141.2, 159.2, and 163.8; mass spectrum (EI), m/z 288.2563 
(M)+ (C19H32N2 requires 288.2566).  
N N
Br
 
5-Bromo-1,4-dimethyl-6-decyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (2.30).121 
To a solution containing 100 mg (0.35 mmol) of 2.29 in 1.4 mL of chloroform was 
added 50.0 mg (0.18 mmol) of 1,3-dibromo-5,5-dimethylhydantoin in five portions at 
0 °C. The reaction mixture was stirred at 0 °C for 30 min. The reaction mixture was 
quenched by the addition of 2 mL of sat aq NaHCO3. The reaction mixture was 
extracted with three 15-mL portions of chloroform. The combined organic layer was 
washed with brine, dried over anh MgSO4, filtered, and concentrated under 
diminished pressure. The residue was purified via flash chromatography on a silica 
gel column (43 x 2.5 cm). Step gradient elution with 1:9 ethyl acetate−hexanes as 
eluant gave 2.30 as a yellow oil: yield 112 mg (87%); silica gel TLC Rf 0.70 (8:1:1 
hexanes−ethyl acetate−methanol); 1H NMR (CDCl3) δ 0.89 (t, 3H, J = 6.8 Hz), 1.23-
1.42 (m, 14H), 1.68 (quint, 2H, J = 7.6 Hz), 2.19 (s, 3H), 2.79 (t, 2H, J = 8.0 Hz), 
2.84-2.90 (m, 5H), and 3.42 (t, 2H, J = 8.0 Hz). 13C NMR (CDCl3) δ 14.3, 19.6, 22.8, 
25.4, 28.8, 29.5, 29.7, 29.7, 29.8, 29.8, 32.1, 33.1, 38.3, 52.6, 111.1, 120.5, 141.2, 
156.9, and 161.9; mass spectrum (FAB), m/z 367.1745 (M+H)+ (C19H32BrN2 requires 
367.1749).  
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N N
AcO
 
1,4-Dimethyl-6-decyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl Acetate (2.7).121 
To a solution containing 293 mg (0.80 mmol) of 2.30 in 7 mL of tetrahydrofuran was 
added 113 µL (87.1 mg, 0.80 mmol) of tetramethylethylenediamine at −78 °C 
followed by 0.94 mL (1.50 mmol) of n-butyllithium (1.6 M in hexanes). After 30 min, 
184 µL (171 mg, 1.65 mmol) of trimethoxyborane was added and the resulting 
reaction mixture was stirred for another 1 h. To the reaction mixture was added 
dropwise 346 µL (125 mg, 393 mg total solution, and 1.65 mmol) of peracetic acid 
(32% wt.) and the solution was then warmed to 0 °C. The reaction mixture was 
diluted with 25 mL of water and extracted with three 35-mL portions of ethyl acetate. 
The combined organic layer was washed with brine, dried over anh MgSO4, filtered, 
and concentrated under diminished pressure. The resulting oil was dissolved in 13 mL 
of dichloromethane at 0 °C, followed by the addition of 606 µL (440 mg, 4.36 mmol) 
of triethylamine, 8.50 mg (0.07 mmol) of 4-dimethylaminopyridine and 205 µL (221 
mg, 2.18 mmol) of acetic anhydride. The reaction mixture was stirred at room 
temperature for 1 h and quenched by the addition of 12 mL of sat aq NH4Cl. The 
solution was extracted with three 40-mL portions of ethyl acetate. The combined 
organic layer was washed with brine, dried over anh MgSO4, filtered, and 
concentrated under diminished pressure. The residue was purified via flash 
chromatography on a silica gel column (43 x 2.5 cm). Step gradient elution with 1:9 
 1:4 ethyl acetate−hexanes as eluant gave 2.7 as a yellow oil: yield 118 mg (43%); 
silica gel TLC Rf 0.25 (3:7 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.88 (t, 3H, J 
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= 6.8 Hz), 1.22-1.37 (m, 14H), 1.62 (quint, 2H, J = 7.6 Hz), 1.94 (s, 3H), 2.30 (s, 3H), 
2.46 (t, 2H, J = 8.0 Hz), 2.83 (t, 2H, J = 8.0 Hz), 2.88 (s, 3H), and 3.42 (t, 2H, J = 8.4 
Hz); 13C NMR (CDCl3) δ 12.9, 14.1, 20.5, 22.7, 24.6, 28.7, 29.3, 29.5, 29.5, 29.6, 
29.6, 31.9, 32.5, 33.3, 52.8, 120.1, 134.7, 136.5, 149.6, 161.1, and 169.9; mass 
spectrum (EI), m/z 346.2624 (M)+ (C21H34N2O2 requires 346.2620).  
N N
HO
.CF3COOH
 
1,4-Dimethyl-6-decyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-ol and its 
Trifluoroacetic Acid Salt (2.6).121 To a solution containing 21.1 mg (48.0 µmol) of 
2.7 in 1.0 mL of dichloromethane was added 190 µL (19 µmol) of 
diisobutylaluminium hydride (1.0 M in toluene) at −78 °C. The reaction mixture was 
stirred at the same temperature for 1 h before 2 mL of sat aq sodium potassium 
tartrate was added slowly. The reaction mixture was warmed slowly to room 
temperature over a period of 30 min. The solution was extracted with three 5-mL 
portions of ethyl acetate. The combined organic layer was washed with brine, dried 
over anh MgSO4, filtered, and concentrated under diminished pressure to give the 
crude product as a yellow oil: silica gel TLC Rf 0.28 (1:9 methanol−hexanes). The 
residue was then dissolved in 1 mL of acetonitrile and 1% aq TFA, frozen and 
lyophilized. The crude product was purified on a Luna C8 reversed phase semi-
preparative (250 x 10 mm) HPLC column using gradients of methanol and 1% aq 
TFA. Linear gradients were employed using 1:4 methanol−1% aq TFA  4:1 
methanol−1% aq TFA over a period of 20 min, and then 4:1 methanol−1% aq TFA  
methanol over a period of 40 min, at a flow rate of 3.5 mL/min (monitoring at 260 
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nm). Fractions containing the desired product eluted at 30 min, and were combined, 
frozen, and lyophilized to give 2.6 as a light yellow solid: yield 15.3 mg (83%); 1H 
NMR (CD3CN) δ 0.88 (t, 3H, J = 7.5 Hz), 1.21-1.35 (m, 14H), 1.53 (quint, 2H, J = 
7.5 Hz), 2.12 (s, 3H), 2.68 (t, 2H, J = 8.0 Hz), 2.99 (t, 2H, J = 8.5 Hz), 3.05 (s, 3H), 
3.73 (t, 2H, J = 8.5 Hz), and 5.57 (br s, 1H); 13C NMR (CD3CN) δ 13.0, 13.4, 22.4, 
24.4, 27.3, 28.6, 29.0, 29.1, 29.1, 29.3, 29.3, 31.7, 32.4, 53.1, 126.2, 131.9, 140.3, 
141.6, and 152.0; mass spectrum (APCI), m/z 305.2593 (M+H)+ (C19H33N2O requires 
305.2593).  
N N
AcO
 
1,4-Dimethyl-6-decyl-1H-pyrrolo[2,3-b]pyridin-5-yl Acetate (2.20). To a solution 
containing 51.0 mg (0.15 mmol) of 2.7 in 4 mL of benzene was added 42.0 mg (0.46 
mmol) of nickel peroxide. The reaction mixture was stirred at reflux for 18 h. The 
reaction mixture was filtered through a silica gel plug and washed with three 20-mL 
portions of benzene, followed by two 20-mL portions of ethyl acetate. The combined 
organic layer was washed with brine, dried over anh MgSO4, filtered, and 
concentrated under diminished pressure. The residue was purified via flash 
chromatography on a silica gel column (27 x 1.7 cm). Step gradient elution with 1:9 
 1:4 ethyl acetate−hexanes as eluant gave 2.20 as a colorless oil: yield 35.0 mg 
(63%); silica gel TLC Rf 0.35 (3:7 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.88 (t, 
3H, J = 6.8 Hz), 1.23-1.40 (m, 14H), 1.73 (quint, 2H, J = 7.6 Hz), 2.32 (s, 3H), 2.37 
(s, 3H), 2.72 (t, 2H, J = 8.0 Hz), 3.83 (s, 3H), 6.37 (d, 1H, J = 3.6 Hz), and 7.07 (d, 
1H, J = 3.6 Hz); 13C NMR (CDCl3) δ 12.8, 14.1, 20.6, 22.7, 28.9, 29.3, 29.5, 29.6, 
 55 
 
29.6, 29.7, 31.3, 31.9, 33.3, 97.8, 119.4, 128.4, 131.0, 138.7, 144.9, 148.3, and 169.5; 
mass spectrum (EI), m/z 344.2459 (M)+ (C21H32N2O2 requires 344.2464).  
N N
HO
.CF3COOH
 
1,4-Dimethyl-6-decyl-1H-pyrrolo[2,3-b]pyridin-5-ol and its Trifluoroacetic Acid 
Salt (2.19). To a solution containing 20.5 mg (59.5 µmol) of 2.20 in 1.0 mL of 
dichloromethane was added 180 µL (180 µmol) of diisobutylaluminium hydride (1.0 
M in toluene) at −78 °C. The reaction mixture was stirred at the same temperature for 
1 h before 2 mL of sat aq sodium potassium tartrate was added slowly. The reaction 
mixture was warmed slowly to room temperature over a period of 30 min. The 
solution was extracted with three 5-mL portions of ethyl acetate. The combined 
organic layer was washed with brine, dried over anh MgSO4, filtered, and 
concentrated under diminished pressure to give the crude product as a yellow oil: 
silica gel TLC Rf 0.43 (1:9 methanol−hexanes). The residue was then dissolved in 1 
mL of acetonitrile and 1% aq TFA, frozen and lyophilized. The crude product was 
purified on a Luna C8 reversed phase semi-preparative (250 x 10 mm) HPLC column 
using gradients of methanol and 1% aq TFA. Linear gradients were employed using 
1:4 methanol−1% aq TFA  4:1 methanol−1% aq TFA over a period of 20 min, and 
then 4:1 methanol−1% aq TFA  methanol over a period of 40 min, at a flow rate of 
3.5 mL/min (monitoring at 260 nm). Fractions containing the desired product eluted at 
31 min, and were combined, frozen, and lyophilized to give 2.19 as a colorless solid: 
yield 12.8 mg (71%); 1H NMR (C6D6) δ 0.91 (t, 3H, J = 7.2 Hz), 1.20-1.48 (m, 14H), 
2.01 (quint, 2H, J = 7.6 Hz), 2.18 (s, 3H), 3.07 (t, 2H, J = 7.6 Hz), 3.42 (s, 3H), 4.13 
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(s, 1H), 6.29 (d, 1H, J = 3.2 Hz), and 6.60 (d, 1H, J = 3.2 Hz); 13C NMR (C6D6) δ 
11.5, 14.0, 22.7, 29.0, 29.4, 29.7, 29.7, 29.8, 29.8, 29.9, 30.5, 31.9, 33.2, 96.8, 119.6, 
123.4, 142.7, 142.9, and 144.6; mass spectrum (APCI), m/z 303.2435 (M+H)+ 
(C19H31N2O requires 303.2436).  
N N
 
1,4-Dimethyl-6-dodecyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (2.31). To a 
solution containing 300 mg (1.85 mmol) of 2.26 in 5 mL of tetrahydrofuran was 
added 1.75 mL (2.80 mmol) of n-butyllithium (1.6 M in hexanes) followed by 498 µL 
(524 mg, 2.23 mmol) of 1-bromoundecane at −78 °C. The reaction mixture was 
warmed slowly to room temperature and stirred for 16 h. The reaction mixture was 
quenched by the addition of 18 mL of sat aq NH4Cl at 0 °C. The reaction mixture was 
extracted with three 30-mL portions of ethyl acetate. The combined organic layer was 
washed with brine, dried over anh MgSO4, filtered, and concentrated under 
diminished pressure. The residue was purified via flash chromatography on a silica 
gel column (28 x 2.5 cm). Step gradient elution with 1:9  1:4 ethyl acetate−hexanes 
as eluant gave 2.31 as a yellow oil: yield 240 mg (41%); silica gel TLC Rf 0.49 (8:1:1 
hexanes−ethyl acetate−methanol); 1H NMR (CDCl3) δ 0.88 (t, 3H, J = 7.2 Hz), 1.20-
1.38 (m, 18H), 1.66 (quint, 2H, J = 7.6 Hz), 2.08 (s, 3H), 2.56 (t, 2H, J = 8.0 Hz), 
2.81 (t, 2H, J = 8.0 Hz), 2.91 (s, 3H), 3.39 (t, 2H, J = 8.4 Hz), and 6.13 (s, 1H); 13C 
NMR (CDCl3) δ 14.2, 18.0, 22.8, 24.5, 29.5, 29.5, 29.7, 29.7, 29.7, 29.8, 29.8, 30.0, 
32.0, 33.3, 38.2, 52.5, 112.5, 118.3, 141.2, 159.3, and 163.8; mass spectrum (EI), m/z 
316.2869 (M)+ (C21H36N2 requires 316.2879).  
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N N
Br
 
5-Bromo-1,4-dimethyl-6-dodecyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (2.32). 
To a solution containing 240 mg (0.61 mmol) of 2.31 in 2.5 mL of chloroform was 
added 85.0 mg (0.31 mmol) of 1,3-dibromo-5,5-dimethylhydantoin in five portions at 
0 °C. The reaction mixture was stirred at 0 °C for 30 min. The reaction mixture was 
quenched by the addition of 3.2 mL of sat aq NaHCO3. The reaction mixture was 
extracted with three 15-mL portions of chloroform. The combined organic layer was 
washed with brine, dried over anh MgSO4, filtered, and concentrated under 
diminished pressure. The residue was purified via flash chromatography on a silica 
gel column (28 x 2.5 cm). Step gradient elution with 1:9  1:4 ethyl acetate−hexanes 
as eluant gave 2.32 as a yellow oil: yield 251 mg (84%); silica gel TLC Rf 0.74 (8:1:1 
hexanes−ethyl acetate−methanol); 1H NMR (CDCl3) δ 0.88 (t, 3H, J = 6.4 Hz), 1.25-
1.40 (m, 18H), 1.67 (quint, 2H, J = 7.6 Hz), 2.17 (s, 3H), 2.78 (t, 2H, J = 8.0 Hz), 
2.82-2.89 (m, 5H), and 3.40 (t, 2H, J = 8.4 Hz); 13C NMR (CDCl3) δ 14.2, 19.6, 22.8, 
25.3, 28.8, 29.5, 29.5, 29.7, 29.7, 29.8, 29.8, 29.8, 32.1, 33.1, 38.3, 52.5, 111.0, 120.4, 
141.2, 156.9, and 161.9; mass spectrum (EI), m/z 394.1980 (M)+ (C21H35BrN2 
requires 394.1984).  
N N
AcO
 
1,4-Dimethyl-6-dodecyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl Acetate 
(2.13). To a solution containing 258 mg (0.65 mmol) of 2.32 in 6.5 mL of 
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tetrahydrofuran was added 100 µL (75.8 mg, 0.65 mmol) of 
tetramethylethylenediamine at −78 °C followed by 815 µL (1.31 mmol) of n-
butyllithium (1.6 M in hexanes). After 30 min, 155 µL (142 mg, 1.37 mmol) of 
trimethoxyborane was added and the resulting reaction mixture was stirred for another 
1 h. To the reaction mixture was added dropwise 290 µL (104 mg, 326 mg total 
solution, 1.37 mmol) of peracetic acid (32% wt.) and the solution was then warmed to 
0 °C. The reaction mixture was diluted with 25 mL of water and extracted with three 
35-mL portions of ethyl acetate. The combined organic layer was washed with brine, 
dried over anh MgSO4, filtered, and concentrated under diminished pressure. The 
resulting oil was dissolved in 13 mL of dichloromethane at 0 °C, followed by the 
addition of 520 µL (376 mg, 3.72 mmol) of triethylamine, 6.40 mg (0.05 mmol) of 4-
dimethylaminopyridine and 180 µL (193 mg, 1.89 mmol) of acetic anhydride. The 
reaction mixture was stirred at room temperature for 1 h and quenched by the addition 
of 12 mL of sat aq NH4Cl. The solution was extracted with three 40-mL portions of 
ethyl acetate. The combined organic layer was washed with brine, dried over anh 
MgSO4, filtered, and concentrated under diminished pressure. The residue was 
purified via flash chromatography on a silica gel column (43 x 2.5 cm). Step gradient 
elution with 1:9  1:4 ethyl acetate−hexanes as eluant gave 2.13 as a yellow oil: 
yield 120 mg (49%); silica gel TLC Rf 0.30 (3:7 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 0.88 (t, 3H, J = 7.2 Hz), 1.25-1.37 (m, 18H), 1.62 (quint, 2H, J = 6.8 Hz), 
1.94 (s, 3H), 2.30 (s, 3H), 2.46 (t, 2H, J = 8.0 Hz), 2.83 (t, 2H, J = 8.4 Hz), 2.88 (s, 
3H), and 3.43 (t, 2H, J = 8.0 Hz); 13C NMR (CDCl3) δ 12.9, 14.1, 20.5, 22.7, 24.6, 
28.7, 29.3, 29.5, 29.5, 29.6, 29.6, 29.7, 29.7, 31.9, 32.5, 33.3, 52.8, 120.1, 134.7, 
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136.5, 149.6, 161.1, and 169.9; mass spectrum (EI), m/z 374.2939 (M)+ (C23H38N2O2 
requires 374.2933).  
N N
HO
.CF3COOH
 
1,4-Dimethyl-6-dodecyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-ol and its 
Trifluoroacetic Acid Salt (2.12). To a solution containing 14.2 mg (37.9 µmol) of 
2.13 in 1.0 mL of dichloromethane was added 120 µL (120 µmol) of 
diisobutylaluminium hydride (1.0 M in toluene) at −78 °C. The reaction mixture was 
stirred at the same temperature for 1 h before 2 mL of sat aq sodium potassium 
tartrate was added slowly. The reaction mixture was warmed slowly to room 
temperature over a period of 30 min. The solution was extracted with three 5-mL 
portions of ethyl acetate. The combined organic layer was washed with brine, dried 
over anh MgSO4, filtered, and concentrated under diminished pressure to give the 
crude product as a yellow oil: silica gel TLC Rf 0.34 (1:9 methanol−hexanes). The 
residue was then dissolved in 1 mL of acetonitrile and 1% aq TFA, frozen and 
lyophilized. The crude product was purified on a Luna C8 reversed phase semi-
preparative (250 x 10 mm) HPLC column using gradients of methanol and 1% aq 
TFA. Linear gradients were employed using 1:4 methanol−1% aq TFA  4:1 
methanol−1% aq TFA over a period of 20 min, and then 4:1 methanol−1% aq TFA  
methanol over a period of 40 min, at a flow rate of 3.5 mL/min (monitoring at 260 
nm). Fractions containing the desired product eluted at 32 min, and were combined, 
frozen, and lyophilized to give 2.12 as a light yellow solid: yield 8.4 mg (67%); 1H 
NMR (CD3CN) δ 0.88 (t, 3H, J = 7.2 Hz), 1.21-1.45 (m, 18 H), 1.54 (m, 2H), 2.12 (s, 
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3H), 2.68 (t, 2H, J = 8.8 Hz), 2.99 (t, 2H, J = 8.4 Hz), 3.05 (s, 3H), 3.73 (t, 2H, J = 8.4 
Hz), and 5.05 (br s, 1H); 13C NMR (CD3CN) δ 13.0, 13.4, 22.3, 24.4, 27.2, 28.6, 29.0, 
29.1, 29.3, 29.3, 29.3, 29.4, 29.9, 31.6, 32.4, 53.1, 126.2, 131.9, 140.3, 141.5, and 
152.0; mass spectrum (APCI), m/z 333.2907 (M+H)+ (C21H37N2O requires 333.2906).  
N N
AcO
 
1,4-Dimethyl-6-dodecyl-1H-pyrrolo[2,3-b]pyridin-5-yl Acetate (2.22). The 
chromatographic procedure described previously to obtain to 2.13 also gave 2.22 as 
colorless solid: yield 58 mg (25%); silica gel TLC Rf 0.40 (3:7 ethyl 
acetate−hexanes); 1H NMR (CDCl3) δ 0.88 (t, 3H, J = 6.8 Hz), 1.23-1.40 (m, 18H), 
1.73 (m, 2H), 2.32 (s, 3H), 2.37 (s, 3H), 2.72 (t, 2H, J = 8.0 Hz), 3.83 (s, 3H), 6.37 (d, 
1H, J = 3.2 Hz), and 7.07 (d, 1H, J = 3.2 Hz). 13C NMR (CDCl3) δ 12.8, 14.1, 14.2, 
20.6, 22.7, 28.9, 29.3, 29.5, 29.6, 29.6, 29.7, 31.2, 31.9, 33.3, 60.3, 97.8, 119.4, 128.3, 
131.0, 138.7, 144.9, 148.3, and 169.5; mass spectrum (ESI), m/z 372.2773 (M)+ 
(C23H36N2O2 requires 372.2777).  
N N
HO
.CF3COOH
 
1,4-Dimethyl-6-dodecyl-1H-pyrrolo[2,3-b]pyridin-5-ol and its Trifluoroacetic 
Acid Salt (2.21). To a solution containing 19.0 mg (59.5 µmol) of 2.22 in 0.8 mL of 
dichloromethane was added 160 µL (160 µmol) of diisobutylaluminium hydride (1.0 
M in toluene) at −78 °C. The reaction mixture was stirred at the same temperature for 
1 h before 2 mL of sat aq sodium potassium tartrate was added slowly. The reaction 
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mixture was warmed slowly to room temperature over a period of 30 min. The 
solution was extracted with three 5-mL portions of ethyl acetate. The combined 
organic layer was washed with brine, dried over anh MgSO4, filtered, and 
concentrated under diminished pressure to give the crude product as a yellow oil: 
silica gel TLC Rf 0.47 (1:9 methanol−hexanes). The residue was then dissolved in 1 
mL of acetonitrile and 1% aq TFA, frozen and lyophilized. The crude product was 
purified on a Luna C8 reversed phase semi-preparative (250 x 10 mm) HPLC column 
using gradients of methanol and 1% aq TFA. Linear gradients were employed using 
1:4 methanol−1% aq TFA  4:1 methanol−1% aq TFA over a period of 20 min, and 
then 4:1 methanol−1% aq TFA  methanol over a period of 40 min, at a flow rate of 
3.5 mL/min (monitoring at 260 nm). Fractions containing the desired product eluted at 
32.5 min, and were combined, frozen, and lyophilized to give 2.21 as a colorless 
solid: yield 9.9 mg (59%); 1H NMR (C6D6) δ 0.92 (t, 3H, J = 6.8 Hz), 1.28-1.55 (m, 
18H), 2.02 (quint, 2H, J = 8.0 Hz), 2.17 (s, 3H), 3.06 (t, 2H, J = 7.6 Hz), 3.42 (s, 3H), 
4.03 (s, 1H), 6.30 (d, 1H, J = 3.6 Hz), and 6.60 (d, 1H, J = 3.6 Hz); 13C NMR (C6D6) 
δ 11.5, 14.0, 22.7, 29.0, 29.4, 29.5, 29.7, 29.7, 29.7, 29.8, 29.8, 29.8, 30.5, 31.9, 33.2, 
96.8, 119.6, 123.3, 142.8, 142.9, and 144.6; mass spectrum (APCI), m/z 331.2741 
(M+H)+ (C21H35N2O requires 331.2749).  
N N
 
1,4-Dimethyl-6-tetradecyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (2.33). To a 
solution containing 300 mg (1.85 mmol) of 2.26 in 5 mL of tetrahydrofuran was 
added 1.75 mL (2.80 mmol) of n-butyllithium (1.6 M in hexanes) followed by 498 µL 
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(524 mg, 2.23 mmol) of 1-bromotridecane at −78 °C. The reaction mixture was 
warmed slowly to room temperature and stirred for 16 h. The reaction mixture was 
quenched by the addition of 18 mL of sat aq NH4Cl at 0 °C. The reaction mixture was 
extracted with three 30-mL portions of ethyl acetate. The combined organic layer was 
washed with brine, dried over anh MgSO4, filtered, and concentrated under 
diminished pressure. The residue was purified via flash chromatography on a silica 
gel column (28 x 2.5 cm). Step gradient elution with 1:9  1:4 ethyl acetate−hexanes 
as eluant gave 2.33 as a yellow oil: yield 240 mg (64%); silica gel TLC Rf 0.53 (8:1:1 
hexanes−ethyl acetate−methanol); 1H NMR (CDCl3) δ 0.88 (t, 3H, J = 6.8 Hz), 1.24-
1.38 (m, 22H), 1.67 (quint, 2H, J = 7.6 Hz), 2.06 (s, 3H), 2.55 (t, 2H, J = 7.6 Hz), 
2.79 (m, 2H), 2.89 (s, 3H), 3.36 (m, 2H), and 6.12 (s, 1H); 13C NMR (CDCl3) δ 14.1, 
17.9, 22.6, 24.4, 29.4, 29.5, 29.5, 29.6, 29.7, 29.7, 29.7, 29.8, 29.9, 31.9, 33.1, 33.2, 
38.1, 52.9, 112.4, 118.1, 140.9, 159.1, and 163.7; mass spectrum (EI), m/z 344.3196 
(M)+ (C23H40N2 requires 344.3192).  
N N
Br
 
5-Bromo-1,4-dimethyl-6-dodecyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (2.34). 
To a solution containing 240 mg (0.61 mmol) of 2.33 in 2.5 mL of chloroform was 
added 85.0 mg (0.31 mmol) of 1,3-dibromo-5,5-dimethylhydantoin in five portions at 
0 °C. The reaction mixture was stirred at 0 °C for 30 min. The reaction mixture was 
quenched by the addition of 3.2 mL of sat aq NaHCO3. The reaction mixture was 
extracted with three 15-mL portions of chloroform. The combined organic layer was 
washed with brine, dried over anh MgSO4, filtered, and concentrated under 
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diminished pressure. The residue was purified via flash chromatography on a silica 
gel column (28 x 2.5 cm). Step gradient elution with 1:9  1:4 ethyl acetate−hexanes 
as eluant gave 2.34 as a yellow oil: yield 251 mg (66%); silica gel TLC Rf 0.76 (8:1:1 
hexanes−ethyl acetate−methanol); 1H NMR (CDCl3) δ 0.89 (t, 3H, J = 6.8 Hz), 1.25-
1.46 (m, 22H), 1.67 (quint, 2H, J = 8.0 Hz), 2.19 (s, 3H), 2.80 (t, 2H, J = 8.4 Hz), 
2.84-2.90 (m, 5H), and 3.42 (t, 2H, J = 8.4 Hz); 13C NMR (CDCl3) δ 14.3, 19.6, 22.8, 
23.1, 23.9, 25.4, 28.8, 29.5, 29.7, 29.8, 29.8, 30.5, 31.4, 32.1, 33.1, 38.3, 38.9, 52.6, 
111.1, 120.5, 141.3, 156.9, and 161.9; mass spectrum (EI), m/z 422.2307 (M)+ 
(C23H39BrN2 requires 422.2297).  
N N
AcO
 
1,4-Dimethyl-6-tetradecyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl Acetate 
(2.15). To a solution containing 490 mg (1.16 mmol) of 2.34 in 11.5 mL of 
tetrahydrofuran was added 175 µL (134 mg, 1.16 mmol) of 
tetramethylethylenediamine at −78 °C followed by 1.44 mL (2.31 mmol) of n-
butyllithium (1.6 M in hexanes). After 30 min, 270 µL (252 mg, 2.43 mmol) of 
trimethoxyborane was added and the resulting mixture was stirred for another 1 h. To 
the reaction mixture was added dropwise 511 µL (185 mg, 577 mg total solution, and 
2.43 mmol) of peracetic acid (32% wt.) and the solution was then warmed to 0 °C. 
The reaction mixture was diluted with 50 mL of water and extracted with three 70-mL 
portions of ethyl acetate. The combined organic layer was washed with brine, dried 
over anh MgSO4, filtered, and concentrated under diminished pressure. The resulting 
oil was dissolved in 23 mL of dichloromethane at 0 °C, followed by the addition of 
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920 µL (667 mg, 6.60 mmol) of triethylamine, 11.0 mg (0.09 mmol) of 4-
dimethylaminopyridine and 317 µL (343 mg, 3.36 mmol) of acetic anhydride. The 
reaction mixture was stirred at room temperature for 1 h and quenched by the addition 
of 25 mL of sat aq NH4Cl. The solution was extracted with three 80-mL portions of 
ethyl acetate. The combined organic layer was washed with brine, dried over anh 
MgSO4, filtered, and concentrated under diminished pressure. The residue was 
purified via flash chromatography on a silica gel column (43 x 2.5 cm). Step gradient 
elution with 1:9  1:4 ethyl acetate−hexanes as eluant gave 2.15 as a yellow oil: 
yield 140 mg (29%); silica gel TLC Rf 0.36 (3:7 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 0.88 (t, 3H, J = 7.2 Hz), 1.20-1.38 (m, 22H), 1.62 (quint, 2H, J = 7.6 Hz), 
1.94 (s, 3H), 2.29 (s, 3H), 2.46 (t, 2H, J = 8.0 Hz), 2.83 (t, 2H, J = 8.4 Hz), 2.88 (s, 
3H), and 3.42 (t, 2H, J = 8.0 Hz); 13C NMR (CDCl3) δ 13.0, 14.3, 20.6, 22.8, 24.8, 
28.7, 28.7, 28.8, 28.8, 28.8, 29.5, 29.6, 29.7, 29.8, 29.8, 32.0, 32.6, 33.4, 52.9, 120.2, 
134.8, 136.7, 149.8, 161.3, and 170.0; mass spectrum (FAB), m/z 403.3326 (M+H)+ 
(C25H43N2O2 requires 403.3325).  
N N
HO
.CF3COOH
 
1,4-Dimethyl-6-tetradecyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-ol and its 
Trifluoroacetic Acid Salt (2.14). To a solution containing 20.0 mg (49.7 µmol) of 
2.15 in 0.8 mL of dichloromethane was added 150 µL (150 µmol) of 
diisobutylaluminium hydride (1.0 M in toluene) at −78 °C. The reaction mixture was 
stirred at the same temperature for 1 h before 2 mL of sat aq sodium potassium 
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tartrate was added slowly. The reaction mixture was warmed slowly to room 
temperature over a period of 30 min. The solution was extracted with three 5-mL 
portions of ethyl acetate. The combined organic layer was washed with brine, dried 
over anh MgSO4, filtered, and concentrated under diminished pressure to give the 
crude product as a yellow oil: silica gel TLC Rf 0.41 (1:9 methanol−hexanes). The 
residue was then dissolved in 1 mL of acetonitrile and 1% aq TFA, frozen and 
lyophilized. The crude product was purified on a Luna C8 reversed phase semi-
preparative (250 x 10 mm) HPLC column using gradients of methanol and 1% aq 
TFA. Linear gradients were employed using 1:4 methanol−1% aq TFA  4:1 
methanol−1% aq TFA over a period of 20 min, and then 4:1 methanol−1% aq TFA  
methanol over a period of 40 min, at a flow rate of 3.5 mL/min (monitoring at 260 
nm). Fractions containing the desired product eluted at 34 min, and were combined, 
frozen, and lyophilized to give 2.14 as a light yellow solid: yield 17.7 mg (99%); 1H 
NMR (CD3CN) δ 0.92 (t, 3H, J = 7.5 Hz), 1.28-1.40 (m, 22H), 1.58 (quint, 2H, J = 
7.0 Hz), 2.16 (s, 3H), 2.72 (t, 2H, J = 8.5 Hz), 3.03 (t, 2H, J = 8.5 Hz), 3.09 (s, 3H), 
3.77 (t, 2H, J = 8.5 Hz), and 4.77 (br s, 1H); 13C NMR (CD3CN) δ 13.0, 13.4, 22.4, 
24.4, 27.3, 28.6, 29.0, 29.1, 29.1, 29.2, 29.3, 29.3, 29.4, 29.4, 29.4, 31.7, 32.4, 53.2, 
126.2, 131.9, 140.3, 141.5, and 152.0; mass spectrum (ESI), m/z 361.3216 (M+H)+ 
(C23H41N2O requires 361.3219).  
N N
AcO
 
1,4-Dimethyl-6-tetradecyl-1H-pyrrolo[2,3-b]pyridin-5-yl Acetate (2.24). The 
chromatographic procedure described previously to obtain to 2.15 also gave 2.24 as 
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colorless solid: yield 80 mg (16%); silica gel TLC Rf 0.49 (3:7 ethyl 
acetate−hexanes); 1H NMR (CDCl3) δ 0.88 (t, 3H, J = 7.2 Hz), 1.23-1.40 (m, 22H), 
1.73 (quint, 2H, J = 7.6 Hz), 2.32 (s, 3H), 2.37 (s, 3H), 2.71 (t, 2H, J = 8.0 Hz), 3.83 
(s, 3H), 6.38 (d, 1H, J = 3.6 Hz), and 7.07 (d, 1H, J = 3.6 Hz). 13C NMR (CDCl3) δ 
12.8, 14.1, 20.6, 22.7, 28.9, 29.3, 29.5, 29.5, 29.6, 29.6, 29.6, 29.7, 29.7, 29.8, 31.3, 
31.9, 33.3, 97.8, 119.4, 128.3, 131.0, 138.7, 144.9, 148.3, and 169.5; mass spectrum 
(FAB), m/z 401.3157 (M+H)+ (C25H41N2O2 requires 401.3168). 
N N
HO
.CF3COOH
 
1,4-Dimethyl-6-tetradecyl-1H-pyrrolo[2,3-b]pyridin-5-ol and its Trifluoroacetic 
Acid Salt (2.23). To a solution containing 20.0 mg (49.7 µmol) of 2.24 in 0.8 mL of 
dichloromethane was added 150 µL (150 µmol) of diisobutylaluminium hydride (1.0 
M in toluene) at −78 °C. The reaction mixture was stirred at the same temperature for 
1 h before 2 mL of sat aq sodium potassium tartrate was added slowly. The reaction 
mixture was warmed slowly to room temperature over a period of 30 min. The 
solution was extracted with three 5-mL portions of ethyl acetate. The combined 
organic layer was washed with brine, dried over anh MgSO4, filtered, and 
concentrated under diminished pressure to give the crude product as a yellow oil: 
silica gel TLC Rf 0.55 (1:9 methanol−hexanes). The residue was then dissolved in 1 
mL of acetonitrile and 1% aq TFA, frozen and lyophilized. The crude product was 
purified on a Luna C8 reversed phase semi-preparative (250 x 10 mm) HPLC column 
using gradients of methanol and 1% aq TFA. Linear gradients were employed using 
1:4 methanol−1% aq TFA  4:1 methanol−1% aq TFA over a period of 20 min, and 
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then 4:1 methanol−1% aq TFA  methanol over a period of 40 min, at a flow rate of 
3.5 mL/min (monitoring at 260 nm). Fractions containing the desired product eluted at 
35 min, and were combined, frozen, and lyophilized to give 2.23 as a colorless solid: 
yield 6.3 mg (35%); 1H NMR (C6D6) δ 0.92 (t, 3H, J = 7.0 Hz), 1.28-1.54 (m, 22H), 
2.02 (quint, 2H, J = 7.5 Hz), 2.16 (s, 3H), 3.06 (t, 2H, J = 7.0 Hz), 3.42 (s, 3H), 3.87 
(br s, 1H), 6.29 (d, 1H, J = 3.5 Hz), and 6.60 (d, 1H, J = 3.0 Hz); 13C NMR (C6D6) δ 
11.9, 14.4, 23.2, 29.3, 29.9, 29.9, 30.0, 30.0, 30.2, 30.2, 30.2, 30.3, 30.3, 30.4, 30.9, 
32.4, 33.6, 97.2, 120.0, 123.6, 143.2, 143.3, and 144.9; mass spectrum (FAB), m/z 
359.3073 (M+H)+ (C23H39N2O requires 359.3062). 
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CHAPTER 3 - SYNTHESIS OF A NEW SERIES OF β-HYDROXYHISTIDINE 
ANALOGUES OF BLEOMYCIN 
3.1 General introduction 
 Umezawa and coworkers isolated the bleomycins (BLMs) in 1966 from 
Streptomyces verticillus.122 These glycopeptides possess anticancer activity and have 
been used against testicular carcinomas,123 Hodgkin’s lymphoma,124 and squamous 
cell carcinomas.125 The activity of BLM is based on the degradation of DNA, or 
possibly RNA,126 caused by a Fe(II)⋅BLM complex in the presence of O2.127 The 
active complex Fe(II)⋅BLM⋅O2 degrades DNA by the abstraction of the 4′-hydrogen 
from a deoxyribose sugar of DNA.128 This hydrogen abstraction triggers a reaction 
cascade that can lead to either of two different mechanisms (Figure 3.1): strand 
scission of DNA in presence of oxygen or an alkali-labile lesion via β-elimination.129 
The strand scission of DNA produces either single strand (ss) or double strand (ds) 
cleavage. Research suggests that the double strand cleavage seems to be responsible 
for the cytotoxicity of BLM.130 Additionally, Fe(II)⋅BLM is reported to cleave transfer 
RNA (tRNA),131 tRNA precursors,132 ribosomal RNA (rRNA),133 messenger RNA 
(mRNA),134 and to inhibit protein synthesis.135 
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Figure 3.1. Proposed mechanism of DNA degradation by Fe(II)⋅BLM⋅O2. The top 
pathway leads to strand scission of DNA while the bottom pathway produces the 
alkali-labile lesion.136 
 
 BLM is composed of four different functional domains (Figure 3.2). Each 
domain has a unique contribution to the selectivity and potency of BLM. Among 
these domains, the metal binding domain is crucial because of its clear role in metal 
coordination and in causing the oxidative damage to DNA by the abstraction of 4’-
hydrogen atoms from DNA.137 The structure of metallobleomycin was obtained by the 
analysis of the stable complex Fe(II)⋅BLM⋅CO138 which mimics the structure of the 
unstable and “active” Fe(II)⋅BLM⋅O2 complex. Subsequent research has been able to 
obtain a stable complex between Fe2+, deglycoBLM (BLM without its disaccharide 
moiety), and carbon monoxide.139 The study of these complexes has provided 
 70 
 
information regarding the possible ligands that could coordinate with Fe2+ which has 
allowed different structures of Fe(II)⋅BLM to be suggested. A proposed structure of 
Fe(II)⋅BLM is presented below (Figure 3.3). In addition, complexes with other metals 
such as cobalt,140 zinc,141 and copper,142 have been reported. The β-hydroxyhistidine 
moiety has been the least studied group of the metal binding domain. Its complete 
function and structural requirements for metal coordination are not yet fully 
understood (Figure 3.4). 
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Figure 3.2. The different domains of BLM A6. The β-hydroxyhistidine moiety is 
highlighted in red. 
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Figure 3.3. Proposed coordination between BLM and Fe(II). The β-hydroxyhistidine 
moiety is highlighted in red. Adapted from reference.143 
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Figure 3.4. Nomenclature and tautomerization of the imidazole moiety in β-
hydroxyhistidine. 
 
 The β-hydroxyhistidine moiety seems to contribute to metal coordination with 
two ligands: the N-3 nitrogen atom of imidazole and the nitrogen atom of the 
amide.144 The contribution of the nitrogen atom of the amide is not universally 
accepted. It is possible that the protonation of the amide impacts the ability of this 
nitrogen to act as a ligand. At pH 6.4, Oppenheimer and coworkers demonstrated 
protonation of the amide showing that it does not interact with Fe(II).138 Conversely, 
Bermel and coworkers showed that at pH 7.0 the deprotonated amide acted as an 
additional ligand for Fe(II).145 To study the manner in which the amide nitrogen of β-
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hydroxyhistidine coordinates with Fe(II), Boger and coworkers synthesized 
deshydroxy deglycoBLM A2 (3.1), its N-methyl amide analogue (3.2), and its ester 
analogue (3.3) (Figure 3.5). Of these three analogues, 3.1 possessed a normal amide 
bond similar to the parent molecule, 3.2 was methylated and only coordinated with 
iron using π shell electrons, and 3.3 was unable to coordinate with Fe(II). Cleavage 
assays of supercoiled DNA showed that only 3.1 had activity comparable to 
deglycoBLM A2, while 3.2 and 3.3 had no activity. These findings suggest that the 
amide nitrogen of β-hydroxyhistidine coordinates with Fe(II) using electrons from its 
σ shell. This nitrogen is only able to use its σ shell electrons for coordination in its 
deprotonated form.146 
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Figure 3.5 Structures of analogues synthesized by Boger and coworkers which were 
used to study the functionality of the nitrogen atom of the amide of β-
hydroxyhistidine.146  
 
 In order to determine which tautomer (Figure 3.4) is crucial for complexation, 
Boger and coworkers studied the coordination of the N-3 nitrogen atom of imidazole 
with Fe(II). Three analogues were synthesized for this study: an analogue in which the 
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imidazole moiety was absent (3.4), an analogue in which oxazole was used instead of 
imidazole (3.5), and an analogue in which imidazole was replaced by pyrrole (3.6) 
(Figure 3.6). The N-3 nitrogen of oxazole 3.4 can only use its π shell electrons which 
suggests that it has the ability to mimic the N1-H tautomer (Figure 3.4). Conversely, 
the N-3 nitrogen of pyrrole 3.5 coordinates mainly using σ electrons, similar to the 
N3-H tautomer (Figure 3.4). Cleavage assays of supercoiled DNA showed that 
oxazole 3.5 had comparable activity with deglycoBLM A2, while 3.4 and 3.6 had no 
activity. These findings indicate that the N-3 nitrogen of the N1-H tautomer (Figure 
3.4) of imidazole coordinates with Fe(II). This suggests that this nitrogen mainly uses 
electrons from its π shell for coordination.147 
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Figure 3.6. Structures of analogues synthesized by Boger and coworkers which were 
used to study the functionality of the nitrogen atom at position 3 of the imidazole of 
β-hydroxyhistidine.147  
 
 In the Hecht laboratory, much progress has been made in elucidating the 
functionality of β-hydroxyhistidine. In a study involving the synthesis of 108 different 
analogues of deglycoBLM by solid-phase synthesis, four different building blocks 
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utilizing the histidine moiety were addressed. All of the chosen compounds were 
commercially available. Thienylalanine (3.7), tryptophan (3.8), methionine (3.9), and 
histidine (Figure 3.7) were selected as β-hydroxyhistidine analogues.148 The 
analogues 3.7, 3.8, and 3.9 showed a significant decrease in overall activity and much 
lower cleavage selectivity than those containing histidine.149  
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Figure 3.7. BLM analogues synthesized by Hecht and coworkers for the BLM library 
study.148 
 
 In order to complement these findings, more extensive research has been done 
in the Hecht laboratory to study which moieties would not only be able to mimic 
histidine but would also be able to show higher potency and selectivity. Hecht and 
coworkers synthesized a new series of analogues 3.11-3.18 (Figure 3.8) including the 
natural β-hydroxyhistidine moiety (3.10) for comparison.150 The synthesized 
imidazole derived analogues were the 2-methyl (3.11), the 2-isobutyl (3.12), and the 
5-methyl (3.13) imidazoles. These analogues have alkyl groups in positions 2 and 5 of 
the imidazole ring in order to increase their electron donating ability. It was expected 
that a greater electron donating character of the ring would increase the activity of the 
Fe(II)⋅BLM complex. However, this addition could also cause steric hindrance.  
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Figure 3.8. β-Hydroxyhistidine analogues synthesized by Hecht and coworkers.150 
 
 A series of thiazole analogues was synthesized in order to study the high 
electron density of the system compared with the imidazole ring. The thiazole 
analogues obtained had similar features when compared to the imidazole analogues: 
unmodified (3.14), 2-methyl (3.15), 2-isobutyl (3.16), 5-methyl (3.17), and 2-amino 
(3.18) thiazole analogues. Compared to imidazole, thiazole possesses a higher 
electron density, therefore, it may be able to better stabilize the metal complex. From 
these analogues, only 3.10, 3.12, 3.14, 3.16 have been incorporated into deglycoBLM 
A6 and tested in DNA cleavage assays. All the deglycoBLMs showed similar single 
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strand cleavage efficiency as deglycoBLM A6, making them promising candidates for 
further characterization assays.150 
 The goal of this project was to prepare at least ten analogues of β-
hydroxyhistidine that could be employed in creating a massive combinatorial BLM 
library in which 105 different BLMs can be obtained. This extensive library will 
hopefully provide interesting BLMs in terms of efficiency and potency. To 
accomplish this, four additional analogues (3.19-3.22) were synthesized (Figure 3.7). 
New schemes were developed utilizing intermediates analogous to those described in 
Elban’s procedure.150 These analogues were proposed in order to study the impact of 
increased steric hindrance in the position 5 of imidazole and thiazole. Previously, only 
methyl was used in this position. These larger alkyl groups will be used to determine 
their effect on DNA cleavage. Additionally, analogues 3.11, 3.13-3.18 were 
synthesized for incorporation in BLMs. 
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Figure 3.9. β-Hydroxyhistidine analogues synthesized in this thesis. 
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3.2 Results and discussion 
3.2.1 Synthesis of β-hydroxyhistidine analogues of bleomycin 
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Scheme 3.1. Synthesis of 5-ethylimidazole analogue (3.19). 
 
The aldehyde intermediate of the 5-ethylimidazole analogue (3.19) was 
synthesized using methyl 3-oxopentanoate as starting material (Scheme 3.1). Methyl 
3-oxopentanoate was chlorinated using sulfuryl chloride in chloroform at reflux to 
give chlorinated intermediate 3.23 in quantitative yield.151 Compound 3.23 was 
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condensed with an excess of formamide in the presence of two equivalents of water to 
obtain imidazole ester 3.24 in 37% yield. From this point, Elban’s procedure was 
followed. Imidazole ester 3.24 was protected with trityl chloride using triethylamine 
in benzene at reflux to give protected imidazole 3.25 in 37% yield. Selective 
reduction with diisobutylaluminium hydride at −78 °C gave aldehyde intermediate 
3.26 in 72% yield.  
Dibutylboron triflate (3.27) was prepared by the reaction between 
tributylborane and trifluoromethanesulfonic acid at room temperature. After distilling 
the reaction mixture under diminished pressure, 3.27 was obtained as a light brown 
transparent liquid. (4R)-4-Isopropyloxazolidin-2-one was functionalized by 
deprotonation with n-butyllithium and coupling with bromoacetyl bromide in 
tetrahydrofuran at −78 °C to give functionalized chiral auxiliary 3.28 in 72% yield. A 
selective aldol condensation between 3.28 and 3.26 in the presence of dibutylboron 
triflate (3.27) at −78 °C gave bromide 3.29 in 50% yield after oxidative workup. 
Bromide 3.29 was converted to azide 3.30 in 86% yield by a SN2 reaction with 
sodium azide in N,N-dimethylformamide at 45 °C. Finally, the chiral auxiliary of 
azide 3.30 was cleaved with lithium hydroxide in tetrahydrofuran. In addition to this, 
the azide was reduced with palladium on carbon, giving a free amine which was 
protected in-situ with N-(9-fluorenylmethoxy-carbonyloxy)succinate to give 5-
ethylimidazole analogue 3.19 as colorless solid in 17% yield.  
The aldehyde intermediate of the 5-propylimidazole analogue (3.20) (Scheme 
3.2) was synthesized using ethyl 3-oxohexanoate as starting material. Ethyl 3-
oxohexanoate was chlorinated using sulfuryl chloride in chloroform at reflux to give 
chlorinated intermediate 3.31 in 98% yield.151 Compound 3.31 was condensed with an 
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excess of formamide in the presence of two equivalents of water to obtain imidazole 
ester 3.32 in 24% yield. Imidazole ester 3.32 was protected with trityl chloride using 
triethylamine in benzene at reflux to give protected imidazole 3.33 in 18% yield. 
Selective reduction with diisobutylaluminium hydride at −78 °C gave aldehyde 
intermediate 3.34 in 63% yield.  
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Scheme 3.2. Synthesis of 5-propylimidazole analogue (3.20). 
 
A selective aldol condensation between 3.28 and 3.34 in the presence of 
dibutylboron triflate (3.27) at −78 °C gave bromide 3.35 in 53% yield after oxidative 
workup. Bromide 3.35 was converted to azide 3.36 in 89% yield by a SN2 reaction 
with sodium azide in N,N-dimethylformamide at 45 °C. Finally, the chiral auxiliary of 
 80 
 
azide 3.36 was cleaved with lithium hydroxide in tetrahydrofuran. In addition to this, 
the azide was reduced with palladium on carbon, giving a free amine which was 
protected in-situ with N-(9-fluorenylmethoxy-carbonyloxy)succinate to give 5-
propylimidazole analogue 3.20 as colorless solid in 28% yield. 
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Scheme 3.3. Synthesis of 5-ethylthiazole analogue (3.21). 
 
The procedure followed for the synthesis of the 5-ethylthiazole analogue 
(3.21) was the same as that used by Elban, but using a different Grignard reagent in 
the first reaction. Diethyl oxalate was treated with n-propylmagnesium chloride in 
diethyl ether at −78 °C to give α-keto ester 3.37 in 77% yield. Compound 3.37 was 
brominated with CuBr2 in a chloroform and ethyl acetate mixture at reflux to give β-
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bromo ester 3.38 in 81% yield. Thioformamide 3.39 was obtained by the thionization 
of formamide with phosphorus pentasulfide in tetrahydrofuran and was used without 
further purification. β-Bromo ester 3.38 was condensed with crude thioformamide 
3.39 in dry ethanol to give imidazole ester 3.40 in 63% yield. Selective reduction of 
ester 3.40 with diisobutylaluminium hydride in dichloromethane at −78 °C gave 
imidazole carboxaldehyde 3.41 in quantitative yield.  
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Scheme 3.4. Synthesis of 5-propylthiazole analogue (3.22). 
 
A selective aldol condensation between 3.28 and 3.41 in the presence of 
dibutylboron triflate (3.27) at −78 °C gave bromide 3.42 in 42% yield after oxidative 
workup. Bromide 3.42 was converted to azide 3.43 in 60% yield by a SN2 reaction 
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with sodium azide in N,N-dimethylformamide at 45 °C. Finally, the chiral auxiliary of 
azide 3.43 was cleaved with lithium hydroxide in tetrahydrofuran. In addition to this, 
the azide was reduced with palladium on carbon, giving a free amine which was 
protected in-situ with N-(9-fluorenylmethoxy-carbonyloxy)succinate to give 5-
ethylthiazole analogue 3.21 as colorless solid in 28% yield.  
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Scheme 3.5. Synthesis of 2-methylimidazole analogue (3.11). 
 
The synthesis of the 5-ethylthiazole analogue (3.22) utilized the same 
reactions as the previous analogue excluding the reagent used in the first reaction. 
Diethyl oxalate was treated with n-butylmagnesium chloride in diethyl ether at −78 °C 
to give α-keto ester 3.44 in 66% yield. Compound 3.44 was brominated with CuBr2 in 
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a chloroform and ethyl acetate mixture at reflux to give β-bromo ester 3.45 in 71% 
yield. β-Bromo ester 3.45 was condensed with crude thioformamide 3.39 in dry 
ethanol to give imidazole ester 3.46 in 82% yield. Selective reduction of ester 3.46 
with diisobutylaluminium hydride in dichloromethane at −78 °C gave imidazole 
carboxaldehyde 3.47 in 91% yield.  
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Scheme 3.6. Synthesis of 5-methylimidazole analogue (3.13). 
 
A selective aldol condensation between 3.28 and 3.47 in the presence of 
dibutylboron triflate (3.27) at −78 °C gave bromide 3.48 in 59% yield after oxidative 
workup. Bromide 3.48 was converted to azide 3.49 in 58% yield by a SN2 reaction 
with sodium azide in N,N-dimethylformamide at 45 °C. Finally, the chiral auxiliary of 
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azide 3.49 was cleaved with lithium hydroxide in tetrahydrofuran. In addition to this, 
the azide was reduced with palladium on carbon, giving a free amine which was 
protected in-situ with N-(9-fluorenylmethoxy-carbonyloxy)succinate to give 5-
propylthiazole analogue 3.22 as colorless solid in 22% yield. 
Additionally, analogues 3.11, 3.13-3.18 were synthesized to be incorporated in 
bleomycins (Schemes 3.5-3.11). 
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Scheme 3.7. Synthesis of thiazole analogue (3.14). 
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Scheme 3.8. Synthesis of 2-methylthiazole analogue (3.15). 
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Scheme 3.9. Synthesis of 2-isobutylthiazole analogue (3.16). 
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Scheme 3.10. Synthesis of 5-methylthiazole analogue (3.17). 
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Scheme 3.11. Synthesis of 5-aminothiazole analogue (3.18). 
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3.3 Experimental Section 
General methods: Chemicals and solvents were of reagent grade and were used 
without further purification. Anhydrous tetrahydrofuran (THF) was distilled from 
sodium/benzophenone under argon. Anhydrous diethyl ether (Et2O) was distilled from 
sodium/benzophenone under argon. Anhydrous dichloromethane (CH2Cl2) was 
distilled from calcium hydride under argon. All reactions involving air or moisture 
sensitive reagents or intermediates were performed under an argon atmosphere. Flash 
chromatography was carried out using Silicycle 200-400 mesh silica gel. Analytical 
TLC was carried out using 0.25 mm EM silica gel 60 F250 plates that were visualized 
by UV irradiation (254 nm) or by staining with ceric ammonium molybdate stain. 1H 
NMR and 13C NMR spectra were obtained using 400 or 500 MHz Varian NMR 
spectrometers. Chemicals shifts were reported in parts per million (ppm, δ) referenced 
to the residual 1H resonance of the solvent (CDCl3, 7.26 ppm). 13C spectra were 
referenced to the residual 13C resonance of the solvent (CDCl3, 77.0 ppm). Splitting 
patterns were designated as follows: s, singlet; br, broad; d, doublet; dd, doublet of 
doublets; t, triplet; q, quartet; m, multiplet. High resolution mass spectra were 
obtained at the Michigan State University Mass Spectrometry Facility or at the 
Arizona State University CLAS High Resolution Mass Spectrometry Laboratory. 
O
OO
Cl
 
Methyl 2-chloro-3-oxo-pentanoate (3.23). To a solution containing 10.4 g (79.7 
mmol) of 3-oxopentanoate in 50 mL of chloroform at 0 °C was added 6.80 mL (11.3 
g, 83.9 mmol) of sulfuryl chloride. The reaction mixture was stirred for 30 min at 
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room temperature, and then at reflux for 2 h. The cooled reaction mixture was diluted 
with 150 mL of ethyl acetate, and then washed successively with 50 mL of water, 50 
mL of sat aq NaHCO3, 50 mL of water and 50 mL of brine. The solution was dried 
over anh MgSO4, filtered, and concentrated under diminished pressure to yield a 
yellow oil. The residue was purified by flash chromatography on a silica gel column 
(43 x 7 cm). Elution with 1:6 ethyl acetate−hexanes as eluant gave 3.23 as a yellow 
oil: yield 13.0 g (quantitative); silica gel TLC Rf 0.33 (1:4 ethyl acetate−hexanes); 1H 
NMR (CDCl3) δ 0.97 (t, 3H, J = 7.2 Hz), 2.62 (q, 2H, J = 7.6 Hz), 3.71 (s, 3H), and 
4.77 (s, 1H); 13C NMR (CDCl3) δ 7.4, 32.4, 53.5, 60.4, 165.5, and 199.4; mass 
spectrum (EI), m/z 164.0235 (M)+ (C6H9O3Cl requires 164.0240). 
N
H
N
O
O
 
5-Ethyl-1H-imidazole-4-carboxylic Acid Methyl Ester (3.24). To a solution 
containing 13.0 g (79.0 mmol) of 3.23 in 32 mL (36.3 g, 806 mmol) of formamide 
was added 2.85 mL (2.85 g, 158 mmol) of distilled water. The reaction mixture was 
heated to 145 °C and stirred for 4 h. The cooled reaction mixture was diluted with 200 
mL of chloroform, and then washed successively with 40 mL of water, 40 mL of sat 
aq NaHCO3, 40 mL of water and 40 mL of brine. The solution was dried over anh 
MgSO4, filtered, and concentrated under diminished pressure to yield a colorless 
solid. The residue was purified by flash chromatography on a silica gel column (43 x 
7 cm). Elution with 1:9 methanol−chloroform as eluant gave 3.24 as a colorless solid: 
yield 4.50 g (37%); silica gel TLC Rf 0.37 (1:9 methanol−chloroform); 1H NMR 
(CDCl3) δ 1.27 (t, 3H, J = 7.5 Hz), 3.03 (q, 2H, J = 7.5 Hz), 3.85 (s, 3H), 7.67 (s, 1H), 
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and 12.75 (s, 1H); 13C NMR (CDCl3) δ 13.8, 19.5, 51.3, 124.3, 135.3, 142.7, and 
163.6; mass spectrum (APCI), m/z 155.0824 (M+H)+ (C7H11N2O2 requires 155.0821). 
N
N
O
O
CPh3
 
5-Ethyl-1-trityl-1H-imidazole-4-carboxylic Acid Methyl Ester (3.25). To a 
solution containing 4.57 g (29.6 mmol) of 3.24 in 220 mL of benzene was added 3.30 
mL (4.54 g, 32.6 mmol) of triethylamine and 9.09 g (32.6 mmol) of trityl chloride. 
The reaction mixture was stirred at reflux for 4 h at which time the reaction mixture 
was washed with three 50-mL portions of water and dried over anh MgSO4. Excess 
solvent was removed under diminished pressure to give a crude colorless solid. The 
residue was purified by flash chromatography on a silica gel column (43 x 5 cm). 
Elution with 1:3 ethyl acetate−hexanes as eluant gave 3.25 as a yellow solid: yield 
4.39 g (37%); silica gel TLC Rf 0.43 (1:3 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
0.06 (t, 3H, J = 6.8 Hz), 2.48 (q, 2H, J = 7.2 Hz), 3.84 (s, 3H), 7.10 (m, 6H), 7.27 (m, 
9H), and 7.32 (s, 1H); 13C NMR (CDCl3) δ 11.1, 21.6, 51.4, 75.5, 128.0, 128.0, 128.0 
128.2, 128.2, 128.2, 128.2, 128.2, 128.2, 129.9, 129.9, 129.9, 129.9, 129.9, 129.9, 
130.7, 137.3, 141.3, 141.3, 141.3, 144.2, and 163.8; mass spectrum (APCI), m/z 
397.1907 (M+H)+ (C26H25N2O2 requires 397.1916). 
N
N
O
CPh3
H
 
5-Ethyl-1-trityl-1H-imidazole-4-carbaldehyde (3.26). To a solution containing 4.39 
g (11.7 mmol) of 3.25 in 85 mL of dichloromethane at −78 °C was added 23.6 mL 
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(5.03 g, 35.4 mmol) of diisobutylaluminium hydride (1.0 M in toluene) over a period 
of 30 min. The reaction mixture was stirred at −78 °C for 4 h at which time the 
reaction was quenched by the addition of 15 mL of methanol followed by 75 mL of 
1:1 sat aq sodium potassium tartrate−pH 7 buffer. The reaction mixture was stirred 
vigorously at room temperature for 16 h, extracted with three 150-mL portions of 
dichloromethane, dried over anh MgSO4, filtered, and concentrated under diminished 
pressure. The residue was purified by flash chromatography on a silica gel column (43 
x 5 cm). Elution with 1:2 ethyl acetate−hexanes as eluant gave 3.26 as a colorless 
solid: yield 2.91 g (72%); silica gel TLC Rf 0.54 (1:1 ethyl acetate−hexanes); 1H 
NMR (CDCl3) δ 0.13 (t, 3H, J = 7.6 Hz), 2.44 (q, 2H, J = 7.2 Hz), 7.10 (m, 6H), 7.28 
(m, 9H), 7.36 (s, 1H), and 9.94 (s, 1H); 13C NMR (CDCl3) δ 11.1, 21.4, 75.5, 128.2, 
128.2, 128.2, 128.3, 128.3, 128.3, 128.3, 128.3, 128.3, 129.8, 129.8, 129.8, 129.8, 
129.8, 129.8, 138.3, 139.2, 141.2, 141.2, 141.2, 143.9, and 187.5; mass spectrum 
(APCI), m/z 367.1800 (M+H)+ (C25H23N2O requires 367.1810). 
ON
OO
Br
 
3-(2-Bromoacetyl)-(4R)-4-isopropyloxazolidin-2-one (3.28).150 To a solution 
containing 2.50 g (19.4 mmol) of (4R)-4-isopropyloxazolidin-2-one in 125 mL of 
tetrahydrofuran at −78 °C was added 12.1 mL (19.4 mmol) of n-butyllithium (1.6 M 
in hexanes) over a period of 30 min. This solution was treated with 1.70 mL (3.94 g, 
19.5 mmol) of bromoacetyl bromide. The cloudy solution was stirred for an additional 
1.5 h. The reaction was quenched with 25 mL of sat aq NH4Cl and 25 mL of sat aq 
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NaHCO3. The solution was permitted to equilibrate at room temperature for 1 h. The 
organic and aqueous phases were separated, and the aqueous phase was extracted with 
three 50-mL portions of ethyl ether. The combined organic phase was washed with 
three 25-mL portions of brine, dried over anh MgSO4, filtered and concentrated under 
diminished pressure to yield a brown solid. The residue was purified by flash 
chromatography on a silica gel column (43 x 4 cm). Elution with 1:3 ethyl 
acetate−hexanes as eluant gave 3.28 as a yellow oil: yield 3.49 g (72%); silica gel 
TLC Rf 0.85 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.89 (dd, 6H, J = 9.5 
and 6.5 Hz), 2.40 (m, 1H), 4.24 (dd, 1H, J = 9.5 and 3.0 Hz), 4.33 (t, 1H, J = 8.5 Hz), 
4.39 (dd, 1H, J = 12.5 and 1.0 Hz), 4.44 (m, 1H), and 4.56 (dd, 1H, J = 12.5 and 1.0 
Hz). 
ON
OO
N
N
OH
Br
CPh3
 
3-[2-R-Bromo-3-R-hydroxy-3-(5-ethyl-1-trityl-1H-imidazol-4-yl)propionyl)]-4-R-
isopropyloxazolidin-2-one (3.29). To a solution containing 1.08 g (4.32 mmol) of 
3.28 in 20 mL of diethyl ether at −78 °C was added 1.15 mL (1.30 g, 4.75 mmol) of 
freshly prepared 3.27, followed immediately by the addition of 0.90 mL (0.66 mg, 
6.48 mmol) of triethylamine. The reaction mixture was stirred for 0.5 h at −78 °C and 
then allowed to warm to room temperature and stirred for an additional 2 h. The 
resulting dark maroon solution was cooled to −78 °C, and a solution containing 1.44 g 
(3.93 mmol) of 3.26 in 8 mL of dichloromethane was added dropwise. The reaction 
mixture was allowed to warm to room temperature and was stirred overnight. The 
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reaction mixture was then diluted with 60 mL of 2:1 diethyl ether−dichloromethane 
and washed with two 45-mL portions of sat aq NaHSO4 and 25 mL of brine. The 
organic phase was concentrated under diminished pressure to give a brown oily 
residue which was dissolved in 20 mL of methanol. To this solution was added 6 mL 
of 30% aq H2O2 and the reaction was stirred for 1 h. The milky solution was 
concentrated under diminished pressure, and the resulting residue was dissolved in 10 
mL of water and extracted with three 25-mL portions of 2:1 diethyl 
ether−dichloromethane. The combined organic phase was washed with two 10-mL 
portions of sat aq NaHCO3 and 5 mL of brine, dried over anh MgSO4, filtered and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (43 x 4 cm). Step gradient elution with 1:4 
ethyl acetate−hexanes  100% ethyl acetate as eluant gave 3.29 as colorless foam: 
yield 1.23 g (50%); silica gel TLC Rf 0.28 (1:1 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 0.22 (t, 3H, J = 7.6 Hz), 0.89 (d, 6H, J = 6.8 Hz), 2.28 (m, 1H), 2.38 (m, 
2H), 3.59 (br s, 1H), 4.18 (m, 2H), 4.30 (m, 1H), 5.10 (d, 1H, J = 8.4 Hz), 6.30 (d, 
1H, J = 8.4 Hz), 7.06 (m, 6H), 7.26 (m, 9H), and 7.28 (s, 1H); 13C NMR (CDCl3) δ 
12.5, 14.8, 17.9, 28.0, 49.7, 58.3, 63.2, 68.3, 74.8, 127.8, 127.8, 127.8, 128.0, 128.0, 
128.0, 128.0, 128.0, 128.0, 130.0, 130.0, 130.0, 130.0, 130.0, 130.0, 133.7, 136.8, 
137.8, 141.9, 141.9, 141.9, 152.6, 168.3, and 187.8. Note: material decomposes 
rapidly, must be used immediately. 
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3-[2-S-Azido-3-R-hydroxy-3-(5-ethyl-1-trityl-1H-imidazol-4-yl)propionyl)]-4-R-
isopropyloxazolidin-2-one (3.30). To a solution containing 1.23 g (2.20 mmol) of 
3.29 in 40 mL of N,N-dimethylformamide was added 0.65 g (10.0 mmol) of sodium 
azide. The reaction mixture was warmed to 45 °C and stirred for 1.25 h at which time 
it was poured into ~45 g of ice and extracted with three 25-mL portions of ethyl 
acetate. The combined organic phase was washed with two 25-mL portions of water 
and 10 mL of brine, dried over anh MgSO4, filtered and concentrated under 
diminished pressure to give a brown oil. The residue was purified via flash 
chromatography on a silica gel column (43 x 4 cm). Step gradient elution with 1:4  
1:1 ethyl acetate−hexanes as eluant gave 3.30 as a colorless foam: yield 1.00 g (86%); 
silica gel TLC Rf 0.45 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.24 (t, 3H, J 
= 7.2 Hz), 0.89 (t, 6H, J = 6.8 Hz), 2.28 (m, 2H), 2.50 (m, 1H), 3.84 (d, 1H, J = 9.2 
Hz), 4.32 (m, 2H), 4.54 (m, 1H), 4.94 (d, 1H, J = 8.8 Hz), 5.86 (d, 1H, J = 8.4 Hz), 
7.18 (m, 6H), 7.32 (m, 9H), and 7.34 (s, 1H); 13C NMR (CDCl3) δ 12.9, 14.7, 17.9, 
28.2, 58.9, 62.3, 63.6, 68.4, 74.9, 127.8, 127.8, 127.8, 128.1, 128.1, 128.1, 128.1, 
128.1, 128.1, 130.0, 130.0, 130.0, 130.0, 130.0, 130.0, 134.0, 137.6, 138.0, 141.8, 
141.8, 141.8, 153.9, 169.8, and 187.8; mass spectrum (APCI), m/z 597.2712 (M+H)+ 
(C33H35N6O4 requires 597.2720). 
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2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-hydroxy-3-(5-ethyl-1-trityl-1H-
imidazol-4-yl)propionic Acid (3.19). To a solution containing 1.00 g (1.73 mmol) of 
3.30 in 90 mL of 4:1 tetrahydrofuran−water was added 0.36 g (8.64 mmol) of 
LiOH⋅H2O. The reaction was stirred for 30 min at room temperature and quenched 
with 1 N HCl until pH 2.5 was reached. The reaction mixture was extracted with three 
25-mL portions of ethyl acetate and two 25-mL portions of chloroform. The 
combined organic phase was washed with two 25-mL portions of brine, dried over 
anh MgSO4, filtered, and concentrated under diminished pressure to give a colorless 
solid. The residue was dissolved in 90 mL of 9:1 tetrahydrofuran−water. To this 
solution was added 0.47 g (3.46 mmol) of K2CO3 and 0.87 g (2.59 mmol) of 
FmocOSu. This solution was added to ~100 mg of 10% Pd/C under an Ar 
atmosphere. The reaction vessel was purged with H2 several times and stirred under 
H2 for 16 h. The reaction mixture was then filtered through a pad of Celite and 
washed thoroughly with two 100-mL portions of 90:8:2 chloroform−methanol−acetic 
acid followed by 50 mL of toluene. Excess solvent was removed under diminished 
pressure and the resulting residue was coevaporated with several portions of toluene 
to give a yellow oil. The residue was purified by flash chromatography on a silica gel 
column (43 x 5 cm). Elution with 90:8:2 chloroform−methanol−acetic acid as eluant 
gave 3.19 as a yellow solid: yield 156 mg (17%); silica gel TLC Rf 0.22 (90:8:2 
chloroform−methanol−acetic acid); 1H NMR (CDCl3) δ 0.24 (t, 3H, J = 6.8 Hz), 2.29 
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(m, 2H), 4.21 (m, 2H), 4.33 (m, 1H), 4.50 (m, 1H), 5.14 (m, 1H), 6.81 (br s, 1H), 7.18 
(m, 7H), 7.28 (m, 14H), 7.63 (m, 2H), 7.78 (m, 2H), and 12.20 (br s, 1H); 13C NMR 
(CDCl3) δ 12.5, 19.9, 21.6, 47.2, 60.1, 67.1, 119.9, 125.4, 125.5, 125.6, 125.6, 127.1, 
127.1, 127.2, 127.2, 127.7, 127.7, 127.7, 128.3, 128.3, 128.3, 128.3, 128.3, 128.3, 
130.0, 130.0, 130.0, 130.0, 130.0, 130.0, 134.6, 138.0, 138.0, 138.0, 140.4, 140.4, 
141.2, 141.3, 143.9, 144.2, 156.1, and 172.6; mass spectrum (APCI), m/z 664.2822 
(M+H)+ (C42H38N3O5 requires 664.2811). 
O
OO
Cl
 
Ethyl 2-chloro-3-oxo-hexanoate (3.31). To a solution containing 19.8 g (125 mmol) 
of 3-oxohexanoate in 80 mL of chloroform at 0 °C was added 13.6 mL (22.8 g, 125 
mmol) of sulfuryl chloride. The reaction mixture was stirred for 30 min at room 
temperature, and then at reflux for 2 h. The cooled reaction mixture was diluted with 
300 mL of ethyl acetate, and then washed successively with 100 mL of water, 50 mL 
of sat aq NaHCO3, 50 mL of water and 50 mL of brine. The solution was dried over 
anh MgSO4, filtered, and concentrated under diminished pressure to yield a yellow 
oil. The residue was purified by flash chromatography on a silica gel column (43 x 7 
cm). Elution with 1:6 ethyl acetate−hexanes as eluant gave 3.31 as a yellow oil: yield 
23.2 g (98%); silica gel TLC Rf 0.35 (1:4 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
0.90 (t, 3H, J = 7.2 Hz), 1.28 (t, 3H, J = 7.2 Hz), 1.63 (m, 2H), 2.64 (q, 2H, J = 7.2 
Hz), 4.26 (q, 2H, J = 7.2 Hz), and 4.74 (s, 1H); 13C NMR (CDCl3) δ 13.3, 13.9, 16.9, 
40.7, 60.9, 63.0, 165.0, and 198.8; mass spectrum (EI), m/z 192.0550 (M)+ 
(C8H13O3Cl requires 192.0553). 
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5-Propyl-1H-imidazole-4-carboxylic Acid Ethyl Ester (3.32). To a solution 
containing 29.1 g (151 mmol) of 3.31 in 60.0 mL (68.1 g, 1.51 mol) of formamide 
was added 5.44 mL (5.44 g, 302 mmol) of distilled water. The reaction mixture was 
heated to 145 °C and stirred for 4 h. The cooled reaction mixture was diluted with 300 
mL of chloroform, and then washed successively with 100 mL of water, 50 mL of sat 
aq NaHCO3, 50 mL of water and 50 mL of brine. The solution was dried over anh 
MgSO4, filtered, and concentrated under diminished pressure to yield a colorless 
solid. The residue was purified by flash chromatography on a silica gel column (43 x 
7 cm). Elution with 1:9 methanol−chloroform as eluant gave 3.32 as a colorless solid: 
yield 6.63 g (24%); silica gel TLC Rf 0.41 (1:9 methanol−chloroform); 1H NMR 
(CDCl3) δ 0.94 (m, 3H), 1.34 (t, 3H, J = 7.2 Hz), 1.69 (m, 2H), 2.95 (t, 2H, J = 8.0 
Hz), 4.34 (q, 2H, J = 7.2 Hz), 7.70 (s, 1H), and 9.58 (s, 1H); 13C NMR (CDCl3) δ 
13.7, 14.3, 22.7, 28.1, 60.3, 124.2, 135.3, 142.9, and 162.9; mass spectrum (APCI), 
m/z 183.1130 (M+H)+ (C9H15N2O2 requires 183.1134). 
N
N
O
O
CPh3
 
5-Propyl-1-trityl-1H-imidazole-4-carboxylic Acid Ethyl Ester (3.33). To a solution 
containing 6.63 g (36.4 mmol) of 3.32 in 270 mL of benzene was added 5.60 mL 
(4.05 g, 40.0 mmol) of triethylamine and 11.2 g (40.0 mmol) of trityl chloride. The 
reaction mixture was stirred at reflux for 4 h at which time the reaction mixture was 
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washed with three 50-mL portions of water and dried over anh MgSO4. Excess 
solvent was removed under diminished pressure to give a crude colorless solid. The 
residue was purified by flash chromatography on a silica gel column (43 x 6 cm). 
Elution with 1:3 ethyl acetate−hexanes as eluant gave 3.33 as a yellow solid: yield 
2.67 g (18%); silica gel TLC Rf 0.47 (1:3 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
0.31 (m, 2H), 0.37 (t, 3H, J = 6.4 Hz), 1.36 (t, 3H, J = 7.2 Hz), 2.38 (m, 2H), 4.32 (q, 
2H, J = 7.2 Hz), 7.13 (m, 6H), and 7.31 (m, 10H); 13C NMR (CDCl3) δ 14.4, 14.6, 
20.7, 30.5, 60.2, 75.5, 128.0, 128.0, 128.0 128.2, 128.2, 128.2, 128.2, 128.2, 128.2, 
129.9, 129.9, 129.9, 129.9, 129.9, 129.9, 130.7, 137.3, 141.3, 141.3, 141.4, 142.9, and 
163.8; mass spectrum (APCI), m/z 425.2227 (M+H)+ (C28H29N2O2 requires 
425.2229). 
N
N
O
CPh3
H
 
5-Propyl-1-trityl-1H-imidazole-4-carbaldehyde (3.34). To a solution containing 
2.67 g (6.50 mmol) of 3.33 in 49 mL of dichloromethane at −78 °C was added 20.8 
mL (2.96 g, 20.8 mmol) of diisobutylaluminium hydride (1.0 M in toluene) over a 
period of 30 min. The reaction mixture was stirred at −78 °C for 4 h at which time the 
reaction was quenched by the addition of 15 mL of methanol followed by 75 mL of 
1:1 sat aq sodium potassium tartrate−pH 7 buffer. The reaction mixture was stirred 
vigorously at room temperature for 16 h, extracted with three 150-mL portions of 
dichloromethane, dried over anh MgSO4, filtered, and concentrated under diminished 
pressure. The residue was purified by flash chromatography on a silica gel column (43 
x 4 cm). Elution with 1:2 ethyl acetate−hexanes as eluant gave 3.34 as a colorless 
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solid: yield 1.57 g (63%); silica gel TLC Rf 0.59 (1:1 ethyl acetate−hexanes); 1H 
NMR (CDCl3) δ 0.31 (m, 5H), 2.36 (m, 2H), 7.12 (m, 6H), 7.32 (m, 9H), 7.37 (s, 1H), 
and 9.95 (s, 1H); 13C NMR (CDCl3) δ 14.4, 20.7, 30.2, 75.6, 128.2, 128.2, 128.2, 
128.3, 128.3, 128.3, 128.3, 128.3, 128.3, 129.9, 129.9, 129.9, 129.9, 129.9, 129.9, 
138.3, 139.2, 141.2, 141.2, 141.2, 142.8, and 187.4; mass spectrum (APCI), m/z 
381.1957 (M+H)+ (C26H25N2O requires 381.1967). 
ON
OO
N
N
OH
Br
CPh3
 
3-[2-R-Bromo-3-R-hydroxy-3-(5-propyl-1-trityl-1H-imidazol-4-yl)propionyl)]-4-
R-isopropyloxazolidin-2-one (3.35). To a solution containing 0.97 g (3.88 mmol) of 
3.28 in 20 mL of diethyl ether at −78 °C was added 1.04 mL (1.17 g, 4.27 mmol) of 
freshly prepared 3.27, followed immediately by the addition of 0.81 mL (0.59 mg, 
5.82 mmol) of triethylamine. The reaction mixture was stirred for 0.5 h at −78 °C and 
then allowed to warm to room temperature and stirred for an additional 2 h. The 
resulting dark maroon solution was cooled to −78 °C, and a solution containing 1.34 g 
(3.52 mmol) of 3.34 in 8 mL of dichloromethane was added dropwise. The reaction 
mixture was allowed to warm to room temperature and was stirred overnight. The 
reaction mixture was then diluted with 60 mL of 2:1 diethyl ether−dichloromethane 
and washed with two 45-mL portions of sat aq NaHSO4 and 25 mL of brine. The 
organic phase was concentrated under diminished pressure to give a brown oily 
residue which was dissolved in 20 mL of methanol. To this solution was added 6 mL 
of 30% aq H2O2 and the reaction was stirred for 1 h. The milky solution was 
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concentrated under diminished pressure, and the resulting residue was dissolved in 10 
mL of water and extracted with three 25-mL portions of 2:1 diethyl 
ether−dichloromethane. The combined organic phase was washed with two 10-mL 
portions of sat aq NaHCO3 and 5 mL of brine, dried over anh MgSO4, filtered and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (43 x 4 cm). Step gradient elution with 1:4 
ethyl acetate−hexanes  100% ethyl acetate as eluant gave 3.35 as colorless foam: 
yield 1.23 g (53%); silica gel TLC Rf 0.31 (1:1 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 0.38 (m, 5H), 0.95 (d, 6H, J = 7.2 Hz), 2.07 (m, 1H), 2.28 (m, 1H), 2.45 
(m, 1H), 3.59 (br s, 1H), 4.20 (m, 2H), 4.36 (m, 1H), 5.12 (d, 1H, J = 8.8 Hz), 6.35 (d, 
1H, J = 9.2 Hz), 7.12 (m, 6H), 7.23 (m, 1H), and 7.31 (m, 9H); 13C NMR (CDCl3) δ 
14.4, 14.8, 17.9, 22.0, 28.0, 49.7, 58.3, 63.1, 68.3, 74.8, 127.8, 127.8, 127.8, 128.0, 
128.0, 128.0, 128.0, 128.0, 128.0, 130.0, 130.0, 130.0, 130.0, 130.0, 130.0, 132.7, 
136.9, 137.8, 141.9, 141.9, 141.9, 152.6, 168.2, and 187.8. Note: material 
decomposes rapidly, must be used immediately. 
ON
OO
N
N
OH
N3
CPh3
 
3-[2-S-Azido-3-R-hydroxy-3-(5-propyl-1-trityl-1H-imidazol-4-yl)propionyl)]-4-R-
isopropyloxazolidin-2-one (3.36). To a solution containing 1.29 g (2.05 mmol) of 
3.35 in 40 mL of N,N-dimethylformamide was added 0.66 g (10.2 mmol) of sodium 
azide. The reaction mixture was warmed to 45 °C and stirred for 1.25 h at which time 
it was poured into ~45 g of ice and extracted with three 25-mL portions of ethyl 
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acetate. The combined organic phase was washed with two 25-mL portions of water 
and 10 mL of brine, dried over anh MgSO4, filtered and concentrated under 
diminished pressure to give a brown oil. The residue was purified via flash 
chromatography on a silica gel column (43 x 4 cm). Step gradient elution with 1:4  
1:1 ethyl acetate−hexanes as eluant gave 3.36 as a colorless foam: yield 1.08 g (89%); 
silica gel TLC Rf 0.48 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.36 (t, 3H, J 
= 5.6 Hz), 0.89 (t, 6H, J = 5.2 Hz), 1.22 (t, 2H, J = 5.2 Hz), 2.18 (m, 2H), 2.44 (m, 
1H), 3.91 (br s, 1H), 4.24 (m, 1H), 4.31 (m, 1H), 4.50 (m, 1H), 4.88 (m, 1H), 5.82 (d, 
1H, J = 7.2 Hz), 7.13 (m, 6H), 7.27 (m, 9H), and 7.31 (s, 1H); 13C NMR (CDCl3) δ 
14.4, 14.8, 17.9, 22.0, 28.2, 58.8, 62.3, 63.6, 68.3, 74.8, 127.8, 127.8, 127.8, 128.0, 
128.0, 128.0, 128.0, 128.0, 128.0, 130.0, 130.0, 130.0, 130.0, 130.0, 130.0, 132.8, 
137.6, 138.1, 141.8, 141.8, 141.8, 153.8, 168.2, and 187.8; mass spectrum (ESI), m/z 
615.2684 (M+Na)+ (C34H36N6O4Na requires 615.2696). 
O
OHFmocHN
HO
N
N
H
H
CPh3
 
2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-hydroxy-3-(5-propyl-1-trityl-1H-
imidazol-4-yl)propionic Acid (3.20). To a solution containing 1.08 g (1.82 mmol) of 
3.36 in 90 mL of 4:1 tetrahydrofuran−water was added 0.38 g (9.12 mmol) of 
LiOH⋅H2O. The reaction was stirred for 30 min at room temperature and quenched 
with 1 N HCl until pH 2.5 was reached. The reaction mixture was extracted with three 
25-mL portions of ethyl acetate and two 25-mL portions of chloroform. The 
combined organic phase was washed with two 25-mL portions of brine, dried over 
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anh MgSO4, filtered, and concentrated under diminished pressure to give a colorless 
solid. The residue was dissolved in 90 mL of 9:1 tetrahydrofuran−water. To this 
solution was added 0.50 g (3.65 mmol) of K2CO3 and 0.92 g (2.74 mmol) of 
FmocOSu. This solution was added to ~100 mg of 10% Pd/C under an Ar 
atmosphere. The reaction vessel was purged with H2 several times and stirred under 
H2 for 16 h. The reaction mixture was then filtered through a pad of Celite and 
washed thoroughly with two 100-mL portions of 90:8:2 chloroform−methanol−acetic 
acid followed by 50 mL of toluene. Excess solvent was removed under diminished 
pressure and the resulting residue was coevaporated with several portions of toluene 
to give a yellow oil. The residue was purified by flash chromatography on a silica gel 
column (43 x 5 cm). Elution with 90:8:2 chloroform−methanol−acetic acid as eluant 
gave 3.20 as a yellow solid: yield 0.35 g (28%); silica gel TLC Rf 0.22 (90:8:2 
chloroform−methanol−acetic acid); 1H NMR (CDCl3) δ 0.37 (m, 5H), 2.18 (m, 2H), 
4.23 (m, 3H), 4.58 (m, 1H), 5.08 (m, 1H), 6.20 (br s, 1H), 7.18 (m, 7H), 7.28 (m, 
14H), 7.62 (m, 2H), 7.78 (d, 2H, J = 7.2 Hz), and 12.72 (br, 1H); 13C NMR (CDCl3) δ 
14.4, 17.9, 22.0, 28.2, 47.1, 58.3, 68.6, 119.9, 125.4, 125.6, 125.6, 125.6, 127.1, 
127.1, 127.2, 127.2, 127.8, 127.8, 127.8, 128.3, 128.3, 128.3, 128.3, 128.3, 128.3, 
130.0, 130.0, 130.0, 130.0, 130.0, 130.0, 134.6, 141.3, 141.3, 141.3, 141.6, 141.6, 
142.0, 142.0, 143.9, 144.2, 156.1, and 172.6; mass spectrum (ESI), m/z 678.2980 
(M+H)+ (C43H40N3O5 requires 678.2968). 
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2-Oxopentanoic Acid Ethyl Ester (3.37). To a solution containing 15.0 mL (16.1 g, 
110 mmol) of diethyl oxalate in 70 mL of diethyl ether at −78 °C was added 60.7 mL 
(12.5 g, 122 mmol) of n-propylmagnesium chloride (2.0 M in diethyl ether). The 
reaction mixture was stirred for 15 min and then allowed to warm to −10 °C for 2 h. 
The reaction mixture was quenched with 50 mL sat aq NH4Cl and extracted with three 
100-mL portions of ethyl acetate. The combined organic phase was dried over anh 
MgSO4, filtered and excess solvent was removed under diminished pressure. The 
residue was purified by flash chromatography on a silica gel column (43 x 7 cm). 
Elution with 1:3 ethyl acetate−hexanes as eluant gave 3.37 as a colorless oil: yield 
12.2 g (77%); silica gel TLC Rf 0.72 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
0.97 (t, 3H, J = 7.2 Hz), 1.37 (t, 3H, J = 6.8 Hz), 1.66 (m, 2H), 2.81 (t, 2H, J = 6.8 
Hz), and 4.31 (q, 2H, J = 7.6 Hz); 13C NMR (CDCl3) δ 13.2, 13.7, 16.3, 40.9, 62.0, 
161.1, and 194.3; mass spectrum (EI), m/z 144.0780 (M)+ (C7H12O3 requires 
144.0787). 
O
O
O
Br
 
3-Bromo-2-oxopentanoic Acid Ethyl Ester (3.38). To a solution containing 12.2 g 
(84.9 mmol) of 3.37 in 300 mL chloroform was added a solution containing 56.9 g 
(255 mmol) of CuBr2 in 600 mL of ethyl acetate. The reaction mixture was stirred at 
reflux for 18 h, cooled, filtered through a silica pad of silica gel, and washed with 
three 100-mL portions of ethyl acetate. The excess solvent was removed under 
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diminished pressure. The residue was purified by flash chromatography on a silica gel 
column (44 x 7 cm). Elution with 1:3 ethyl acetate−hexanes as eluant gave 3.38 as a 
yellow oil: yield 15.4 g (81%); silica gel TLC Rf 0.64 (1:1 ethyl acetate−hexanes); 1H 
NMR (CDCl3) δ 1.10 (t, 3H, J = 7.2 Hz), 1.41 (t, 3H, J = 6.8 Hz), 2.14 (m, 2H), 4.40 
(q, 2H, J = 7.2 Hz), and 5.03 (dd, 1H, J = 8.0 and 1.6 Hz); 13C NMR (CDCl3) δ 11.6, 
13.8, 25.3, 50.0, 62.8, 160.4, and 185.7; mass spectrum (EI), m/z 221.9895 (M)+ 
(C7H11O3Br requires 221.9892). 
H NH2
S
 
Thioformamide (3.39).150 To a solution containing 5.00 g (111 mmol) of formamide 
in 34 mL of tetrahydrofuran at 0 °C was added 4.94 g (22.2 mmol) of P2S5. The 
reaction mixture was stirred while warming to room temperature for 3 h. The reaction 
mixture was filtered through a course glass frit and was washed with 50 mL of diethyl 
ether. The organic phase was concentrated under diminished pressure. The reaction 
crude was used without any further purification for the next reaction. Diminished 
pressure gave 3.39 as a yellow oil: yield 4.88 g (72%). 
S
NO
O
 
5-Ethylthiazole-4-carboxylic Acid Ethyl Ester (3.40). To a solution containing 15.0 
mL (17.0 g, 278 mmol) of 3.39 in 82 mL of ethanol was added 15.4 g (70.0 mmol) of 
3.38. The reaction mixture was stirred at reflux for 3 h at which time solid NaHCO3 
was added carefully until no bubbling was observed. The reaction mixture was poured 
into 150 mL of water and extracted with three 250-mL portions of ethyl acetate. The 
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combined organic phase was dried over anh MgSO4, filtered, and concentrated under 
diminished pressure to afford a crude residue. The residue was purified by flash 
chromatography on a silica gel column (42 x 7 cm). Step gradient elution with 1:4  
1:1 ethyl acetate−hexanes as eluant gave 3.40 as a colorless oil: yield 8.11 g (63%); 
silica gel TLC Rf 0.39 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 1.36 (t, 3H, J 
= 7.6 Hz), 1.42 (t, 3H, J = 7.6 Hz), 3.28 (q, 2H, J = 7.2 Hz), 4.40 (q, 2H, J = 7.2 Hz), 
and 8.71 (s, 1H); 13C NMR (CDCl3) δ 13.9, 15.5, 20.6, 60.5, 140.7, 149.2, 161.7, and 
185.2; mass spectrum (EI), m/z 185.0514 (M)+ (C8H11NO2S requires 185.0510). 
S
N
O
H
 
5-Ethylthiazole-4-carbaldehyde (3.41). To a solution containing 8.11 g (43.8 mmol) 
of 3.40 in 300 mL of dichloromethane at −78 °C was added 140 mL (19.9 g, 140 
mmol) of diisobutylaluminium hydride (1.0 M in toluene) over a period of 30 min. 
The reaction mixture was stirred at −78 °C for 4 h at which time the reaction was 
quenched by the addition of 15 mL of methanol followed by 150 mL of 1:1 sat aq 
sodium potassium tartrate−pH 7 buffer. The reaction mixture was stirred vigorously at 
room temperature for 16 h, extracted with three 150-mL portions of dichloromethane, 
dried over anh MgSO4, filtered, and concentrated under diminished pressure. The 
residue was purified by flash chromatography on a silica gel column (43 x 5 cm). 
Elution with 1:2 ethyl acetate−hexanes as eluant gave 3.41 as a colorless solid: yield 
6.18 g (quantitative); silica gel TLC Rf 0.49 (1:1 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 1.14 (t, 3H, J = 5.6 Hz), 3.09 (q, 2H, J = 6.4 Hz), 8.49 (s, 1H), and 9.99 (s, 
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1H); 13C NMR (CDCl3) δ 15.7, 20.2, 148.4, 150.0, 152.7, and 186.1; mass spectrum 
(EI), m/z 141.0242 (M)+ (C6H7NOS requires 141.0248). 
ON
OO
N
S
OH
Br
 
3-[2-R-Bromo-3-R-hydroxy-3-(5-ethylthiazol-4-yl)propionyl)]-4-R-
isopropyloxazolidin-2-one (3.42). To a solution containing 2.50 g (10.0 mmol) of 
3.28 in 50 mL of diethyl ether at −78 °C was added 2.67 mL (3.01 g, 11.0 mmol) of 
freshly prepared 3.27, followed immediately by the addition of 2.09 mL (1.52 g, 15.0 
mmol) of triethylamine. The reaction mixture was stirred for 0.5 h at −78 °C and then 
allowed to warm to room temperature and stirred for an additional 2 h. The resulting 
dark maroon solution was cooled to −78 °C, and a solution containing 1.41 g (10.0 
mmol) of 3.41 in 25 mL of dichloromethane was added dropwise. The reaction 
mixture was allowed to warm to room temperature and was stirred overnight. The 
reaction mixture was then diluted with 60 mL of 2:1 diethyl ether−dichloromethane 
and washed with two 45-mL portions of sat aq NaHSO4 and 25 mL of brine. The 
organic phase was concentrated under diminished pressure to give a brown oily 
residue which was dissolved in 20 mL of methanol. To this solution was added 6 mL 
of 30% aq H2O2 and the reaction was stirred for 1 h. The milky solution was 
concentrated under diminished pressure, and the resulting residue was dissolved in 10 
mL of water and extracted with three 25-mL portions of 2:1 diethyl 
ether−dichloromethane. The combined organic phase was washed with two 10-mL 
portions of sat aq NaHCO3 and 5 mL of brine, dried over anh MgSO4, filtered and 
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concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (43 x 4 cm). Step gradient elution with 1:4 
ethyl acetate−hexanes  100% ethyl acetate as eluant gave 3.42 as colorless foam: 
yield 1.65 g (42%); silica gel TLC Rf 0.28 (1:1 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 0.93 (dd, 6H, J = 12.5 and 4.5 Hz), 1.33 (t, 3H, J = 7.5 Hz), 2.36 (m, 1H), 
3.01 (m, 2H), 3.55 (br s, 1H), 4.22 (m, 2H), 4.32 (m, 1H), 5.33 (d, 1H, J = 7.5 Hz), 
6.32 (d, 1H, J = 8.0 Hz), and 8.56 (s, 1H); 13C NMR (CDCl3) δ 14.6, 14.7, 17.7, 28.0, 
49.3, 58.4, 63.4, 68.6, 77.2, 139.9, 148.3, 149.9, 152.6, and 168.0. Note: material 
decomposes rapidly, must be used immediately. 
ON
OO
N
S
OH
N3
 
3-[2-S-Azido-3-R-hydroxy-3-(5-ethylthiazol-4-yl)propionyl)]-4-R-
isopropyloxazolidin-2-one (3.43). To a solution containing 1.65 g (4.23 mmol) of 
3.42 in 53 mL of N,N-dimethylformamide was added 1.37 g (21.1 mmol) of sodium 
azide. The reaction mixture was warmed to 45 °C and stirred for 1.25 h at which time 
it was poured into ~45 g of ice and extracted with three 25-mL portions of ethyl 
acetate. The combined organic phase was washed with two 25-mL portions of water 
and 10 mL of brine, dried over anh MgSO4, filtered and concentrated under 
diminished pressure to give a brown oil. The residue was purified via flash 
chromatography on a silica gel column (43 x 4 cm). Step gradient elution with 1:4  
1:1 ethyl acetate−hexanes as eluant gave 3.43 as a colorless foam: yield 0.90 g (60%); 
silica gel TLC Rf 0.45 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.96 (d, 6H, J 
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= 7.2 Hz), 1.36 (t, 3H, J = 7.6 Hz), 2.49 (m, 1H), 2.96 (q, 2H, J = 7.6 Hz), 3.60 (d, 
1H, J = 6.4 Hz), 4.31 (m, 1H), 4.38 (m, 1H), 4.55 (m, 1H), 5.09 (t, 1H, J = 8.8 Hz), 
5.69 (d, 1H, J = 8.8 Hz), and 8.66 (s, 1H); 13C NMR (CDCl3) δ 14.6, 16.6, 17.8, 19.4, 
28.2, 59.0, 62.1, 63.8, 68.8, 139.9, 149.0, 150.6, 154.0, and 169.7; mass spectrum 
(FAB), m/z 354.1236 (M+H)+ (C14H20N5O4S requires 354.1236). 
O
OHFmocHN
HO
S
N
H
H
 
2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-hydroxy-3-(5-ethylthiazol-4-
yl)propionic Acid (3.21). To a solution containing 0.90 g (2.55 mmol) of 3.42 in 44 
mL of 4:1 tetrahydrofuran−water was added 0.53 g (12.7 mmol) of LiOH⋅H2O. The 
reaction was stirred for 30 min at room temperature and quenched with 1 N HCl until 
pH 2.5 was reached. The reaction mixture was extracted with three 25-mL portions of 
ethyl acetate and two 25-mL portions of chloroform. The combined organic phase 
was washed with two 25-mL portions of brine, dried over anh MgSO4, filtered, and 
concentrated under diminished pressure to give a colorless solid. The residue was 
dissolved in 53 mL of 9:1 tetrahydrofuran−water. To this solution was added 0.70 g 
(5.09 mmol) of K2CO3 and 1.29 g (3.82 mmol) of FmocOSu. This solution was added 
to ~200 mg of 10% Pd/C under an Ar atmosphere. The reaction vessel was purged 
with H2 several times and stirred under H2 for 16 h. The reaction mixture was then 
filtered through a pad of Celite and washed thoroughly with two 100-mL portions of 
90:8:2 chloroform−methanol−acetic acid followed by 50 mL of toluene. Excess 
solvent was removed under diminished pressure and the resulting residue was 
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coevaporated with several portions of toluene to give a yellow oil. The residue was 
purified by flash chromatography on a silica gel column (43 x 5 cm). Elution with 
90:8:2 chloroform−methanol−acetic acid as eluant gave 3.21 as a light yellow solid: 
yield 0.35 g (28%); silica gel TLC Rf 0.22 (90:8:2 chloroform−methanol−acetic acid); 
1H NMR (CDCl3) δ 1.26 (m, 3H), 2.87 (m, 2H), 4.21 (m, 1H), 4.37 (m, 4H), 4.68 (m, 
1H), 5.32 (s, 1H), 6.62 (d, 1H, J = 7.2 Hz), 7.28 (m, 2H), 7.37 (m, 2H), 7.60 (t, 2H, J 
= 7.6 Hz), 7.73 (d, 2H, J = 7.2 Hz), and 8.61 (s, 1H); 13C NMR (CDCl3) δ 17.5, 19.5, 
47.1, 58.4, 67.4, 68.7, 119.9, 125.2, 125.3, 127.1, 127.1, 127.7, 127.7, 139.9, 141.2, 
141.2, 143.8, 143.8, 148.1, 150.9, 156.4, 160.8, and 171.7; mass spectrum (FAB), m/z 
439.1323 (M+H)+ (C23H23N2O5S requires 439.1328). 
O
O
O
 
2-Oxohexanoic Acid Ethyl Ester (3.44). To a solution containing 15.0 mL (16.1 g, 
110 mmol) of diethyl oxalate in 70 mL of diethyl ether at −78 °C was added 60.7 mL 
(14.3 g, 122 mmol) of n-butylmagnesium chloride (2.0 M in diethyl ether). The 
reaction mixture was stirred for 15 min and then allowed to warm to −10 °C for 2 h. 
The reaction mixture was quenched with 50 mL sat aq NH4Cl and extracted with three 
100-mL portions of ethyl acetate. The combined organic phase was dried over anh 
MgSO4, filtered and excess solvent was removed under diminished pressure. The 
residue was purified by flash chromatography on a silica gel column (43 x 7 cm). 
Elution with 1:3 ethyl acetate−hexanes as eluant gave 3.44 as a colorless oil: yield 
11.5 g (66%); silica gel TLC Rf 0.78 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
0.94 (t, 3H, J = 7.6 Hz), 1.38 (m, 5H), 1.63 (quint, 2H, J = 7.6 Hz), 2.85 (t, 2H, J = 
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7.6 Hz), and 4.31 (q, 2H, J = 7.6 Hz); 13C NMR (CDCl3) δ 13.2, 13.7, 14.3, 16.3, 
40.9, 62.0, 161.1, and 194.3; mass spectrum (EI), m/z 158.0940 (M)+ (C8H14O3 
requires 158.0943). 
O
O
O
Br
 
3-Bromo-2-oxohexanoic Acid Ethyl Ester (3.45). To a solution containing 11.5 g 
(72.9 mmol) of 3.44 in 300 mL chloroform was added a solution containing 48.8 g 
(219 mmol) of CuBr2 in 600 mL of ethyl acetate. The reaction mixture was stirred at 
reflux for 18 h, cooled, filtered through a silica pad of silica gel, and washed with 
three 100-mL portions of ethyl acetate. The excess solvent was removed under 
diminished pressure. The residue was purified by flash chromatography on a silica gel 
column (43 x 7 cm). Elution with 1:3 ethyl acetate−hexanes as eluant gave 3.45 as a 
yellow oil: yield 12.3 g (71%); silica gel TLC Rf 0.66 (1:1 ethyl acetate−hexanes); 1H 
NMR (CDCl3) δ 0.99 (t, 3H, J = 7.2 Hz), 1.45 (m, 1H), 1.57 (m, 1H), 2.00 (m, 3H), 
4.10 (q, 2H, J = 7.2 Hz), 4.38 (q, 2H, J = 7.2 Hz), and 5.07 (dd, 1H, J = 8.0 and 1.6 
Hz); 13C NMR (CDCl3) δ 13.1, 13.6, 20.1, 33.6, 48.1, 62.6, 160.2, and 185.5; mass 
spectrum (FAB), m/z 237.0175 (M+H)+ (C8H14O3Br requires 237.0126). 
S
NO
O
 
5-Propylthiazole-4-carboxylic Acid Ethyl Ester (3.46). To a solution containing 
15.0 mL (17.0 g, 278 mmol) of 3.39 in 60 mL of ethanol was added 12.3 g (51.8 
mmol) of 3.45. The reaction mixture was stirred at reflux for 3 h at which time solid 
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NaHCO3 was added carefully until no bubbling was observed. The reaction mixture 
was poured into 150 mL of water and extracted with three 250-mL portions of ethyl 
acetate. The combined organic phase was dried over anh MgSO4, filtered, and 
concentrated under diminished pressure to afford a crude residue. The residue was 
purified by flash chromatography on a silica gel column (43 x 7 cm). Step gradient 
elution with 1:4  1:1 ethyl acetate−hexanes as eluant gave 3.46 as a yellow oi: yield 
8.47 g (82%); silica gel TLC Rf 0.45 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
1.02 (t, 3H, J = 7.6 Hz), 1.43 (t, 3H, J = 7.6 Hz), 1.74 (m, 2H), 3.26 (t, 2H, J = 8.0 
Hz), 4.42 (q, 2H, J = 7.2 Hz), and 8.64 (s, 1H); 13C NMR (CDCl3) δ 13.6, 14.2, 24.8, 
29.0, 60.9, 141.3, 149.2, 150.3, and 162.1; mass spectrum (EI), m/z 199.0676 (M)+ 
(C9H13NO2S requires 199.0667). 
.
S
N
O
H
 
5-Propylthiazole-4-carbaldehyde (3.47). To a solution containing 8.32 g (41.8 
mmol) of 3.46 in 300 mL of dichloromethane at −78 °C was added 134 mL (19.0 g, 
134 mmol) of diisobutylaluminium hydride (1.0 M in toluene) over a period of 30 
min. The reaction mixture was stirred at −78 °C for 4 h at which time the reaction was 
quenched by the addition of 15 mL of methanol followed by 150 mL of 1:1 sat aq 
sodium potassium tartrate−pH 7 buffer. The reaction mixture was stirred vigorously at 
room temperature for 16 h, extracted with three 150-mL portions of dichloromethane, 
dried over anh MgSO4, filtered, and concentrated under diminished pressure. The 
residue was purified by flash chromatography on a silica gel column (43 x 7 cm). 
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Elution with 1:2 ethyl acetate−hexanes as eluant gave 3.47 as a colorless solid: yield 
5.90 g (91%); silica gel TLC Rf 0.60 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
0.81 (t, 3H, J = 8.0 Hz), 1.54 (m, 2H), 3.06 (t, 2H, J = 7.6 Hz), 8.52 (s, 1H), and 10.01 
(s, 1H); 13C NMR (CDCl3) δ 13.5, 24.7, 28.2, 148.7, 150.3, 150.9, 186.0; mass 
spectrum (FAB), m/z 156.0483 (M+H)+ (C7H10NOS requires 156.0483). 
ON
OO
N
S
OH
Br
 
3-[2-R-Bromo-3-R-hydroxy-3-(5-propylthiazol-4-yl)propionyl)]-4-R-
isopropyloxazolidin-2-one (3.48). To a solution containing 2.50 g (10.0 mmol) of 
3.28 in 50 mL of diethyl ether at −78 °C was added 2.67 mL (3.01 g, 11.0 mmol) of 
freshly prepared 3.27, followed immediately by the addition of 2.09 mL (1.52 g, 15.0 
mmol) of triethylamine. The reaction mixture was stirred for 0.5 h at −78 °C and then 
allowed to warm to room temperature and stirred for an additional 2 h. The resulting 
dark maroon solution was cooled to −78 °C, and a solution containing 1.55 g (10.0 
mmol) of 3.47 in 25 mL of dichloromethane was added dropwise. The reaction 
mixture was allowed to warm to room temperature and was stirred overnight. The 
reaction mixture was then diluted with 60 mL of 2:1 diethyl ether−dichloromethane 
and washed with two 45-mL portions of sat aq NaHSO4 and 25 mL of brine. The 
organic phase was concentrated under diminished pressure to give a brown oily 
residue which was dissolved in 20 mL of methanol. To this solution was added 6 mL 
of 30% aq H2O2 and the reaction was stirred for 1 h. The milky solution was 
concentrated under diminished pressure, and the resulting residue was dissolved in 10 
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mL of water and extracted with three 25-mL portions of 2:1 diethyl 
ether−dichloromethane. The combined organic phase was washed with two 10-mL 
portions of sat aq NaHCO3 and 5 mL of brine, dried over anh MgSO4, filtered and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (43 x 4 cm). Step gradient elution with 1:4 
ethyl acetate−hexanes  100% ethyl acetate as eluant gave 3.48 as colorless foam: 
yield 2.41 g (59%); silica gel TLC Rf 0.36 (1:1 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 0.93 (dd, 6H, J = 12.5 and 4.5 Hz), 1.01 (t, 3H, J = 7.2 Hz), 1.70 (q, 2H, J 
= 7.2 Hz), 2.35 (m, 1H), 2.93 (m, 2H), 3.44 (br s, 1H), 4.22 (m, 2H), 4.30 (m, 1H), 
5.31 (m, 1H), 6.30 (d, 1H, J = 7.6 Hz), and 8.55 (s, 1H); 13C NMR (CDCl3) δ 13.7, 
14.7, 17.6, 25.1, 27.8, 27.9, 49.2, 58.0, 62.3, 68.5, 138.0, 148.7, 149.9, 152.5, and 
167.9. Note: material decomposes rapidly, must be used immediately. 
ON
OO
N
S
OH
N3
 
3-[2-S-Azido-3-R-hydroxy-3-(5-propylthiazol-4-yl)propionyl)]-4-R-
isopropyloxazolidin-2-one (3.49). To a solution containing 2.41 g (5.95 mmol) of 
3.48 in 75 mL of N,N-dimethylformamide was added 1.93 g (29.7 mmol) of sodium 
azide. The reaction mixture was warmed to 45 °C and stirred for 1.25 h at which time 
it was poured into ~60 g of ice and extracted with three 25-mL portions of ethyl 
acetate. The combined organic phase was washed with two 25-mL portions of water 
and 10 mL of brine, dried over anh MgSO4, filtered and concentrated under 
diminished pressure to give a brown oil. The residue was purified via flash 
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chromatography on a silica gel column (43 x 4 cm). Step gradient elution with 1:4  
1:1 ethyl acetate−hexanes as eluant gave 3.49 as a colorless foam: yield 1.26 g (58%); 
silica gel TLC Rf 0.52 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.98 (d, 6H, J 
= 7.2 Hz), 1.03 (t, 3H, J = 6.0 Hz), 1.74 (m, 2H), 2.51 (m, 1H), 2.90 (t, 2H, J = 6.0 
Hz), 3.40 (d, 1H, J = 8.0 Hz), 4.30 (m, 1H), 4.37 (m, 1H), 4.55 (m, 1H), 5.06 (t, 1H, J 
= 7.2 Hz), 5.70 (d, 1H, J = 6.8 Hz), and 8.66 (s, 1H); 13C NMR (CDCl3) δ 13.7, 14.7, 
17.9, 25.4, 27.8, 28.3, 59.1, 62.1, 63.8, 69.0, 138.0, 149.5, 150.8, 154.0, and 169.8; 
mass spectrum (FAB), m/z 368.1403(M+H)+ (C15H22N5O4S requires 368.1393). 
O
OHFmocHN
HO
S
N
H
H
 
2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-hydroxy-3-(5-propylthiazol-4-
yl)propionic Acid (3.22). To a solution containing 1.26 g (3.43 mmol) of 3.49 in 60 
mL of 4:1 tetrahydrofuran−water was added 0.72 g (17.1 mmol) of LiOH⋅H2O. The 
reaction was stirred for 30 min at room temperature and quenched with 1 N HCl until 
pH 2.5 was reached. The reaction mixture was extracted with three 25-mL portions of 
ethyl acetate and two 25-mL portions of chloroform. The combined organic phase 
was washed with two 25-mL portions of brine, dried over anh MgSO4, filtered, and 
concentrated under diminished pressure to give a colorless solid. The residue was 
dissolved in 71 mL of 9:1 tetrahydrofuran−water. To this solution was added 0.95 g 
(6.86 mmol) of K2CO3 and 1.74 g (5.14 mmol) of FmocOSu. This solution was added 
to ~200 mg of 10% Pd/C under an Ar atmosphere. The reaction vessel was purged 
with H2 several times and stirred under H2 for 16 h. The reaction mixture was then 
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filtered through a pad of Celite and washed thoroughly with two 100-mL portions of 
90:8:2 chloroform−methanol−acetic acid followed by 50 mL of toluene. Excess 
solvent was removed under diminished pressure and the resulting residue was 
coevaporated with several portions of toluene to give a yellow oil. The residue was 
purified by flash chromatography on a silica gel column (43 x 5 cm). Elution with 
90:8:2 chloroform−methanol−acetic acid as eluant gave 3.22 as a light yellow solid: 
yield 0.31 g (22%); silica gel TLC Rf 0.28 (90:8:2 chloroform−methanol−acetic acid). 
1H NMR (CDCl3) δ 1.26 (m, 3H), 1.65 (m, 2H), 2.81 (t, 2H, J = 7.2 Hz), 4.19 (t, 2H, 
J = 7.2 Hz), 4.35 (m, 3H), 4.75 (m, 1H), 5.32 (s, 1H), 6.66 (d, 1H, J = 8.0 Hz), 7.28 
(m, 2H), 7.37 (m, 2H), 7.60 (t, 2H, J = 7.6 Hz), 7.72 (d, 2H, J = 7.6 Hz); and 8.61 (s, 
1H); 13C NMR (CDCl3) δ 13.7, 17.9, 25.1, 27.7, 58.4, 67.4, 68.7, 119.9, 125.2, 125.3, 
127.1, 127.1, 127.7, 127.7, 138.1, 141.2, 141.2, 143.7, 143.9, 148.8, 151.1, 156.4, 
161.6, and 171.9; mass spectrum (FAB), m/z 453.1486 (M+H)+ (C24H25N2O5S 
requires 453.1484). 
N
H
N
OTBS
 
4-(tert-Butyl-dimethylsilanyloxymethyl)-1H-imidazole (3.50).150 To a solution 
containing 1.00 g (51.0 mmol) of 3-imidazolemethanol hydrochloride in 25 mL of 
N,N-dimethylformamide was added 1.52 g (22.3 mmol) of imidazole, 1.23 g (8.18 
mmol) of tert-butyldimethylsilyl chloride, and a catalytic amount of 4-
dimethylaminopyridine. The reaction mixture was stirred for 16 h. The reaction 
mixture was quenched with 25 mL of water and extracted with three 150-mL portions 
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of ethyl acetate. The combined organic phase was washed with three 15-mL portions 
of brine, dried over anh MgSO4, filtered, and excess solvent was removed under 
diminished pressure to give 3.50 as a yellow oil: yield 1.59 g (98%); silica gel TLC Rf 
0.65 (10:1:0.1 dichloromethane−methanol−ammonium hydroxide); 1H NMR (CDCl3) 
δ 0.12 (s, 6H), 0.95 (s, 9H), 4.78 (s, 2H), 6.99 (s, 1H) and 7.62 (s, 1H). 
N
N
OTBS
CPh3
 
4-(tert-Butyldimethylsilanyloxymethyl)-1-trityl-1H-imidazole (3.51).150 To a 
solution containing 1.55 g (7.30 mmol) of 3.50 in 60 mL of benzene was added 1.12 
mL (0.80 g, 8.02 mmol) of triethylamine and 2.38 g (8.02 mmol) of trityl chloride. 
The reaction mixture was stirred at reflux for 1.5 h. The cooled reaction mixture was 
washed with three 25-mL portions of water, dried over anh MgSO4, filtered, and 
concentrated under diminished pressure to give a crude yellow oil. The residue was 
purified by flash chromatography on a silica gel column (34 x 5 cm). Step gradient 
elution with 1:3  1:1 ethyl acetate–hexanes as eluant gave 3.51 as a yellow solid: 
yield 2.20 g (60%); silica gel TLC Rf 0.38 (1:4 ethyl acetate–hexanes); 1H NMR 
(CDCl3) δ 0.07 (s, 6H), 0.88 (s, 9H), 4.75 (s, 2H), 6.78 (s, 1H), 7.18 (m, 6H), 7.37 (m, 
9H), and 7.51 (s, 1H). 
 
 
 116 
 
N
N
OTBS
CPh3
 
4-(tert-Butyldimethylsilanyloxymethyl)-2-methyl-1-trityl-1H-imidazole (3.52).150 
To a solution containing 2.20 g (4.83 mmol) of 3.51 in 60 mL of tetrahydrofuran at 
−78 °C was added 5.70 mL (9.68 mmol) of tert-butyllithium (1.7 M in pentane) over 
5 min. The resulting red solution was stirred at −78 °C for 2 h at which time 0.60 mL 
(1.37 g, 9.68 mmol) of methyl iodide was added during 5 min. The resulting brown 
solution was allowed to warm to room temperature and was stirred for 18 h. The 
reaction mixture was quenched with 25 mL of sat aq NH4Cl and extracted with three 
25-mL portions of chloroform. The combined organic phase was dried over anh 
MgSO4, filtered, and concentrated under diminished pressure to give a dark solid. The 
solid was recrystallized from 1:4 ethyl acetate−hexanes. The remaining solvent was 
removed under diminished pressure to give a brown residue. The residue was purified 
by flash chromatography on a silica gel column (38 x 5 cm). Elution with 1:2 ethyl 
acetate–hexanes as eluant gave 3.52 as a brown solid: yield 1.38 g (61%); silica gel 
TLC Rf 0.47 (1:2 ethyl acetate–hexanes); 1H NMR (CDCl3) δ 0.03 (s, 6H), 0.84 (s, 
9H), 1.61 (s, 3H), 4.66 (s, 2H), 6.59 (s, 1H), 7.13 (m, 6H), and 7.31 (m, 9H). 
N
N
OH
CPh3
 
(2-Methyl-1-trityl-1H-imidazol-4-yl)methanol (3.53).150 To a solution containing 
61.38 g (2.94 mmol) of 3.52 in 40 mL of tetrahydrofuran was added 1.02 g (3.24 
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mmol) of TBAF⋅3H2O. The reaction mixture was stirred at room temperature for 48 h. 
The resulting milky white solution was diluted with 30 mL of water and extracted 
with three 50-mL portions of chloroform. The combined organic phase was washed 
with three 15-mL portions of sat aq NaHCO3 and 10 mL of brine, dried over anh 
MgSO4, filtered, and concentrated under diminished pressure to give a colorless solid 
which was recrystallized from ethanol. The remaining solvent was removed under 
diminished pressure to give a colorless oil. The residue was purified by flash 
chromatography on a silica gel column (39 x 4 cm). Elution with 1:4 
methanol−dichloromethane as eluant gave 3.53 as a colorless solid: yield 0.75 g 
(72%); silica gel TLC Rf 0.66 (1:4 methanol−dichloromethane); 1H NMR (CDCl3) δ 
1.68 (s, 3H), 4.56 (s, 2H), 6.70 (s, 1H), 7.17 (m, 6H), and 7.31 (m, 9H). 
N
N
O
CPh3
H
 
2-Methyl-1-trityl-1H-imidazole-4-carbaldehyde (3.54).150 To a solution containing 
0.75 g (2.11 mmol) of 3.53 in 40 mL of dioxane was added 0.90 g (10.5 mmol) of 
activated MnO2. The reaction mixture was stirred at reflux for 18 h. The reaction 
mixture was filtered through a Celite pad and washed with three 60-mL portions of 
hot dioxane. Excess solvent was removed under diminished pressure to give a 
colorless solid. The residue was purified by flash chromatography on a silica gel 
column (30 x 4 cm). Elution with 1:2 ethyl acetate–hexanes as eluant gave 3.54 as a 
colorless solid: yield 0.47 g (63%); silica gel TLC Rf 0.58 (1:2 ethyl acetate–hexanes); 
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1H NMR (CDCl3) δ 1.74 (s, 3H), 7.19 (m, 6H), 7.40 (m, 9H), 7.56 (s, 1H), and 9.84 
(s, 1H). 
ON
OO
N
N
OH
Br
CPh3
 
3-[2-R-Bromo-3-R-hydroxy-3-(2-methyl-1-trityl-1H-imidazol-4-yl)propionyl)]-4-
R-isopropyloxazolidin-2-one (3.55).150 To a solution containing 0.53 g (2.12 mmol) 
of 3.28 in 20 mL of diethyl ether at −78 °C was added 0.56 mL (0.64 g, 2.33 mmol) 
of freshly prepared 3.27, followed immediately by the addition of 0.33 mL (0.24 g, 
2.33 mmol) of triethylamine. The reaction mixture was stirred for 0.5 h at −78 °C and 
then allowed to warm to room temperature and stirred for an additional 2 h. The 
resulting dark maroon solution was cooled to −78 °C, and a solution containing 0.75 g 
(2.12 mmol) of 3.54 in 8 mL of dichloromethane was added dropwise. The reaction 
mixture was allowed to warm to room temperature and was stirred overnight. The 
reaction mixture was then diluted with 60 mL of 2:1 diethyl ether−dichloromethane 
and washed with two 45-mL portions of sat aq NaHSO4 and 25 mL of brine. The 
organic phase was concentrated under diminished pressure to give a brown oily 
residue which was dissolved in 20 mL of methanol. To this solution was added 6 mL 
of 30% aq H2O2 and the reaction was stirred for 1 h. The milky solution was 
concentrated under diminished pressure, and the resulting residue was dissolved in 10 
mL of water and extracted with three 25-mL portions of 2:1 diethyl 
ether−dichloromethane. The combined organic phase was washed with two 10-mL 
portions of sat aq NaHCO3 and 5 mL of brine, dried over anh MgSO4, filtered and 
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concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (41 x 4 cm). Step gradient elution with 1:4 
ethyl acetate−hexanes  100% ethyl acetate as eluant gave 3.55 as colorless oil: yield 
0.31 g (24%); silica gel TLC Rf 0.31 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
0.97 (d, 6H, J = 6.9 Hz), 1.61 (s, 3H), 2.43 (m, 1H), 4.32 (m, 2H), 4.44 (quint, 1H, J = 
4.2 Hz), 5.16 (d, 1H, J = 5.7 Hz), 6.04 (d, 1H, J = 6.0 Hz), 6.82 (s, 1H), 7.14 (m, 6H), 
and 7.34 (m, 9H). Note: material decomposes rapidly, must be used immediately. 
ON
OO
N
N
OH
N3
CPh3
 
3-[2-S-Azido-3-R-hydroxy-3-(2-methyl-1-trityl-1H-imidazol-4-yl)propionyl)]-4-R-
isopropyloxazolidin-2-one (3.56).150 To a solution containing 250 mg (0.41 mmol) of 
3.55 in 20 mL of N,N-dimethylformamide was added 134 mg (2.08 mmol) of sodium 
azide. The reaction mixture was warmed to 45 °C and stirred for 1.25 h at which time 
it was poured into ~15 g of ice and extracted with three 25-mL portions of ethyl 
acetate. The combined organic phase was washed with two 25-mL portions of water 
and 10 mL of brine, dried over anh MgSO4, filtered and concentrated under 
diminished pressure to give a brown oil. The residue was purified via flash 
chromatography on a silica gel column (40 x 2.5 cm). Step gradient elution with 1:4 
 1:1 ethyl acetate−hexanes as eluant gave 3.56 as a colorless oil: yield 129 mg 
(55%); silica gel TLC Rf 0.51 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.90 
(dd, 6H, J = 6.9 and 1.2 Hz), 1.63 (s, 3H), 2.31 (m, 1H), 4.31 (m, 2H), 4.51 (quint, 
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1H, J = 3.9 Hz), 4.93 (d, 1H, J = 7.8 Hz), 5.60 (d, 1H, J = 8.4 Hz), 6.81 (s, 1H), 7.16 
(m, 6H), and 7.32 (m, 9H). 
O
OHFmocHN
HO
N
N
H
H
CPh3
 
2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-hydroxy-3-(2-methyl-1-trityl-1H-
imidazol-4-yl)propionic Acid (3.11).150 To a solution containing 141 mg (0.25 
mmol) of 3.56 in 20 mL of 4:1 tetrahydrofuran−water was added 52 mg (1.25 mmol) 
of LiOH⋅H2O. The reaction was stirred for 30 min at room temperature and quenched 
with 1 N HCl until pH 2.5 was reached. The reaction mixture was extracted with three 
25-mL portions of ethyl acetate and two 25-mL portions of chloroform. The 
combined organic phase was washed with two 25-mL portions of brine, dried over 
anh MgSO4, filtered, and concentrated under diminished pressure to give a colorless 
solid. The residue was dissolved in 30 mL of 9:1 tetrahydrofuran−water. To this 
solution was added 70 mg (0.50 mmol) of K2CO3 and 126 mg (0.37 mmol) of 
FmocOSu. This solution was added to ~30 mg of 10% Pd/C under an Ar atmosphere. 
The reaction vessel was purged with H2 several times and stirred under H2 for 16 h. 
The reaction mixture was then filtered through a pad of Celite and washed thoroughly 
with two 100-mL portions of 90:8:2 chloroform−methanol−acetic acid followed by 50 
mL of toluene. Excess solvent was removed under diminished pressure and the 
resulting residue was coevaporated with several portions of toluene to give a yellow 
oil. The residue was purified by flash chromatography on a silica gel column (42 x 4 
cm). Elution with 90:8:2 chloroform−methanol−acetic acid as eluant gave 3.11 as a 
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colorless solid: yield 27 mg (17%); silica gel TLC Rf 0.70 (88:10:2 
dichloromethane−methanol−acetic acid); 1H NMR (CDCl3) δ 1.48 (s, 3H), 4.19 (m, 
3H), 4.32 (m, 1H), 4.71 (m, 1H), 6.62 (s, 1H), 7.05 (d, 6H, J = 7.0 Hz), 7.35 (m, 
13H), 7.68 (t, 2H, J = 9.0 Hz), and 7.88 (d, 1H, J = 7.0 Hz). 
N
H
N
OTBS
 
4-(tert-Butyldimethylsilanyloxymethyl)-5-methyl-1H-imidazole (3.57).150 To a 
solution containing 3.00 g (20.2 mmol) of 4-hydroxymethyl-5-methylimidazole in 75 
mL of N,N-dimethylformamide was added4.12 g (60.6 mmol) of imidazole, 3.35 g 
(22.2 mmol) of tert-butyldimethylsilyl chloride, and a catalytic amount of 4-
dimethylaminopyridine. The reaction mixture was stirred for 16 h at room 
temperature. The reaction mixture was quenched with 25 mL of water and extracted 
with three 100-mL portions of ethyl acetate. The combined organic phase was washed 
with three 25-mL portions of brine, dried over anh MgSO4, filtered, and concentrated 
under diminished pressure to give 3.57 as a colorless foam: yield 4.53 (99%); silica 
gel TLC Rf 0.1 (1:1 hexanes−ethyl acetate); 1H NMR (CDCl3) δ 0.01 (s, 6H), 0.85 (s, 
9H), 2.22 (s, 3H), 4.63 (s, 2H), and 7.47 (s, 1H). 
N
N
OTBS
CPh3
 
4-(tert-Butyldimethylsilanyloxymethyl)-5-methyl-1-trityl-1H-imidazole (3.58).150 
To a solution containing 4.20 g (18.6 mmol) of 3.57 in 250 mL of benzene was added 
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2.86 mL (2.06 g, 20.4 mmol) of triethylamine and 5.70 g (20.4 mmol) of trityl 
chloride. The reaction mixture was stirred at reflux for 4 h. The reaction mixture was 
washed with three 25-mL portions of water and dried over anh MgSO4. Excess 
solvent was removed under diminished pressure to give a crude colorless solid. The 
residue was purified by flash chromatography on a silica gel column (35 x 7 cm). Step 
gradient elution with 1:3  1:1 ethyl acetate–hexanes as eluant gave 3.58 as a 
colorless solid: yield 1.69 g (19%); silica gel TLC Rf 0.77 (1:1 ethyl acetate–hexanes); 
1H NMR (CDCl3) δ 0.05 (s, 6H), 0.86 (s, 9H), 1.46 (s, 3H), 4.03 (s, 2H), 7.12 (m, 
6H), 7.22 (s, 1H), and 7.28 (m, 9H). 
N
N
OH
CPh3
 
(5-Methyl-1-trityl-1H-imidazol-4-yl)methanol (3.59).150 To a solution containing 
1.00 g (2.13 mmol) of 3.58 in 50 mL of tetrahydrofuran was added 0.74 g (2.34 
mmol) of TBAF⋅3H2O. The reaction mixture was stirred at room temperature for 18 h 
and the resulting milky white solution was diluted with 30 mL of water and was 
extracted with three 50-mL portions of ethyl acetate. The combined organic phase 
was washed with three 20-mL portions of sat aq NaHCO3 and 10 mL of brine, dried 
over anh MgSO4, filtered, and excess solvent was removed under diminished 
pressure. The residue was purified by flash chromatography on a silica gel column (33 
x 4 cm). Elution with 1:4 methanol–dichloromethane as eluant gave 3.59 as a 
colorless solid: yield 2.93 g (93%); silica gel TLC Rf 0.47 (1:4 
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methanol−dichloromethane); 1H NMR (CDCl3) δ 1.45 (s, 3H), 4.53 (s, 2H), 7.13 (m, 
6H), and 7.31 (m, 10H). 
N
N
O
CPh3
H
 
5-Methyl-1-trityl-1H-imidazole-4-carbaldehyde (3.60).150 To a solution containing 
0.70 g (3.09 mmol) of 3.59 in 50 mL of dioxane was added 0.90 g (9.88 mmol) of 
activated MnO2. The reaction mixture was stirred at reflux for 16 h. The reaction 
mixture was filtered through a Celite pad and washed with three 80-mL portions of 
hot dioxane. Excess solvent was removed under diminished pressure to give a 
colorless solid. The residue was purified by flash chromatography on a silica gel 
column (37 x 4 cm). Elution with 1:2 ethyl acetate–hexanes as eluant gave 3.60 as a 
colorless solid: yield 3.33 g (62%); silica gel TLC Rf 0.44 (1:1 ethyl acetate–
hexanes); 1H NMR (CDCl3) δ 1.99 (s, 3H), 7.27 (m, 6H), 7.45 (m, 9H), 7.60 (s, 1H), 
and 10.14 (s, 1H). 
ON
OO
N
N
OH
Br
CPh3
 
3-[2-R-Bromo-3-R-hydroxy-3-(5-methyl-1-trityl-1H-imidazol-4-yl)propionyl)]-4-
R-isopropyloxazolidin-2-one (3.61).150 To a solution containing 0.43 g (1.72 mmol) 
of 3.28 in 50 mL of diethyl ether at −78 °C was added 0.50 mL (0.52 g, 1.90 mmol) 
of freshly prepared 3.27, followed immediately by the addition of 0.26 mL (0.19 mg, 
1.90 mmol) of triethylamine. The reaction mixture was stirred for 0.5 h at −78 °C and 
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then allowed to warm to room temperature and stirred for an additional 2 h. The 
resulting dark maroon solution was cooled to −78 °C, and a solution containing 0.63 g 
(1.72 mmol) of 3.60 in 8 mL of dichloromethane was added dropwise. The reaction 
mixture was allowed to warm to room temperature and was stirred overnight. The 
reaction mixture was then diluted with 60 mL of 2:1 diethyl ether−dichloromethane 
and washed with two 45-mL portions of sat aq NaHSO4 and 25 mL of brine. The 
organic phase was concentrated under diminished pressure to give a brown oily 
residue which was dissolved in 20 mL of methanol. To this solution was added 6 mL 
of 30% aq H2O2 and the reaction was stirred for 1 h. The milky solution was 
concentrated under diminished pressure, and the resulting residue was dissolved in 10 
mL of water and extracted with three 25-mL portions of 2:1 diethyl 
ether−dichloromethane. The combined organic phase was washed with two 10-mL 
portions of sat aq NaHCO3 and 5 mL of brine, dried over anh MgSO4, filtered and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (40 x 4 cm). Step gradient elution with 1:4 
ethyl acetate−hexanes  100% ethyl acetate as eluant gave 3.61 as colorless foam: 
yield 0.13 g (12%); silica gel TLC Rf 0.32 (1:1 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 0.94 (dd, 6H, J = 6.5 and 2.4 Hz), 1.55 (s, 3H), 2.42 (m, 1H), 4.31 (m, 3H), 
5.13 (d, 1H, J = 8.4 Hz), 6.21 (d, 1H, J = 8.4 Hz), 7.14 (m, 6H), 7.31 (m, 9H), and 
7.39 (s, 1H). Note: material decomposes rapidly, must be used immediately. 
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3-[2-S-Azido-3-R-hydroxy-3-(5-methyl-1-trityl-1H-imidazol-4-yl)propionyl)]-4-R-
isopropyloxazolidin-2-one (3.62).150 To a solution containing 0.14 g (0.22 mmol) of 
3.61 in 50 mL of N,N-dimethylformamide was added 0.08 g (1.07 mmol) of sodium 
azide. The reaction mixture was warmed to 45 °C and stirred for 1.25 h at which time 
it was poured into ~45 g of ice and extracted with three 25-mL portions of ethyl 
acetate. The combined organic phase was washed with two 25-mL portions of water 
and 10 mL of brine, dried over anh MgSO4, filtered and concentrated under 
diminished pressure to give a colorless oil. The residue was purified via flash 
chromatography on a silica gel column (37 x 4 cm). Step gradient elution with 1:4  
1:1 ethyl acetate−hexanes as eluant gave 3.62 as a colorless foam: yield 0.09 g (65%); 
silica gel TLC Rf 0.45 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.91 (m, 6H), 
1.53 (s, 3H), 2.46 (m, 1H), 4.25 (m, 1H), 4.35 (t, 1H, J = 9.3 Hz), 4.54 (m, 1H), 4.87 
(d, 1H, J = 7.8 Hz) 5.77 (d, 1H, J = 9.0 Hz), 7.18 (m, 6H), 7.33 (m, 9H), and 7.36 (s, 
1H). 
O
OHFmocHN
HO
N
N
H
H
CPh3
 
2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-hydroxy-3-(5-methy-1-trityl-1H-
imidazol-4-yl)propionic Acid (3.13).150 To a solution containing 0.33 g (0.58 mmol) 
of 3.62 in 30 mL of 4:1 tetrahydrofuran−water was added 0.35 g (2.11 mmol) of 
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LiOH⋅H2O. The reaction was stirred for 30 min at room temperature and quenched 
with 1 N HCl until pH 2.5 was reached. The reaction mixture was extracted with three 
25-mL portions of ethyl acetate and two 25-mL portions of chloroform. The 
combined organic phase was washed with two 25-mL portions of brine, dried over 
anh MgSO4, filtered, and concentrated under diminished pressure to give a colorless 
solid. The residue was dissolved in 30 mL of 9:1 tetrahydrofuran−water. To this 
solution was added 0.18 g (1.10 mmol) of K2CO3 and 0.28 g (0.94 mmol) of 
FmocOSu. This solution was added to ~100 mg of 10% Pd/C under an Ar 
atmosphere. The reaction vessel was purged with H2 several times and stirred under 
H2 for 16 h. The reaction mixture was then filtered through a pad of Celite and 
washed thoroughly with two 100-mL portions of 90:8:2 chloroform−methanol−acetic 
acid followed by 50 mL of toluene. Excess solvent was removed under diminished 
pressure and the resulting residue was coevaporated with several portions of toluene 
to give a yellow oil. The residue was purified by flash chromatography on a silica gel 
column (42 x 5 cm). Elution with 90:8:2 chloroform−methanol−acetic acid as eluant 
gave 3.13 as a colorless solid: yield 86 mg (14%); silica gel TLC Rf 0.68 (88:10:2 
dichloromethane−methanol−acetic acid); 1H NMR (CDCl3) δ 1.57 (s, 3H), 4.18 (m, 
3H), 4.36 (m, 1H), 5.20 (m, 1H), 7.09 (m, 7H), 7.31 (m, 13H), 7.59 (m, 2H), and 7.72 
(m, 2H). 
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Thiazole-4-carboxylic Acid Ethyl Ester (3.63).150 To a solution containing 22.1 mL 
(25.1 g, 410 mmol) of 3.39 in 120 mL of ethanol was added 14.3 mL (12.9 g, 103 
mmol) of 3-bromo-2-oxopropionic acid ethyl ester. The reaction mixture was stirred 
at reflux for 3 h at which time solid NaHCO3 was added carefully until no bubbling 
was observed. The reaction mixture was poured into 150 mL of water and extracted 
with three 250-mL portions of ethyl acetate. The combined organic phase was dried 
over anh MgSO4, filtered, and concentrated under diminished pressure to afford a 
crude residue. The residue was purified by flash chromatography on a silica gel 
column (43 x 7 cm). Step gradient elution with 1:4  1:1 ethyl acetate−hexanes as 
eluant gave 3.63 as a yellow solid: yield 13.2 g (82%); silica gel TLC Rf 0.70 (1:1 
ethyl acetate−hexanes); 1H NMR (CDCl3) δ 1.37 (t, 3H, J = 7.2 Hz), 4.38 (q, 2H, J = 
7.2 Hz), 8.21 (s, 1H), and 8.82 (s, 1H). 
S
N
O
H
 
Thiazole-4-carbaldehyde (3.64).150 To a solution containing 6.00 g (38.2 mmol) of 
3.63 in 300 mL of dichloromethane at −78 °C was added 122 mL (17.3 g, 122 mmol) 
of diisobutylaluminium hydride (1.0 M in toluene) over a period of 30 min. The 
reaction mixture was stirred at −78 °C for 4 h at which time the reaction was 
quenched by the addition of 15 mL of methanol followed by 150 mL of 1:1 sat aq 
sodium potassium tartrate−pH 7 buffer. The reaction mixture was stirred vigorously at 
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room temperature for 16 h, extracted with three 150-mL portions of dichloromethane, 
dried over anh MgSO4, filtered, and concentrated under diminished pressure. The 
residue was purified by flash chromatography on a silica gel column (43 x 7 cm). 
Elution with 1:2 ethyl acetate−hexanes as eluant gave 3.64 as a yellow solid: yield 
3.15 g (73%); silica gel TLC Rf 0.51 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
8.17 (s, 1H), 8.81 (s, 1H), and 9.92 (s, 1H). 
ON
OO
N
S
OH
Br
 
3-(2-R-Bromo-3-R-hydroxy-3-thiazol-4-ylpropionyl)-4-R-isopropyloxazolidin-2-
one (3.65).150 To a solution containing 2.20 g (10.0 mmol) of 3.28 in 100 mL of 
diethyl ether at −78 °C was added 2.35 mL (2.65 g, 9.68 mmol) of freshly prepared 
3.27, followed immediately by the addition of 1.84 mL (1.34 g, 13.2 mmol) of 
triethylamine. The reaction mixture was stirred for 0.5 h at −78 °C and then allowed 
to warm to room temperature and stirred for an additional 2 h. The resulting dark 
maroon solution was cooled to −78 °C, and a solution containing 1.00 g (10.0 mmol) 
of 3.64 in 15 mL of dichloromethane was added dropwise. The reaction mixture was 
allowed to warm to room temperature and was stirred overnight. The reaction mixture 
was then diluted with 60 mL of 2:1 diethyl ether−dichloromethane and washed with 
two 45-mL portions of sat aq NaHSO4 and 25 mL of brine. The organic phase was 
concentrated under diminished pressure to give a brown oily residue which was 
dissolved in 20 mL of methanol. To this solution was added 6 mL of 30% aq H2O2 
and the reaction was stirred for 1 h. The milky solution was concentrated under 
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diminished pressure, and the resulting residue was dissolved in 10 mL of and 
extracted with three 25-mL portions of 2:1 diethyl ether−dichloromethane. The 
combined organic phase was washed with two 10-mL portions of sat aq NaHCO3 and 
5 mL of brine, dried over anh MgSO4, filtered and concentrated under diminished 
pressure. The residue was purified by flash chromatography on a silica gel column (43 
x 24 cm). Step gradient elution with 1:4 ethyl acetate−hexanes  100% ethyl acetate 
as eluant gave 3.65 as colorless oil: yield 1.03 g (32%); silica gel TLC Rf 0.28 (1:1 
ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.92 (dd, 6H, J = 15.0 and 5.4 Hz), 2.36 
(m, 1H), 4.24 (m, 2H), 4.47 (m, 1H), 5.36 (dd, 1H, J = 3.0 and 1.2 Hz), 6.16 (d, 1H, J 
= 3.9 Hz), 7.84 (dd, 1H, J = 1.2 and 0.9 Hz), and 8.75 (d, 1H, J = 2.1 Hz). 
ON
OO
N
S
OH
N3
 
3-(2-S-Azido-3-R-hydroxy-3-thiazol-4-ylpropionyl))-4-R-isopropyloxazolidin-2-
one (3.66).150 To a solution containing 1.03 g (2.84 mmol) of 3.65 in 40 mL of N,N-
dimethylformamide was added 0.92 g (14.2 mmol) of sodium azide. The reaction 
mixture was warmed to 45 °C and stirred for 1.25 h at which time it was poured into 
~45 g of ice and extracted with three 25-mL portions of ethyl acetate. The combined 
organic phase was washed with two 25-mL portions of water and 10 mL of brine, 
dried over anh MgSO4, filtered and concentrated under diminished pressure to give a 
brown oil. The residue was purified via flash chromatography on a silica gel column 
(43 x 4 cm). Step gradient elution with 1:4  1:1 ethyl acetate−hexanes as eluant 
gave 3.66 as a colorless oil: yield 0.55 g (60%); silica gel TLC Rf 0.45 (1:1 ethyl 
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acetate−hexanes); 1H NMR (CDCl3) δ 0.89 (dd, 6H, J = 7.2 and 2.7 Hz), 2.37 (m, 
1H), 4.27 (m, 2H), 4.54 (m, 1H), 5.31 (d, 1H, J = 7.5 Hz), 5.65 (d, 1H, J = 7.5 Hz), 
7.54 (d, 1H, J = 2.1 Hz), and 8.84 (d, 1H, J = 2.1 Hz). 
O
OHFmocHN
HO
S
N
H
H
 
2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-hydroxy-3-thiazol-4-ylpropionic 
Acid (3.14).150 To a solution containing 0.55 g (1.69 mmol) of 3.66 in 20 mL of 4:1 
tetrahydrofuran−water was added 0.35 g (8.45 mmol) of LiOH⋅H2O. The reaction was 
stirred for 30 min at room temperature and quenched with 1 N HCl until pH 2.5 was 
reached. The reaction mixture was extracted with three 25-mL portions of ethyl 
acetate and two 25-mL portions of chloroform. The combined organic phase was 
washed with two 25-mL portions of brine, dried over anh MgSO4, filtered, and 
concentrated under diminished pressure to give a colorless solid. The residue was 
dissolved in 20 mL of 9:1 tetrahydrofuran−water. To this solution was added 0.47 g 
(3.38 mmol) of K2CO3 and 0.85 g (2.54 mmol) of FmocOSu. This solution was added 
to ~100 mg of 10% Pd/C under an Ar atmosphere. The reaction vessel was purged 
with H2 several times and stirred under H2 for 16 h. The reaction mixture was then 
filtered through a pad of Celite and washed thoroughly with two 100-mL portions of 
90:8:2 chloroform−methanol−acetic acid followed by 50 mL of toluene. Excess 
solvent was removed under diminished pressure and the resulting residue was 
coevaporated with several portions of toluene to give a yellow oil. The residue was 
purified by flash chromatography on a silica gel column (43 x 5 cm). Elution with 
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90:8:2 chloroform−methanol−acetic acid as eluant gave 3.14 as a colorless solid: yield 
0.18 g (28%); silica gel TLC Rf 0.22 (88:10:2 dichloromethane−methanol−acetic 
acid); 1H NMR (DMSO-d6) δ 4.19 (m, 3H), 4.57 (m, 1H), 5.06 (d, 1H, J = 5.5 Hz), 
7.32 (t, 2H, J = 7.5 Hz), 7.42 (t, 2H, J = 7.5 Hz), 7.51 (s, 1H), 7.67 (d, 2H, J = 7.5 
Hz), 7.88 (d, 2H, J = 7.5 Hz), and 9.05 (s, 1H). 
S
NO
O
 
2-Methylthiazole-4-carboxylic Acid Ethyl Ester (3.67).150 To a solution containing 
500 mg (6.65 mmol) of thioacetamide in 5 mL of ethanol was added 0.82 mL (1.23 g, 
6.63 mmol) of 3-bromo-2-oxopropionic acid ethyl ester. The reaction mixture was 
stirred at reflux for 3 h at which time solid NaHCO3 was added carefully until no 
bubbling was observed. The reaction mixture was poured into 100 mL of water and 
extracted with three 150-mL portions of ethyl acetate. The combined organic phase 
was dried over anh MgSO4, filtered, and concentrated under diminished pressure to 
afford a crude residue. The residue was purified by flash chromatography on a silica 
gel column (43 x 4 cm). Step gradient elution with 1:4  1:1 ethyl acetate−hexanes 
as eluant gave 3.67 as a colorless solid: yield 0.73 g (72%); silica gel TLC Rf 0.51 
(1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 1.34 (t, 3H, J = 7.2 Hz), 2.71 (s, 3H), 
4.34 (q, 2H, J = 7.2 Hz), and 7.98 (s, 1H). 
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2-Methylthiazole-4-carbaldehyde (3.68).150 To a solution containing 0.73 g (4.26 
mmol) of 3.67 in 50 mL of dichloromethane at −78 °C was added 13.2 mL (1.90 g, 
13.2 mmol) of diisobutylaluminium hydride (1.0 M in toluene) over a period of 30 
min. The reaction mixture was stirred at −78 °C for 4 h at which time the reaction was 
quenched by the addition of 15 mL of methanol followed by 150 mL of 1:1 sat aq 
sodium potassium tartrate−pH 7 buffer. The reaction mixture was stirred vigorously at 
room temperature for 16 h, extracted with three 100-mL portions of dichloromethane, 
dried over anh MgSO4, filtered, and concentrated under diminished pressure. The 
residue was purified by flash chromatography on a silica gel column (43 x 4 cm). 
Elution with 1:1 ethyl acetate−hexanes as eluant gave 3.68 as a colorless solid: yield 
0.26 g (40%); silica gel TLC Rf 0.53 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
2.63 (s, 3H), 7.95 (s, 1H), and 9.81 (s, 1H). 
ON
OO
N
S
OH
Br
 
3-[2-R-Bromo-3-R-hydroxy-3-(2-metylthiazol-4-yl)propionyl]-4-R-
isopropyloxazolidin-2-one (3.69).150 To a solution containing 420 mg (1.68 mmol) of 
3.28 in 20 mL of diethyl ether at −78 °C was added 0.45 mL (0.51 g, 1.85 mmol) of 
freshly prepared 3.27, followed immediately by the addition of 0.26 mL (0.19 g, 1.85 
mmol) of triethylamine. The reaction mixture was stirred for 0.5 h at −78 °C and then 
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allowed to warm to room temperature and stirred for an additional 2 h. The resulting 
dark maroon solution was cooled to −78 °C, and a solution containing 0.21 g (1.68 
mmol) of 3.68 in 8 mL of dichloromethane was added dropwise. The reaction mixture 
was allowed to warm to room temperature and was stirred overnight. The reaction 
mixture was then diluted with 60 mL of 2:1 diethyl ether−dichloromethane and 
washed with two 45-mL portions of sat aq NaHSO4 and 25 mL of brine. The organic 
phase was concentrated under diminished pressure to give a brown oily residue which 
was dissolved in 20 mL of methanol. To this solution was added 6 mL of 30% aq 
H2O2 and the reaction was stirred for 1 h. The milky solution was concentrated under 
diminished pressure, and the resulting residue was dissolved in 10 mL of water and 
extracted with three 25-mL portions of 2:1 diethyl ether−dichloromethane. The 
combined organic phase was washed with two 10-mL portions of sat aq NaHCO3 and 
5 mL of brine, dried over anh MgSO4, filtered and concentrated under diminished 
pressure. The residue was purified by flash chromatography on a silica gel column (41 
x 4 cm). Step gradient elution with 1:4 ethyl acetate−hexanes  100% ethyl acetate 
as eluant gave 3.69 as colorless oil: yield 0.23 g (36%); silica gel TLC Rf 0.37 (1:1 
ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.90 (d, 6H, J = 7.0 Hz), 2.35 (m, 1H), 
2.64 (s, 3H), 4.21 (d, 1H, J = 9.0 Hz), 4.29 (t, 1H, J = 9.0 Hz), 4.46 (m, 1H), 5.25 (s, 
1H), 6.06 (s, 1H), and 7.21 (s, 1H). 
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3-[2-S-Azido-3-R-hydroxy-3-(2-methylthiazol-4-ylpropionyl)]-4-R-
isopropyloxazolidin-2-one (3.70).150 To a solution containing 0.30 g (0.61 mmol) of 
3.69 in 20 mL of N,N-dimethylformamide was added 0.20 g (3.05 mmol) of sodium 
azide. The reaction mixture was warmed to 45 °C and stirred for 1.25 h at which time 
it was poured into ~45 g of ice and extracted with three 25-mL portions of ethyl 
acetate. The combined organic phase was washed with two 25-mL portions of water 
and 10 mL of brine, dried over anh MgSO4, filtered and concentrated under 
diminished pressure to give a brown oil. The residue was purified via flash 
chromatography on a silica gel column (42 x 4 cm). Step gradient elution with 1:4  
1:1 ethyl acetate−hexanes as eluant gave 3.70 as a colorless foam: yield 124 mg 
(60%); silica gel TLC Rf 0.54 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.89 
(dd, 6H, J = 6.6 and 3.9 Hz), 2.43 (m, 1H), 2.68 (s, 1H), 4.25 (m, 2H), 4.51 (m, 1H), 
5.10 (t, 1H, J = 8.1 Hz), 5.56 (d, 1H, J = 7.8 Hz), and 7.23 (s, 1H). 
O
OHFmocHN
HO
S
N
H
H
 
2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-hydroxy-3-(2-methylthiazol-4-
yl)propionic Acid (3.15).150 To a solution containing 0.23 g (0.68 mmol) of 3.70 in 5 
mL of 4:1 tetrahydrofuran−water was added 0.14 g (3.39 mmol) of LiOH⋅H2O. The 
reaction was stirred for 30 min at room temperature and quenched with 1 N HCl until 
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pH 2.5 was reached. The reaction mixture was extracted with three 25-mL portions of 
ethyl acetate and two 25-mL portions of chloroform. The combined organic phase 
was washed with two 25-mL portions of brine, dried over anh MgSO4, filtered, and 
concentrated under diminished pressure to give a colorless solid. The residue was 
dissolved in 10 mL of 9:1 tetrahydrofuran−water. To this solution was added 0.19 g 
(1.36 mmol) of K2CO3 and 0.34 g (1.01 mmol) of FmocOSu. This solution was added 
to ~40 mg of 10% Pd/C under an Ar atmosphere. The reaction vessel was purged with 
H2 several times and stirred under H2 for 16 h. The reaction mixture was then filtered 
through a pad of Celite and washed thoroughly with two 100-mL portions of 90:8:2 
chloroform−methanol−acetic acid followed by 50 mL of toluene. Excess solvent was 
removed under diminished pressure and the resulting residue was coevaporated with 
several portions of toluene to give a yellow oil. The residue was purified by flash 
chromatography on a silica gel column (43 x 4 cm). Elution with 90:8:2 
chloroform−methanol−acetic acid as eluant gave 3.15 as a light yellow solid: yield 34 
mg (12%); silica gel TLC Rf 0.60 (1:9 methanol−dichloromethane); 1H NMR 
(DMSO-d6) δ 2.51 (s, 3H), 4.21 (m, 3H), 4.56 (t, 1H, J = 6.0 Hz) 4.90 (d, 1H, J = 4.5 
Hz), 7.24 (s, 1H), 7.31 (m, 5H), 7.68 (d, 2H, J = 7.5 Hz), and 7.89 (d, 1H, J = 7.5 Hz). 
NH2
S
 
Thioisovaleramide (3.71).150 To a solution containing 2.00 g (19.8 mmol) of 
isovaleramide in 50 mL tetrahydrofuran at 0 °C was added 0.88 g (3.95 mmol) of 
P2S5. The reaction mixture was stirred while warming to room temperature for 3 h. 
The reaction mixture was filtered through a course glass frit and was washed with 50 
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mL of diethyl ether. The organic phase was concentrated under diminished pressure. 
The reaction crude was used without any further purification for the next reaction. 
Diminished pressure gave 3.71 as a yellow oil: yield 2.22 g (96%). 
S
NO
O
 
2-Isobutylthiazole-4-carboxylic Acid Ethyl Ester (3.72).150 To a solution containing 
122 mg (1.05 mmol) of 3.71 in 50 mL of ethanol was added 0.14 mL (0.22 g, 1.14 
mmol) of 3-bromo-2-oxopropionic acid ethyl ester. The reaction mixture was stirred 
at reflux for 3 h at which time solid NaHCO3 was added carefully until no bubbling 
was observed. The reaction mixture was poured into 15 mL of water and extracted 
with three 25-mL portions of ethyl acetate. The combined organic phase was dried 
over anh MgSO4, filtered, and concentrated under diminished pressure to afford a 
crude residue. The residue was purified by flash chromatography on a silica gel 
column (43 x 5 cm). Step gradient elution with 1:4  1:1 ethyl acetate−hexanes as 
eluant gave 3.72 as a yellow oil: yield 127 mg (50%); silica gel TLC Rf 0.80 (1:1 
ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.93 (d, 6H, J = 6.6 Hz), 1.35 (t, 3H, J = 
7.2 Hz), 2.08 (m, 1H), 2.87 (d, 2H, J = 7.2 Hz), 4.33 (q, 2H, J = 7.1 Hz), and 8.01 (s, 
1H). 
S
N
O
H
 
2-Isobutylthiazole-4-carbaldehyde (3.73).150 To a solution containing 127 mg (0.60 
mmol) of 3.72 in 20 mL of dichloromethane at −78 °C was added 1.85 mL (266 mg, 
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1.85 mmol) of diisobutylaluminium hydride (1.0 M in toluene) over a period of 30 
min. The reaction mixture was stirred at −78 °C for 4 h at which time the reaction was 
quenched by the addition of 1.5 mL of methanol followed by 15 mL of 1:1 sat aq 
sodium potassium tartrate−pH 7 buffer. The reaction mixture was stirred vigorously at 
room temperature for 16 h, extracted with three 10-mL portions of dichloromethane, 
dried over anh MgSO4, filtered, and concentrated under diminished pressure. The 
residue was purified by flash chromatography on a silica gel column (43 x 2.5 cm). 
Elution with 1:1 ethyl acetate−hexanes as eluant gave 3.73 as a brown oil: yield 71 
mg (71%); silica gel TLC Rf 0.84 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
0.89 (d, 6H, J = 6.6 Hz), 2.05 (quint, 1H, J = 6.6 Hz), 2.81 (d, 2H, J = 7.2 Hz), 8.01 
(s, 1H), and 9.89 (s, 1H). 
ON
OO
N
S
OH
Br
 
3-[2-R-Bromo-3-R-hydroxy-3-(2-isobutylthiazol-4-yl)propionyl]-4-R-
isopropyloxazolidin-2-one (3.74).150 To a solution containing 84 mg (0.34 mmol) of 
3.28 in 4 mL of diethyl ether at −78 °C was added 90 µL (100 mg, 0.37 mmol) of 
freshly prepared 3.27, followed immediately by the addition of 51 µL (37 mg, 0.37 
mmol) of triethylamine. The reaction mixture was stirred for 0.5 h at −78 °C and then 
allowed to warm to room temperature and stirred for an additional 2 h. The resulting 
dark maroon solution was cooled to −78 °C, and a solution containing 57 mg (0.34 
mmol) of 3.73 in 1.5 mL of dichloromethane was added dropwise. The reaction 
mixture was allowed to warm to room temperature and was stirred overnight. The 
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reaction mixture was then diluted with 15 mL of 2:1 diethyl ether−dichloromethane 
and washed with two 5-mL portions of sat aq NaHSO4 and 2 mL of brine. The 
organic phase was concentrated under diminished pressure to give a brown oily 
residue which was dissolved in 3 mL of methanol. To this solution was added 1 mL of 
30% aq H2O2 and the reaction was stirred for 1 h. The milky solution was 
concentrated under diminished pressure, and the resulting residue was dissolved in 10 
mL of water and extracted with three 10-mL portions of 2:1 diethyl 
ether−dichloromethane. The combined organic phase was washed with two 5-mL 
portions of sat aq NaHCO3 and 5 mL of brine, dried over anh MgSO4, filtered and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (41 x 2.5 cm). Step gradient elution with 1:4 
ethyl acetate−hexanes  100% ethyl acetate as eluant gave 3.74 as colorless foam: 
yield 42 mg (30%); silica gel TLC Rf 0.59 (1:1 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 0.86 (m, 12H), 1.94 (m, 1H), 2.33 (m, 1H), 2.74 (d, 2H, J = 7.2 Hz), 4.21 
(m, 2H), 4.40 (m, 1H), 5.23 (d, 1H, J = 4.8 Hz), 6.07 (d, 1H, J = 4.8 Hz), and 7.20 (s, 
1H). 
ON
OO
N
S
OH
N3
 
3-[2-S-Azido-3-R-hydroxy-3-(2-isobutylthiazol-4-ylpropionyl)]-4-R-
isopropyloxazolidin-2-one (3.75).150 To a solution containing 42 mg (0.10 mmol) of 
3.74 in 5 mL of N,N-dimethylformamide was added 32 mg (0.50 mmol) of sodium 
azide. The reaction mixture was warmed to 45 °C and stirred for 1.25 h at which time 
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it was poured into ~4 g of ice and extracted with three 10-mL portions of ethyl 
acetate. The combined organic phase was washed with two 10-mL portions of water 
and 5 mL of brine, dried over anh MgSO4, filtered and concentrated under diminished 
pressure to give a brown oil. The residue was purified via flash chromatography on a 
silica gel column (42 x 2 cm). Step gradient elution with 1:4  1:1 ethyl 
acetate−hexanes as eluant gave 3.75 as a colorless oil: yield 25 mg (65%); silica gel 
TLC Rf 0.75 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.85 (m, 12H), 1.99 (m, 
1H), 2.37 (m, 1H), 2.75 (d, 2H, J = 7.2 Hz), 4.22 (m, 2H), 4.44 (m, 1H), 5.09 (m, 1H), 
5.49 (d, 1H, J = 7.5 Hz), and 7.19 (s, 1H). 
O
OHFmocHN
HO
S
N
H
H
 
2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-hydroxy-3-(2-isobutylthiazol-4-
yl)propionic Acid (3.16).150 To a solution containing 350 mg (0.91 mmol) of 3.75 in 
20 mL of 4:1 tetrahydrofuran−water was added 192 mg (4.60 mmol) of LiOH⋅H2O. 
The reaction was stirred for 30 min at room temperature and quenched with 1 N HCl 
until pH 2.5 was reached. The reaction mixture was extracted with three 25-mL 
portions of ethyl acetate and two 25-mL portions of chloroform. The combined 
organic phase was washed with two 25-mL portions of brine, dried over anh MgSO4, 
filtered, and concentrated under diminished pressure to give a colorless solid. The 
residue was dissolved in 20 mL of 9:1 tetrahydrofuran−water. To this solution was 
added 253 mg (1.83 mmol) of K2CO3 and 460 mg (1.38 mmol) of FmocOSu. This 
solution was added to ~100 mg of 10% Pd/C under an Ar atmosphere. The reaction 
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vessel was purged with H2 several times and stirred under H2 for 16 h. The reaction 
mixture was then filtered through a pad of Celite and washed thoroughly with two 
100-mL portions of 90:8:2 chloroform−methanol−acetic acid followed by 50 mL of 
toluene. Excess solvent was removed under diminished pressure and the resulting 
residue was coevaporated with several portions of toluene to give a yellow oil. The 
residue was purified by flash chromatography on a silica gel column (43 x 4 cm). 
Elution with 90:8:2 chloroform−methanol−acetic acid as eluant gave 3.16 as a 
colorless solid: yield 100 mg (24%); silica gel TLC Rf 0.44 (88:10:2 
dichloromethane−methanol−acetic acid); 1H NMR (DMSO-d6) δ 0.87 (d, 6H, J = 6.6 
Hz), 1.93 (m, 1H), 2.77 (d, 2H, J = 7.2 Hz), 4.20 (m, 3H), 4.44 (m, 1H,) 4.90 (d, 1H, J 
= 5.7 Hz), 7.31 (m, 5H), 7.31 (m, 5H), 7.65 (d, 2H, J = 7.2 Hz), and 7.87 (d, 1H, J = 
7.5 Hz). 
O
O
O
 
2-Oxobutanoic Acid Ethyl Ester (3.76).150 To a solution containing 1.00 mL (1.08 g, 
6.82 mmol) of diethyl oxalate in 20 mL of diethyl ether at −78 °C was added 2.27 mL 
(0.89 g, 6.82 mmol) of ethylmagnesium bromide (3.0 M in diethyl ether). The 
reaction mixture was stirred for 15 min and then allowed to warm to −10 °C for 2 h. 
The reaction mixture was quenched with 10 mL sat aq NH4Cl and extracted with three 
50-mL portions of ethyl acetate. The combined organic phase was dried over anh 
MgSO4, filtered and excess solvent was removed under diminished pressure. The 
residue was purified by flash chromatography on a silica gel column (43 x 4 cm). 
Elution with 1:3 ethyl acetate−hexanes as eluant gave 3.76 as a colorless oil: yield 
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0.72 g (80%); silica gel TLC Rf 0.89 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
1.04 (t, 3H, J = 7.2 Hz), 1.28 (t, 3H, J = 6.8 Hz), 2.77 (q, 2H, J = 7.5 Hz), and 4.22 (q, 
2H, J = 6.9 Hz). 
O
O
O
Br
 
3-Bromo-2-oxobutanoic Acid Ethyl Ester (3.77).150 To a solution containing 720 
mg (5.53 mmol) of 3.76 in 30 mL chloroform was added a solution containing 2.38 g 
(16.6 mmol) of CuBr2 in 60 mL of ethyl acetate. The reaction mixture was stirred at 
reflux for 18 h, cooled, filtered through a silica pad of silica gel, and washed with 
three 50-mL portions of ethyl acetate. The excess solvent was removed under 
diminished pressure. The residue was purified by flash chromatography on a silica gel 
column (43 x 4 cm). Elution with 1:3 ethyl acetate−hexanes as eluant gave 3.77 as a 
yellow oil: yield 537 mg (46%); silica gel TLC Rf 0.82 (1:2 ethyl acetate−hexanes); 
1H NMR (CDCl3) δ 1.31 (t, 3H, J = 6.9 Hz), 1.71 (d, 3H, J = 6.9 Hz), 4.28 (q, 2H, J = 
7.2 Hz), and 5.09 (q, 1H, J = 6.9 Hz). 
S
NO
O
 
5-Methylthiazole-4-carboxylic Acid Ethyl Ester (3.78).150 To a solution containing 
0.76 g (12.4 mmol) of 3.39 in 40 mL of ethanol was added 0.52 g (2.48 mmol) of 
3.77. The reaction mixture was stirred at reflux for 3 h at which time solid NaHCO3 
was added carefully until no bubbling was observed. The reaction mixture was poured 
into 15 mL of water and extracted with three 50-mL portions of ethyl acetate. The 
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combined organic phase was dried over anh MgSO4, filtered, and concentrated under 
diminished pressure to afford a crude residue. The residue was purified by flash 
chromatography on a silica gel column (43 x 4 cm). Step gradient elution with 1:4  
1:1 ethyl acetate−hexanes as eluant gave 3.78 as a colorless solid: yield 469 mg 
(44%); silica gel TLC Rf 0.33 (1:2 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.99 
(t, 3H, J = 7.0 Hz), 2.36 (s, 3H), 3.97 (q, 2H, J = 7.0 Hz), and 8.23 (s, 1H). 
S
N
O
H
 
5-Methylthiazole-4-carbaldehyde (3.79).150 To a solution containing 2.11 g (12.3 
mmol) of 3.78 in 300 mL of dichloromethane at −78 °C was added 38 mL (5.51 g, 
38.6 mmol) of diisobutylaluminium hydride (1.0 M in toluene) over a period of 30 
min. The reaction mixture was stirred at −78 °C for 4 h at which time the reaction was 
quenched by the addition of 15 mL of methanol followed by 150 mL of 1:1 sat aq 
sodium potassium tartrate−pH 7 buffer. The reaction mixture was stirred vigorously at 
room temperature for 16 h, extracted with three 150-mL portions of dichloromethane, 
dried over anh MgSO4, filtered, and concentrated under diminished pressure. The 
residue was purified by flash chromatography on a silica gel column (43 x 2.5 cm). 
Elution with 1:2 ethyl acetate−hexanes as eluant gave 3.79 as a colorless solid: yield 
0.74 g (47%); silica gel TLC Rf 0.61 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
2.60 (s, 3H), 8.47 (s, 1H), and 9.97 (s, 1H). 
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3-[2-R-Bromo-3-R-hydroxy-3-(5-methylthiazol-4-yl)propionyl)]-4-R-
isopropyloxazolidin-2-one (3.80).150 To a solution containing 2.00 g (8.15 mmol) of 
3.28 in 50 mL of diethyl ether at −78 °C was added 2.18 mL (2.50 g, 8.98 mmol) of 
freshly prepared 3.27, followed immediately by the addition of 1.25 mL (0.90 g, 8.98 
mmol) of triethylamine. The reaction mixture was stirred for 0.5 h at −78 °C and then 
allowed to warm to room temperature and stirred for an additional 2 h. The resulting 
dark maroon solution was cooled to −78 °C, and a solution containing 1.00 g (5.91 
mmol) of 3.79 in 20 mL of dichloromethane was added dropwise. The reaction 
mixture was allowed to warm to room temperature and was stirred overnight. The 
reaction mixture was then diluted with 60 mL of 2:1 diethyl ether−dichloromethane 
and washed with two 45-mL portions of sat aq NaHSO4 and 25 mL of brine. The 
organic phase was concentrated under diminished pressure to give a brown oily 
residue which was dissolved in 20 mL of methanol. To this solution was added 6 mL 
of 30% aq H2O2 and the reaction was stirred for 1 h. The milky solution was 
concentrated under diminished pressure, and the resulting residue was dissolved in 10 
mL of water and extracted with three 25-mL portions of 2:1 diethyl 
ether−dichloromethane. The combined organic phase was washed with two 10-mL 
portions of sat aq NaHCO3 and 5 mL of brine, dried over anh MgSO4, filtered and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (43 x 4 cm). Step gradient elution with 1:4 
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ethyl acetate−hexanes  100% ethyl acetate as eluant gave 3.80 as colorless oil: yield 
640 mg (20%); silica gel TLC Rf 0.54 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) 
δ 0.86 (m, 6H), 2.27 (m, 1H), 2.51 (s, 3H), 4.18 (m, 3H), 5.31 (d, 1H, J = 8.1 Hz), 
6.17 (d, 1H, J = 8.1 Hz), and 8.60 (s, 1H). Note: material decomposes rapidly, must 
be used immediately. 
ON
OO
N
S
OH
N3
 
3-[2-S-Azido-3-R-hydroxy-3-(5-methylthiazol-4-yl)propionyl)]-4-R-
isopropyloxazolidin-2-one (3.81).150 To a solution containing 640 mg (1.70 mmol) of 
3.80 in 53 mL of N,N-dimethylformamide was added 550 mg (8.50 mmol) of sodium 
azide. The reaction mixture was warmed to 45 °C and stirred for 1.25 h at which time 
it was poured into ~45 g of ice and extracted with three 50-mL portions of ethyl 
acetate. The combined organic phase was washed with two 25-mL portions of water 
and 10 mL of brine, dried over anh MgSO4, filtered and concentrated under 
diminished pressure to give a brown oil. The residue was purified via flash 
chromatography on a silica gel column (43 x 4 cm). Step gradient elution with 1:4  
1:1 ethyl acetate−hexanes as eluant gave 3.81 as a colorless oil: yield 218 mg (38%); 
silica gel TLC Rf 0.65 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.92 (t, 1H, J 
= 6.3 Hz), 2.43 (m, 1H), 2.52 (s, 3H), 4.24 (m, 1H), 4.34 (t, 1H, J = 9.0 Hz), 4.51 (m, 
1H), 5.05 (t, 1H, J = 8.7 Hz), 5.61 (d, 1H, J = 9.0 Hz), and 8.59 (s, 1H) 
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2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-hydroxy-3-(5-methylthiazol-4-
yl)propionic Acid (3.17).150 To a solution containing 218 mg (0.64 mmol) of 3.81 in 
10 mL of 4:1 tetrahydrofuran−water was added 134 mg (3.21 mmol) of LiOH⋅H2O. 
The reaction was stirred for 30 min at room temperature and quenched with 1 N HCl 
until pH 2.5 was reached. The reaction mixture was extracted with three 25-mL 
portions of ethyl acetate and two 25-mL portions of chloroform. The combined 
organic phase was washed with two 25-mL portions of brine, dried over anh MgSO4, 
filtered, and concentrated under diminished pressure to give a colorless solid. The 
residue was dissolved in 15 mL of 9:1 tetrahydrofuran−water. To this solution was 
added 177 mg (1.28 mmol) of K2CO3 and 325 mg (1.97 mmol) of FmocOSu. This 
solution was added to ~50 mg of 10% Pd/C under an Ar atmosphere. The reaction 
vessel was purged with H2 several times and stirred under H2 for 16 h. The reaction 
mixture was then filtered through a pad of Celite and washed thoroughly with two 
100-mL portions of 90:8:2 chloroform−methanol−acetic acid followed by 50 mL of 
toluene. Excess solvent was removed under diminished pressure and the resulting 
residue was coevaporated with several portions of toluene to give a yellow oil. The 
residue was purified by flash chromatography on a silica gel column (43 x 4 cm). 
Elution with 90:8:2 chloroform−methanol−acetic acid as eluant gave 3.17 as a 
colorless solid: yield 68 mg (25%); silica gel TLC Rf 0.76 (88:10:2 
dichloromethane−methanol−acetic acid); 1H NMR (CDCl3) δ 2.34 (s, 3H), 4.19 (m, 
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2H), 4.48 (m, 1H), 4.68 (m, 1H), 5.36 (s, 1H), 6.90 (br s, 1H), 7.17 (m, 4H), 7.59 (t, 
1H, J = 8.4 Hz), 7.73 (t, 1H, J = 7.5 Hz), and 8.57 (s, 1H). 
S
NO
O
NH2
 
2-Aminothiazole-4-carboxylic Acid Ethyl Ester (3.82).150 To a solution containing 
17.9 g (225 mmol) of thiourea in 200 mL of ethanol was added 28.3 mL (44.0 g, 225 
mmol) of 3-bromo-2-oxopropionic acid ethyl ester. The reaction mixture was stirred 
at reflux for 3 h at which time solid NaHCO3 was added carefully until no bubbling 
was observed. The reaction mixture was poured into 150 mL of water and extracted 
with three 250-mL portions of ethyl acetate. The combined organic phase was dried 
over anh MgSO4, filtered, and concentrated under diminished pressure to afford a 
crude residue. The residue was purified by flash chromatography on a silica gel 
column (43 x 7 cm). Step gradient elution with 1:4  1:1 ethyl acetate−hexanes as 
eluant gave 3.82 as a colorless solid: yield 13.7 g (35%); silica gel TLC Rf 0.51 (10% 
methanol in 1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 1.36 (t, 3H, J = 7.2 Hz), 
4.32 (q, 2H, J = 7.2 Hz), 3.85 (br, 2H), and 7.39 (s, 1H). 
S
N
O
H NHBoc
 
(4-Formylthiazol-2-yl)carbamic Acid tert-Butyl Ester (3.83).150 To a solution 
containing 13.70 g (79.0 mmol) of 3.82 in 100 mL of dichloromethane at −78 °C was 
added 19.10 g (86.9 mmol) of di-tert-butyl dicarbonate. The reaction was stirred for 2 
h at room temperature. Quenched with 50 mL of brine, and extracted with three 100-
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mL portions of dichloromethane. The combined organic phase was dried over anh 
MgSO4, filtered, and concentrated at diminished pressure. The residue was taken up 
in 60 mL of dichloromethane, it was cooled at −78 °C and 80.0 mL (7.09 g, 80.0 
mmol) of diisobutylaluminium hydride (1.0 M in toluene) were added over a period of 
30 min. The reaction mixture was stirred at −78 °C for 4 h at which time the reaction 
was quenched by the addition of 15 mL of methanol followed by 150 mL of 1:1 sat aq 
sodium potassium tartrate−pH 7 buffer. The reaction mixture was stirred vigorously at 
room temperature for 16 h, extracted with three 100-mL portions of dichloromethane, 
dried over anh MgSO4, filtered, and concentrated under diminished pressure. The 
residue was purified by flash chromatography on a silica gel column (43 x 6 cm). 
Elution with 1:1 ethyl acetate−hexanes as eluant gave 3.83 as a colorless solid: yield 
6.20 g (34%); silica gel TLC Rf 0.63 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
1.46 (s, 9H), 7.80 (s, 1H), and 9.89 (s, 1H). 
ON
OO
N
S
OH
BrBocHN
 
{4-[2-R-Bromo-1-R-hydroxy-3-(4-R-isopropyl-2-oxooxazolidin-3-yl)-3-
oxopropyl]thiazol-2-yl}carbamic Acid tert-Butyl Ester (3.84).150 To a solution 
containing 1.45 g (5.80 mmol) of 3.28 in 40 mL of diethyl ether at −78 °C was added 
1.55 mL (1.75 g, 6.40 mmol) of freshly prepared 3.27, followed immediately by the 
addition of 0.90 mL (0.64 g, 6.40 mmol) of triethylamine. The reaction mixture was 
stirred for 0.5 h at −78 °C and then allowed to warm to room temperature and stirred 
for an additional 2 h. The resulting dark maroon solution was cooled to −78 °C, and a 
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solution containing 0.68 g (11.0 mmol) of 3.83 in 20 mL of dichloromethane was 
added dropwise. The reaction mixture was allowed to warm to room temperature and 
was stirred overnight. The reaction mixture was then diluted with 60 mL of 2:1 
diethyl ether−dichloromethane and washed with two 45-mL portions of sat aq 
NaHSO4 and 25 mL of brine. The organic phase was concentrated under diminished 
pressure to give a brown oily residue which was dissolved in 20 mL of methanol. To 
this solution was added 6 mL of 30% aq H2O2 and the reaction was stirred for 1 h. 
The milky solution was concentrated under diminished pressure, and the resulting 
residue was dissolved in 10 mL of water and extracted with three 25-mL portions of 
2:1 diethyl ether−dichloromethane. The combined organic phase was washed with 
two 10-mL portions of sat aq NaHCO3 and 5 mL of brine, dried over anh MgSO4, 
filtered and concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (41 x 4 cm). Step gradient elution with 1:4 
ethyl acetate−hexanes  100% ethyl acetate as eluant gave 3.84 as colorless foam: 
yield 145 mg (5%); silica gel TLC Rf 0.23 (1:2 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 0.85 (d, 6H, J = 6.9 Hz), 1.50 (s, 9H), 2.29 (m, 1H), 4.19 (m, 2H), 4.35 (m, 
1H), 4.66 (br s, 1H), 5.21 (m, 1H), 6.01 (m, 1H), and 6.90 (s, 1H). 
ON
OO
N
S
OH
N3
BocHN
 
{4-[2-S-Azido-1-R-hydroxy-3-(4-R-isopropyl-2-oxooxazolidin-3-yl)-3-
oxopropyl]thiazol-2-yl}carbamic Acid tert-Butyl Ester (3.85).150 To a solution 
containing 145 mg (0.30 mmol) of 3.84 in 10 mL of N,N-dimethylformamide was 
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added 100 mg (1.52 mmol) of sodium azide. The reaction mixture was warmed to 45 
°C and stirred for 1.25 h at which time it was poured into ~8 g of ice and extracted 
with three 25-mL portions of ethyl acetate. The combined organic phase was washed 
with two 25-mL portions of water and 10 mL of brine, dried over anh MgSO4, filtered 
and concentrated under diminished pressure to give a brown oil. The residue was 
purified via flash chromatography on a silica gel column (42 x 4 cm). Step gradient 
elution with 1:4  1:1 ethyl acetate−hexanes as eluant gave 3.85 as a colorless oil: 
yield 71 mg (53%); silica gel TLC Rf 0.51 (1:1 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 0.81 (dd, 6H, J = 16.8 and 7.2 Hz), 1.50 (s, 9H), 2.33 (m, 1H), 4.15 (dd, 
6H, J = 9.0 and 3.0 Hz), 4.27 (t, 1H, J = 9.0 Hz), 4.44 (m, 1H), 4.58 (br s, 1H), 4.95 
(m, 1H), 5.55 (d, 1H, J = 9.0 Hz), and 6.92 (s, 1H). 
O
OHFmocHN
OH
S
N
H
H NHBoc
 
3-(2-tert-Butoxycarbonylaminothiazol-4-yl)-2-(9H-Fluoren-9-
ylmethoxycarbonylamino)-3-hydroxypropionic Acid (3.18).150 To a solution 
containing 71 mg (0.15 mmol) of 3.85 in 20 mL of 4:1 tetrahydrofuran−water was 
added 31 mg (0.74 mmol) of LiOH⋅H2O. The reaction was stirred for 30 min at room 
temperature and quenched with 1 N HCl until pH 2.5 was reached. The reaction 
mixture was extracted with three 25-mL portions of ethyl acetate and two 25-mL 
portions of chloroform. The combined organic phase was washed with two 25-mL 
portions of brine, dried over anh MgSO4, filtered, and concentrated under diminished 
pressure to give a colorless solid. The residue was dissolved in 20 mL of 9:1 
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tetrahydrofuran−water. To this solution was added 41 mg (0.30 mmol) of K2CO3 and 
75 mg (0.22 mmol) of FmocOSu. This solution was added to ~100 mg of 10% Pd/C 
under an Ar atmosphere. The reaction vessel was purged with H2 several times and 
stirred under H2 for 16 h. The reaction mixture was then filtered through a pad of 
Celite and washed thoroughly with two 100-mL portions of 90:8:2 
chloroform−methanol−acetic acid followed by 50 mL of toluene. Excess solvent was 
removed under diminished pressure and the resulting residue was coevaporated with 
several portions of toluene to give a yellow oil. The residue was purified by flash 
chromatography on a silica gel column (43 x 2.5 cm). Elution with 90:8:2 
chloroform−methanol−acetic acid as eluant gave 3.18 as a colorless solid: yield 21 mg 
(25%); silica gel TLC Rf 0.68 (88:10:2 dichloromethane−methanol−acetic acid); 1H 
NMR (CDCl3) δ 1.50 (s, 9H), 4.19 (m, 1H), 4.36 (m, 1H), 4.60 (m, 1H,) 4.86 (m, 1H), 
5.42 (br, 1H), 5.73 (m, 1H), 6.66 (s, 1H), 7.28 (m, 4H), 7.54 (d, 1H, J = 7.2 Hz), and 
7.74 (d, 1H, J = 7.5 Hz). 
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